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Abstract
Endocrine and anti-EGFR strategies are used to treat breast cancer. 
Unfortunately, resistance can be acquired. Deciphering resistance mechanisms 
remains essential to design treatments for this adverse state. Oxidative stress is 
the cellular imbalance of pro-oxidants (promoting cell death) and antioxidants 
(facilitating cell survival and chemotherapy/radiotherapy resistance). 
However, it remains unexplored whether endocrine or anti-EGFR resistance 
also associates with altered redox balance. In this project, redox balance was 
examined using in vitro human resistant breast cancer models TAMR, FASR, 
X-MCF and NEW DUBS, comparing with responsive w/tMCF7 cells using 
microarray analysis, PCR, and TAC, ROS, or MTT assays. Pro-oxidant levels 
increased significantly in all resistant models but this did not impact adversely 
on growth. Significantly increased antioxidant levels were also observed in all 
resistant models, perhaps limiting pro-oxidant increases to maintain cell 
survival. Antioxidants were also significantly induced by antihormones in 
w/tMCF7 cells that may limit apoptosis with early treatment. Expression of 15 
antioxidant genes increased in resistant cells spanning multiple resistant states. 
While gefitinib challenge revealed many antioxidant genes were EGFR/kinase 
signalling-regulated in TAMR cells, gefitinib and further signal transduction 
inhibitors (STIs) indicated total antioxidant capacity was not. Thus, additional 
genes/signalling probably drive increased antioxidants in resistant cells; future 
deciphering and depletion of antioxidants could feasibly block cell survival in 
multiple resistant states. Several STIs further increased pro-oxidants in TAMR 
cells, indicating oxidative stress was also not EGFR/kinase-promoted; since 
STIs also further increased antioxidant capacity, this may again limit pro­
oxidant increases and hence apoptotic effect. Importantly, the thesis revealed 
resistant cells may be particularly sensitive to agents inducing excessive 
oxidative stress. Redox balance and feasibility of agents influencing redox 
remains complex. However, new findings and concepts emerging from this 
thesis are worthy of future exploration for potential treatments for resistance to 
endocrine/anti-EGFR agents.
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1.1 Introduction
Various endocrine strategies, notably anti-oestrogen and oestrogen deprivation 
treatments, have been designed to compromise oestrogen signalling and are 
valuable in treating oestrogen receptor positive (ER+) breast cancer (Dowsett 
et al., 2005; Gee et al., 2005; Nicholson & Johnson, 2005). However, despite 
initial responses, resistance is commonly acquired during treatment where this 
event can be associated with poorer prognosis (Katzenellenbogen et al., 1995). 
Therefore, discovery of the mechanisms driving endocrine resistant growth is 
essential to design therapies to better treat this adverse state.
The Tenovus Centre for Cancer Research (and others) have previously 
identified through use of in vitro models that epidermal growth factor receptor 
(EGFR) signalling is one factor that can be important in acquired tamoxifen 
(TAM) resistance. EGFR and its associated signalling is hence being targeted 
in clinical trials using anti-EGFR agents such as gefitinib and further ErbB 
inhibitors and signal transduction inhibitors (STIs) (Gee et al., 2003; Hiscox et 
al., 2004; Jones et al., 2004; Gee et al., 2005; Jones et al., 2005). However, 
emerging experience indicates that such newer targeted agents will not be 
spared the phenomenon of resistance. Therefore, continued deciphering of the 
biology underlying resistant states remains essential to reveal ways to improve 
treatment. This investigation will look at the role of oxidative stress in 
endocrine and anti-EGFR resistant states by studying various acquired resistant 
breast cancer models in vitro.
2
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Oxidative stress can be defined as an imbalance of pro-oxidants and 
antioxidants within the cell. An excess of oxidants, such as superoxide (O2 ), 
hydrogen peroxide (H2O2), and hydroxyl radicals (OH*), can promote DNA 
damage and lipid peroxidation leading to cell death (Mathews CK, et al., 
1999). However, there is an increase in antioxidants generated by the cell in 
response to oxidative stress such as: superoxide dismutase (SOD) (Housset, 
1987; Pani et al., 2004); catalase (CAT) (Spitz et al., 1993; Suematsu et al., 
2002); peroxiredoxins (PRDX) (Iwao-Koizumi et al., 2005); glutathione 
peroxidases (GPX) (Housset, 1987; Szatrowski & Nathan, 1991; Toyokuni et 
al., 1994); and thioredoxin (TXN) (Yokomizo et al., 1995; Sinha et al., 1998; 
Gorgan et al., 2000; Hedley et al., 2004; Ahmadi et al., 2006), that can 
facilitate cell survival. Indeed, the antioxidant response has in some instances 
been reported to confer resistance to chemotherapeutics whose anti-tumour 
mechanism is known to involve the induction of oxidative stress (Toyokuni et 
al., 1994).
While previously not significantly explored, endocrine or anti-EGFR agent 
treatments and subsequently acquired resistance might also feasibly be 
associated with changes in redox balance. Antioxidants might thus again 
actively contribute to cell survival in the presence of such drugs and hence 
contribute to resistant growth. In this project, the relevance of antioxidants to 
resistant growth and also evaluation of oxidative stress will be assessed with 
the aim of determining new mechanisms and thereby potential future 
therapeutic approaches for resistant states.
3
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1.2 Breast Cancer
An Egyptian papyrus first referred to tumours of the breast between 3000-1500 
BC (CancerStats: a brief history of cancer—UK, 2006). The Greek physician 
Hippocrates, the "Father of Medicine", was the first to recognise the difference 
between benign and malignant tumours around 400 BC (Adams, 2004; 
CancerStats: a brief history of cancer-UK, 2006). He named malignant 
tumours “Carcinos” (crab/crayfish), resembling their appearance, and later this 
included the suffix -oma (swelling), giving the name “Carcinoma” (Adams,
2004). Breast carcinoma is now the most common cancer in the UK, and in 
2006, over 45,500 women and 300 men were diagnosed with breast cancer. 
(CancerStats: Breast Cancer-UK, 2006). Mortality rates have declined by 25% 
since 1987 due to earlier detection and improved treatment, notably including 
the endocrine agent tamoxifen (TAM) (Lacey et al., 2005; CancerStats: a brief 
history of cancer-UK, 2006). However, there are still many deaths associated 
with the disease (12,400 annually (30% of all breast cancer patients) 
CancerStats: Breast Cancer-UK, 2006), and so improved treatments remain 
critical.
Breast cancer has been related to increased age, alcohol consumption, diet, and 
genetic make-up. However, in particular female steroid hormones are 
implicated in breast cancer development and subsequent growth, as women are 
clearly at a higher risk of developing the disease than men (99% of sufferers 
being women, and only 1% being men) (Brekelmans, 2003; CancerStats: 
Breast Cancer-UK, 2006). There is much evidence supporting the fact that
4
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breast cancer is a disease related to the steroid hormone oestrogen and its 
signalling, with a higher risk of developing the disease associated with a 
women’s increased lifetime exposure to oestrogen, for example associating 
with an early menarche, late menopause, or reproductive factors such as late 
first pregnancy (Madigan et al., 1995; Brekelmans, 2003), as well as exposure 
to exogenous steroid hormones through use of hormone replacement therapy 
(Brekelmans, 2003). In 1896, Sir George Beatson reported regression of an 
advanced mammary cancer in one of his patients (Murphy, 1998). This was 
achieved by surgical removal of the ovaries, the organs now known to 
comprise the predominant source of oestrogen in the premenopausal woman, 
data directly associating this steroid hormone with maintenance of some 
established mammary tumours. Such findings also had therapeutic 
implications, although nowadays emphasis is placed on the use of 
pharmacological inhibitors of oestrogen production as well as drugs to interfere 
with the oestrogen signalling mechanism (Murphy, 1998).
1.2.1 Oestrogen Receptor
There are two receptors by which oestrogen can signal to promote its cellular 
actions, namely ERa and ERp (Jenson & Jacobson, 1962; Kuiper et al, 1996). 
These receptor proteins have some homology as members of the steroid 
receptor superfamily (Figure 1.1), however, they are encoded on different 
chromosomes and have distinct patterns of distribution, differences in structure, 
and ligand binding affinity (Kuiper et al., 1997). The ratio of ERa to ERP at a 
target site might be significant in tissue modulation, as predominance of
5
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functional ERa to ERp correlates with very high levels of proliferation, 
whereas a high ERp over ERa correlates with low levels of proliferation 
(Roger et al., 2001; Shaaban et al., 2003; Paruthiyil et al., 2004; Acconcia et 
al., 2005). However, it is ERa that is the most predominant receptor protein in 
breast cancer, expressed in at least 70% of tumours in the breast cancer 
epithelial cell nuclei (Green et al., 1986; Kuiper et al., 1997; Fuqua et al., 2003) 
and conferring an “ER positive” (ER*) tumour status.
The ERa protein (subsequently referred to as ER in this thesis) is somewhat 
larger than ERp, containing 595 versus 530 amino acids respectively (Figure 
1.1) (Fuqua et al., 1999; Fuqua et al., 2003). Like other steroid hormone 
receptors, ER is a nuclear transcription factor with an NH2-terminal (A/B) 
domain bearing a ligand-independent transcriptional activation function 1 (AF- 
1), a ligand-binding (E) domain near the COOH-terminal with a hormone- 
dependent transcriptional activation function 2 (AF-2), a central DNA-binding 
domain (C) and a hinge domain (D) permitting dimerisation of the receptor 
(Tsai et al., 1994; Ribeiro et al., 1995; Fuqua et al., 2003). The AF-1 and AF-2 
regions are crucial for interactions with other co-regulatory proteins to 
subsequently drive gene transcription activity that can promote cell survival 
and proliferation of breast cancer cells (Jordan, 2007).
6
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Figure 1.1 Functional Domains of, and % homology between, ERa 
and ERp
ERa 1 595aa
— COOHA/B
17% 30% 55% 18%
ERp  COOHA/B
1
530aa
Transcriptional ^ ^ ^
Activation AF-1 AF-2
Nuclear Localization
Dimerization 
DNA- Binding 
Co-Activator Binding 
Co-repressor Binding 
L igand B inding
Schematic representation o f  the human oestrogen receptors ERa and ERp. The 
percentage identity between the two receptors is indicated. Both receptors 
consist o f  functional domains, comprising the ligand-independent activation 
function AF-1 in the aminoterminal domain (A/B), DNA-binding domain (C), 
hinge (D), the ligand-dependent activation function AF-2 at the ligand-binding 
domain (E), as well as agonist/antagonist distinction site (F). This diagram is 
adapted from Kling (2000).
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1.2.2 Oestrogen Receptor Signalling
In the absence of a ligand the ER is found in the cell nuclei within an inhibitory 
protein complex of heat shock proteins 90 and 70, and cyclophilin-40 and p23 
(Pratt & Toft, 1997). Classical ligand dependant signalling of the ER is 
induced in the presence of oestradiol. The steroid hormone diffuses through 
the cell plasma membrane to translocate to the nucleus, and binds to the ER 
causing subsequent alterations to the ligand binding domain and 
phosphorylation of the ER, releasing it from the inactive oligomeric complex 
(Roa, 1981; Osborne & Schiff, 2005). This allows ER dimerisation and DNA 
binding of the ER to the oestrogen receptor elements (ERE) in the promoter 
sequence of oestrogen responsive genes (Osborne & Schiff, 2005). Once 
attached to the DNA and through specific recruitment of co-regulatory 
transcription factors, the receptor complex can regulate target gene 
transcription via synergistic activity of AF-2 and AF-1. There are ER co­
regulators such as Co-Activators or Co-Repressors that can influence 
recruitment of the general transcriptional machinery and other co-factors, 
modifying the chromatin environment surrounding the promoter of the targeted 
gene to further facilitate gene activation or inactivation respectively (McKenna 
et al., 1999; Kling, 2001; Dobrzycka et al., 2003). In the presence of 
oestrogens, predominant Co-Activator recruitment to the ER facilitates 
increased gene transcription of ER-regulated genes (McKenna et al., 1999; 
Kling, 2001; Dobrzycka et al., 2003).
8
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In breast cancer, non-classical ER signalling can also occur when ligand bound 
nuclear ER can interact with other DNA bound transcription factors, such as c- 
fos and c-jun, to promote the expression of genes that contain the AP-1 
response element in their promoter region, such as cyclin Dl, and the growth 
factor ligand IGF-1 (Kushner et al.,2000). The endpoint of oestrogen/ER 
signalling in breast cancer is expression of genes that can promote tumour cell 
proliferation and survival (McKenna et al., 1999; Kling, 2001; Dobrzycka et 
al., 2003).
In addition to nuclear ER, however, cytoplasmic ER and plasma membrane ER 
have also been found to be present at low levels in breast cancer cells (Losel et 
al., 2003). Interestingly, the membrane ER (probably identical to ERa) has 
experimentally been shown to be able to activate growth factor signalling 
pathways, such as the epidermal growth factor receptor (EGFR), where 
membrane ER has been linked to very rapid cellular responses to steroid 
hormone (Filardo et al., 2000; Levin, 2003; Gee et al., 2005). This crosstalk 
with growth factor receptors is reported to result in the downstream activation 
of mitogen activated protein kinase (MAPK) and serine/threonine protein 
kinase (Akt) signalling pathways, elements that in turn can activate nuclear ER 
by phosphorylation of the Seri 18 and Seri 67 residues present in the AF-1 
domain of the ER receptor to trigger gene transcription (Martin et al., 2000; 
Kato et al., 1995).
9
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1.2.3 Endocrine Therapy in Breast Cancer
The development of endocrine therapies to block the activation of ER 
signalling by steroid hormone, either by competitively inhibiting oestrogen 
binding to ER and depleting activity (and in some instances level) of the ER, or 
by depleting oestrogen in the body, has proven valuable in treating breast 
cancers that express ER and hence may use signalling via this receptor for their 
growth (ER+ disease). Tumours lacking the receptor (ER’) are inappropriate 
for endocrine treatment, being inherently resistant and thus to date suitable 
only for chemotherapy.
Tamoxifen was until recently the gold standard endocrine agent for the 
treatment or prevention of ER+ breast cancer (Fisher et al., 1998). Tamoxifen 
is a non-steroidal triphenylethylene derivative that acts by competitive 
blockade of the ER, and is hence an “anti oestrogen” (Figure 1.2) 
(Katzenellenbogen et al., 1995; Nicholson & Johnson, 2005). Tamoxifen 
competes with oestrogen for binding to ER, changing the receptor 
conformation and thus blocking AF2 function to limit subsequent ER-regulated 
gene expression. Proliferation can thus be substantially inhibited in ER+ breast 
cancer cells, resulting in a positive therapeutic response in -60% of ER+ breast 
cancer patients (Gee et al., 2005). However, ligand-independent AF-1 activity 
remains unchanged and in some tissues such as uterus and bone (where 
coactivator / kinase compliment is appropriate to allow constitutive AF-1 
phosphorylation and subsequent transcriptional activation), tamoxifen behaves
10
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as an agonist. Because of this mixed antagonist/agonist profile, tamoxifen has 
therefore been termed a selective ER modulator (SERM) (Santen et al., 2003).
Figure 1.2 Structure of the antioestrogens tamoxifen and faslodex
Tamoxifen
NMe.
HO ' (CH2)9SO(CH2)3CF2CF.
Faslodex
However, ~40% of ER* disease patients are intrinsically {de novo) resistant to 
tamoxifen, and moreover despite initial responses many more patients 
eventually progress on such treatment since their tumour cells acquire 
resistance to tamoxifen, despite their tumours commonly retaining ER 
(Katzenellenbogen et al., 1995). The requirement for a novel drug that would 
potentially improve the response rate in ER+ women by treating ER+ tamoxifen 
resistant breast cancer, while also avoiding unwanted agonist effects on the 
uterus, led to the synthesis of the steroidal ER antagonist fulvestrant, referred 
to in this report as faslodex (FAS) (Figure 1.2) (Dowsett et al., 2005; Nicholson 
& Johnson, 2005). Faslodex proved a more effective anti-oestrogen than 
tamoxifen in ER+ breast cancer cells (such as MCF-7 cells) in vitro. It has a 
higher affinity for ER with a binding affinity of 0.89, versus tamoxifen’s
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binding affinity of 0.025 (Wakeling et al., 1991; Osbome et al.,1995). Faslodex 
thus more effectively competes with oestrogen to bind to ER and prevents 
oestrogen signalling. Faslodex also radically alters the ER conformation, 
preventing receptor dimerisation and also blocking AF1 function as well as 
AF2 function, such that any FAS-ER complex formed that enters the nucleus 
is transcriptionally inactive (Dowsett et al., 2005). Critically however, 
faslodex also results in a reduction of ER protein level (and so has been termed 
a selective oestrogen receptor down-regulator or ‘SERD’), and in total 
therefore, there is very effective inhibition of oestrogen signalling with this 
agent (Robertson, 2001; Osbome et al., 2004). Moreover, unlike tamoxifen, 
faslodex is not associated with agonist activity but is a pure anti-oestrogen 
(Wakeling et al., 1991; Robertson et al., 2003; Dowsett et al., 2005). The agent 
can bring about responses in tamoxifen (or aromatase inhibitor -  see below) 
ER+ resistant disease clinically, and is thus approved in 2nd and 3rd line 
treatment in ER+breast cancer (Wakeling et al., 1991; Robertson et al., 2003; 
Dowsett et al., 2005). It is currently undergoing further trials to examine if it 
has potential in additional aspects of ER+ disease management (Wakeling et al., 
1991; Robertson et al., 2003; Dowsett et al., 2005).
Of further interest in the treatment of ER+ breast cancer is an alternative 
endocrine therapeutic approach, oestrogen deprivation, that is increasingly 
replacing tamoxifen as the gold standard postmenopausal endocrine approach. 
Synthesis of residual oestrogen from androgens persists in postmenopausal 
women through activation of the cytochrome P450 (CYP450) enzyme
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aromatase in peripheral tissues, where this enzyme is also found in some ER+ 
breast cancers (Nicholson & Johnston, 2005). Therefore, aromatase inhibitors, 
now having reached potent ‘third generation* agents such as the steroidal agent 
exemestane and the non-steroidal agent anastrozole (Nicholson & Johnston,
2005), have been developed to suppress aromatase activity in postmenopausal 
ER+ breast cancer patients, profoundly reducing oestrogen levels in the body 
and therefore depriving the ER+ breast cancer cells of their growth input (Smith 
& Dowsett, 2003). Such oestrogen deprivation is proving highly effective in 
treating ER+ postmenopausal breast cancer, without conferring unwanted 
uterine agonistic effects (Lonning & Kvinnsland, 1998; Lonning, 1999). Of 
note, in ER+ premenopausal breast cancer patients, oestrogen deprivation can 
also be effective, but in this instance by use of the Gonadotropin-releasing 
hormone 1 (GNRH1) agonist Zoladex that acts centrally to block 
hypothalamic/pituitary regulation of oestrogen synthesis by the ovaries during 
the menstrual cycle (Lonning & Kvinnsland, 1998; Lonning, 1999).
1.2.4 Resistance Acquired to Endocrine Therapy
Unfortunately, aromatase inhibitors have not been spared the phenomenon of 
acquired resistance (Lonning & Kvinnsland, 1998; Lonning, 1999), and groups 
including the Tenovus Centre for Cancer Research have previously identified, 
through use of in vitro models, that resistance is also acquired to treatment with 
faslodex, where clinical experiences confirm this phenomena also occurs 
during therapy (McClelland et al., 2001; Robertson, 2001). The exact 
mechanisms driving resistance to endocrine therapy and thus ER+ relapse
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during treatment remain elusive. Some tamoxifen resistant cells have been 
shown from experimental and clinical evidence to have acquired the ability to 
be stimulated, rather than inhibited, by tamoxifen after prolonged treatment 
(Legault-Poisson et al., 1979; Gottardis et al., 1988; Osbome et al., 1991; 
Osbome et al., 1994; Osbome et al., 1995). DeGregorio and colleagues found 
that treatment with tamoxifen suppressed tumour growth for several months; 
however, growth eventually resumed, stimulated by tamoxifen (Osbome et al., 
1991). Several early studies using breast cancer in vivo models explored 
potential mechanisms for resistant growth including altered hormone 
(tamoxifen) uptake, metabolism, and altered ER (Legault-Poisson et al., 1979; 
Gottardis et al., 1988; Osbome et al., 1994; Osbome & Fuqua, 1994; Wolf et 
al., 1994; Osbome et al., 1995), although in general none revealed mechanisms 
that proved clinically relevant.
More recently, increased understanding of growth factor pathways has 
highlighted the importance of such signalling, and its interplay with ER in 
driving growth of ER+ tamoxifen resistant cell lines. Deregulation of growth 
factor pathways and ER-growth factor receptor cross-talk is thought to be one 
of the determinants of tamoxifen resistance that can either be apparent at 
primary (de novo) ER+ resistance or be acquired by responsive ER+ breast 
cancer cells after varying durations of tamoxifen treatment (Nicholson et al., 
2004). Of particular relevance to tamoxifen resistance is increased EGFR / 
ErbB2 signaling. The ErbB family of the receptor tyrosine kinases (RTKs) 
comprises EGFR (ErbBl or HER1, a 175kDa protein), ErbB2 (HER2/Neu,
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185kDa protein), ErbB3 and ErbB4 (HER3, and HER4 respectively, 180- 
190kDa proteins) that play a key role in cell growth, proliferation, 
differentiation, and cell survival. The increased kinase signalling of such 
receptors, in particular EGFR and ErbB2, has been implicated in the 
development of some types of endocrine resistance, notably to antioestrogens 
in in vitro and in vivo models but also with emerging evidence in clinical de 
novo and acquired resistance to tamoxifen (Ullrich et al., 1984; Nicholson et 
al., 2001; Gee et al., 2003; Knowlden et al., 2003; Nicholson et al., 2004; Gee 
et al., 2005; Rhee et al., 2005). For example, increased EGFR and ErbB2 can 
clinically be associated with reduced anti-proliferative effect of tamoxifen in 
ER+ tumours (Dowsett et al., 2005), where in addition there is an established 
relationship between elevated EGFR and ER" disease (Nicholson et al., 2001). 
Increased levels of EGFR and ErbB2 have also been reported in the acquired 
TAMR in vitro tamoxifen resistant model from Knowlden and colleagues 
(2003), where such receptors can heterodimerise and become activated, 
triggering downstream kinases and tamoxifen resistant cell proliferation and 
survival, such cells also gaining invasive behaviour via additional increases in 
c-Src activity (Knowlden et al, 2003; Hiscox et al., 2004; Hiscox et al., 2006).
It is known from in vitro models, such as these acquired TAMR cells from 
Knowlden and colleagues (2003), that increased EGFR/ErbB2 signalling 
gained by such cells can crosstalk with ER to promote tamoxifen resistant 
growth. In this model, MAPK and Akt activity promoted by the increased 
upstream EGFR/ErbB2 activity augment the ligand-independent transactivation
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function of nuclear ERa in the presence of tamoxifen through their 
phosphorylation of Seri 67 and Seri 18 within the ERAF1 domain (Figure 1.3) 
(Masuhiro et al., 2005; Britton et al., 2006; Kim et al., 2006). This results in 
increased ER-regulated expression of growth factor ligands such as the EGFR 
ligand amphiregulin, which further drives elevated EGFR signalling, and also 
IGF production (Britton et al., 2006). The agonistic effect of TAM/ER can thus 
be further enhanced by increases in interplay with insulin like growth factor 
receptor (IGFR) signalling, which further facilitates EGFR activity via Src 
(Knowlden et al., 2003, 2005). Thus there is an autocrine growth regulatory 
pathway in the TAMR model since EGFR driven crosstalk with ER promotes 
ER-regulated growth factors that in turn facilitate EGFR/IGFR signalling that 
impact on ER despite the presence of tamoxifen. The resultant effect of this 
autocrine loop is increased proliferation in the presence of tamoxifen and hence 
resistant growth (Knowlden et al., 2003,2005).
The Tenovus Centre for Cancer Research has targeted EGFR in these TAMR 
cells using a selective EGFR tyrosine kinase inhibitor (TKI), gefitinib (Gee et 
al., 2003; Knowlden et al., 2003; Hiscox et al., 2004; Jones et al., 2004; Gee et 
al., 2005; Jones et al., 2005). This agent (as well as others targeting the 
downstream kinases, and also targeting of Src or ErbB2) promotes substantial 
inhibition of TAMR models, confirming the EGFR signalling loop is dominant 
in driving growth (Knowlden et al., 2003). Of note, there is also some 
contribution for increased EGFR in some FASR models in vitro, where EGFR 
signalling can again be increased (McClelland, et al., 2001).
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Figure 1.3 Increased EGFR and ER crosstalk in Tamoxifen resistant ER+ 
breast cancer cells in vitro.
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Moreover, altered growth factor signalling has also been implicated in ER+ 
breast cancer with acquired resistance to oestrogen deprivation, as evident by 
models such as the long term oestrogen deprived LTED models from Martin 
and colleagues (2003), and Santen and colleagues (2004), where increased 
ErbB2 and IGFR downstream kinase signalling have been implicated in 
nuclear ER crosstalk and also crosstalk with membrane ER to trigger resistant 
growth (Martin et al., 2003; Santen et al., 2004). Again growth inhibitory 
responses to anti-growth factor agents such as gefitinib, anti-IGFR, and also 
various kinase inhibitors (e.g. MAPK, PI3K/Akt pathways) can invariably be 
observed in these resistant models (Martin et al., 2003; Santen et al., 2004). 
These models are usually derived in the presence of serum growth factors that 
could feasibly force the resistance mechanism towards growth factor 
signalling. However, the Tenovus Centre for Cancer Research developed a 
new in vitro model, MCF-7X (referred to in this report as X-MCF), under 
conditions of severe oestrogen and growth factor depletion. Although not 
driven by classical growth factor receptors, again these acquired oestrogen 
deprivation resistant cells respond to PI3K/Akt blockade and there is kinase 
crosstalk with nuclear ER to drive their resistant growth (Staka et al., 2005).
Clearly, growth factor signalling can contribute to endocrine resistant growth 
and its targeting may be of therapeutic value, an area currently being explored 
through many clinical trials (Johnston, 2005). However, emerging clinical and 
experimental experience indicates that anti growth factor strategies will also 
not be spared the phenomenon of resistance, exemplified by studies with the
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EGFR-TKI gefitinib (Jones et al., 2004). By example, in the Tenovus Centre 
for Cancer Research, a model (NEW DUBS), of acquired resistance to gefitinib 
was successfully developed followed prolonged treatment of TAMR cells with 
this EGFR-TKI, despite initial tumour cell responsiveness. Furthermore, 
gefitinib resistance frequently occurs in the clinic in cancer patients (Jones et 
al., 2004). Again, in vitro gefitinib resistance can be promoted by further 
growth factor pathway deregulation, for example by increased IGFR receptor 
signalling in NEW DUBS where some growth inhibitory responses to anti- 
IGFR agents are consequently observed (Jones et al., 2004; Knowlden et al.,
2003). However, since resistance can again emerge after such STI treatment 
(Jones et al., 2004), it is clear that continued deciphering of the biology 
underlying these various acquired endocrine and anti-EGFR therapeutic 
resistant states remains essential to reveal new ways of improving treatment, 
particularly as studies in Tenovus Centre for Cancer Research have shown both 
endocrine and anti-EGFR resistance is associated with increased invasive 
capacity (Hiscox et al., 2004; Jones et al., 2004).
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1.3 Oxidative Stress
Commoner and colleagues first discovered the presence of highly reactive 
molecules, termed ‘free radicals', in biological materials just over 50 years ago 
(Commoner et al., 1954). Soon thereafter in 1956, Denham Harman 
hypothesized that these free radicals may be formed as by-products of enzymic 
reactions in vivo, namely from the mitochondria and termed ‘reactive oxygen 
species’ or ROS. He suggested that such free radicals, when excessive, might 
contribute to gross cellular damage, mutagenesis, cancer, and the degenerative 
process of biological aging (Harman, 1956; Harman, 1981). Numerous 
researchers have since linked dysregulation of redox homeostasis with over 
100 disease states. The main diseases identified include cancer, diabetes 
mellitus, hypoxia, atherosclerosis, neurodegenerative disease, ischemia / 
reperfusion injury, inflammatoiy dysfunction, and aging (Cai & Harrison, 
2000; Batandier et al., 2002). Imbalances in the redox homeostasis are now 
referred to as ‘oxidative stress’, and are known to be caused either by an 
increase in ROS produced by pro-oxidant mechanisms, or by insufficient 
endogenous antioxidants, which are produced by cells in response to oxidative 
stress in an attempt to quench ROS (Mathews et al., 2000; Lee et al., 2001). 
Any deregulated ROS can potentially cause damage to the cells own DNA, 
proteins, and essential fatty acids, leading to oxidative DNA damage and lipid 
peroxidation (Cai & Harrison, 2000; Batandier et al., 2002).
ROS can also influence the balance of cell proliferation, differentiation and cell 
survival or death (Eyries et al., 2004). While ROS is produced for the
20
Chapter 1 -  Introduction
phagocyte “oxygen burst reaction” as a normal host defence mechanism by the 
cell against invading microorganisms (Hensley et al., 2000; Suematsu, et al., 
2002), production of ROS also plays an important role in many biological 
processes such as modulating signal transduction pathways that may lead to the 
proliferation of cancer cells (Droge, 2002). Indeed, it was more recently found 
that human tumour cells (such as prostate cancer cells) have elevated levels of 
ROS, such as O2* and H2O2 (Kurdi & Booz, 2007; Lien et al., 2008). However, 
excessive ROS can cause cell death, exemplified by the impact of 
chemotherapy/radiotherapy, which in some instances exerts its anti-tumour 
effect via increasing ROS (Szatrowski & Nathan, 1991; Spitz et al., 1993; 
Toyokuni S, et al., 1994).
Of note, increased antioxidant levels occur within tumour cells in response to 
chemotherapy/radiotherapy, and interestingly, this may ultimately lead to 
resistance of tumour cells to these therapies whose mechanism relies on the 
induction of oxidative stress (Szatrowski & Nathan, 1991; Spitz et al., 1993; 
Toyokuni S, et al., 1994). Spitz and colleagues found that in such instances, 
tumour cells were found to have acquired resistance by up regulating their 
CAT and glutathione (GSH) antioxidant activity levels (Spitz et al., 1993; 
Suematsu et al., 2002). While largely unexplored, it is feasible that changes in 
redox balance may also be relevant to further therapeutic strategies and 
contribute to associated resistance.
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1.3.1 Pro-Oxidant Mechanisms of ROS Production
A key site of ROS production within the cell is the electron transport chain 
(ETC) in the mitochondria in living cells. Approximately 1 -  3 % of the total 
molecular oxygen (O2) consumed by the mitochondria is incompletely reduced 
leading to ROS production (Boveris et al., 1972; Boveris & Chance, 1973). 
ROS is formed as a result of “electron leakage” during mitochondrial 
respiration, where the primary radical superoxide anion (0 2 **) is generated by 
the addition of a single electron to an oxygen molecule (Boveris et al., 1972; 
Loschen et al., 1974; Chance et al., 1979; Babior, 1999; Cai & Harrison 2000). 
The transfer of a single free electron to molecular oxygen occurs at the level of 
NADH CoQ reductase (Complex I) and CoQ cytochrome C reductase 
(Complex III), generating O2’ and indirectly further potent oxidants such as 
H2O2 , OH* and peroxynitrite (OONO*) (Boveris et al., 1972; Loschen et al., 
1974; Chance et al., 1979; Cai & Harrison 2000).
Moreover, the addition of two electrons to molecular oxygen can form 
peroxide, which then undergoes protonation to yield the further oxidant H2O2 
(Ushio-Fukai et al., 1998). H2O2 is not a free radical; however it is still a ROS 
and a detrimental oxidant that through a variety of mechanisms, including the 
Haber-Weiss reaction (Figure 1.4), can produce a very short lived and reactive 
form of oxygen named singlet oxygen (*6 2 ) (Zalba et al., 2001).
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Haber-Weiss reaction:
h 2o 2 + o 2’— o h '  + o h + ' o 2 (1 )
The addition of a third electron to molecular oxygen can yield a further 
oxidant, OH*, through the Fenton reaction shown below (Toufektsian et al., 
2001). The majority of OH’ formed in vivo can lead to inflammation, and 
comes from the metal-catalysed breakdown of hydrogen peroxide according to 
this reaction (Figure 1.4).
Fenton reaction:
M1* + H20 2 — M(n+1>* + OH* + OH* (2)
Here, M"* is a transition metal ion, and in vivo production of OH* through the 
Fenton reaction is most common when Mn+ is iron or copper, chromium, 
cobalt, or other metals (Platenik et al., 2001; Liochev & Fridovich, 2002). OH’ 
generated by iron catalysis of H20 2 (from tissue ferritin) reacts with biological 
targets at 109 M' 1 Sec*1, making it more reactive than other free radicals such as 
0 2* (rate constant 2.9 x 109 M' 1 Sec'1) (Biemond et al., 1986; Toufektsian et al., 
2001).
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ROS formation can also be achieved within the cell through enzyme systems 
such as nitric oxide synthase (NOS), cytochrome P450s, xanthine, amino acid, 
and NADH / NAD(P)H oxidases, arachidonic acid pathway enzymes, 
cyclooxygenase, as well as through exposure to cytokines and growth factor 
signalling (Babior, 1999; Sakai et al., 2003; Eyries et al., 2004). For example, 
Nitric oxide (NO*), a reactive nitrogen species (RNS), is synthesised from O2 
by NOSs that can be membrane associated endothelial NOS (eNOS), inducible 
NOS (iNOS), or cytosolic neuronal NOS (nNOS), where NOS function 
requires the co-factors L-arginine or 6 (R)-tetrahydro-L-biopterin (BH4) (Figure 
1.4) (Xiong et al., 2005). NO’ regulates the function of the endothelium 
(Oberley & Oberley, 1997), along with other useful biological activities that 
include inhibition of platelet and leukocyte activation, attenuation of smooth 
muscle cell proliferation, and vasorelaxation depending on soluble guanylate 
cyclase (Auch-Schwelk et al., 1992). However, in the absence of the co-factors 
L-arginine and BH4 , NO* can be very detrimental as eNOS can become 
uncoupled and produce O2’ resulting in H2O2 production. The ROS free radical 
O2’ can also readily react with NO’ to form further RNS OONO* (Figure 1.4) 
(Beckman et al., 1990; Subbarao & Richardson, 1990). Interestingly, growth 
factor signalling has also been documented to be able to promote ROS. For 
example, activated EGFR can facilitate the formation of ROS via its well 
documented Ras/Rac pathway (Figure 1.5) (Rao, 1996). In addition to enzyme 
and growth factor mechanisms, exogenous inducers of ROS also exist and can 
be used to treat tumour cells, including chemotherapy and radiotherapy 
(Tokoyuni et al., 1995; La Torre et al., 1997).
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Figure 1.4 General overview of oxidative stress pathw ays
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O2* (and other ROS in red) produced either by NADPH oxidase or free in the 
cytosol can be dismutised by the antioxidant SOD to form O2 and H2O2. O2 is 
converted to NO’ through NOS in the presence o f  cofactor L-arginine, and can 
react with O2’ to form OONO*. H2O2 generates the very reactive OH* through 
the Fenton reaction, or *02 in conjugation with O2’ by the Haber-Weiss 
reaction. Further antioxidants (green), such as enzymatic antioxidants CAT and 
GPX are shown here to be able to convert ‘key player’ H2O2 into H2O and O2, 
or H2O2 can be quenched as shown by non-enzymatic antioxidants such as 
GSH, TXN, and PRDX that trap H2O2 before it can enter the Fenton or Haber- 
W eiss reactions. Any unquenched ROS can activate events such as Lipid 
peroxidation, DNA damage and cell death, but also triggers growth promoting 
signalling pathways by activating tyrosine kinases such as EGFR as well as 
carcinogenic events.
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Figure 1.5 EGFR induced generation of ROS and its potential cellular 
consequences.
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EGFR is activated either by its family o f  EGF-like ligands or at its 1173 
autophosphorylation site by H2O2 resulting in the RAS/RAC pathway as 
shown. O2* produced as a result o f  subsequently activated NADPH oxidase 
promotes further ROS, as shown in Figure 1.4. ROS (red) can go on to have 
detrimental effects on cellular components through activation o f  tyrosine 
kinases, lipid peroxidation (resulting in the production o f  further reactive 
species HNE and MDA) and DNA damage, also potentially further promoting 
signalling through growth factor pathways (including back onto EGFR 
signalling via H2O2) to impact on proliferation and cell survival.
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1.3.2 Downstream Cellular Effects of Oxidative Stress
In the presence of increased oxidative stress (for example, where antioxidants 
are insufficient at quenching the free radicals), formation of cellular ROS can 
go on to initiate cell death by lipid peroxidation in cells (Biemond et al., 1986). 
ROS can also react with all components of the DNA molecule, damaging 
purine and pyrimidine bases along with the deoxyribose backbone that in 
excess can also lead to cell death (Figure 1.4) (Dizdaroglu et al., 2002). 
Increases of oxidised DNA damage in living systems may thus be due to an 
increase in the steady state level of ROS, and/or to a decrease in the antioxidant 
capacity of the cell (Brown & Borutaite, 2001). In addition to ROS, RNS such 
as NO* and OONO* have also been implicated in both lipid peroxidation and 
DNA damage (Brown & Borutaite, 2001), where the RNS OONO’is reported 
to also induce lipid peroxidation and initiate single stranded breakage of DNA 
(Figure 1.4) (Backman et al., 1990; Subbarao & Richardson, 1990). However, 
in addition to the events that can promote cell death, ROS can influence 
signalling pathways in cells that impact on cell proliferation and cell survival, 
as well as mutagenic events, leading to cancer formation (Yang et al., 2003).
1.3,2.1 Lipid Peroxidation
Lipid peroxidation involves three main stages of initiation, propagation and 
termination in a chain reaction, commonly initiated by the ROS OH’ (Pinchuk 
et al., 1998; Mathews et al., 2000; Nyska & Kohen, 2002). Lipid radicals 
produced by lipid peroxidation have a myriad of adverse effects on cellular 
function including alteration in ion channel configuration and hence altered ion
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flux, leakage of plasmalemma, and membrane bound receptor dysfunction all 
implicated in cell death (Cai & Harrison, 2000; Nelson et al., 2005). Fatty 
acids in membrane lipids are oxidised by OH* in the first instance to generate 
further radicals such as fatty acid peroxyl radical (R-COO*) (Mathews et al., 
2000). Once formed, R-COO* is rearranged by a cyclisation reaction to form 
endoperoxides that are precursors of malondialdehyde (MDA) that can be 
mutagenic and carcinogenic (Mamett, 1999). This is thus an example of one 
way in which excess ROS can also promote cancer.
R-COO’ can initiate a further peroxidation reaction by attacking adjacent fatty 
acid side chains (Herbst et al., 1999). These lipid peroxidation chain reaction 
mechanisms can go on for some time following initiation, resulting in the 
accumulation of fatty acid hydroperoxides and phospholipid hydroperoxides 
(Herbst et al., 1999; Yang et al., 2003; Nelson et al., 2005). Fatty acid carbon 
chains are also cleaved during lipid peroxidation yielding highly reactive 
compounds including exocyclic DNA adducts, pentane radical, ethane radical, 
and a,p-unsaturated aldehydes such as 4-hydroxy-2-nonenal (HNE) (Yang et 
al., 2003). HNE is thus found at high levels in biological membranes under 
oxidative stress (Yang et al., 2003). HNE is weakly mutagenic and has the 
same triggering effects on EGFR signalling as H2O2 , therefore having the 
potential to influence signal transduction pathways that have major effects on 
the phenotypic characteristics of cells and cancer growth as shown in Figures 
1.4 and 1.5 (see below, section 1.3.2.3) (Yang et al., 2003).
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13.2.2 Oxidative DNA Damage
Oxidative DNA damage that can also be a consequence of ROS is the first step 
involved in mutagenesis and carcinogenesis. Over 100 products have been 
identified from the oxidation of DNA to date, resulting from ROS-induced 
single- or double-stranded DNA breaks, DNA cross-links, purine, pyrimidine, 
and deoxyribose modifications (Mamett, 2000; Cooke et al., 2003). Oxidative 
DNA damage can result in induction of signal transduction pathways, either 
causing arrest or induction of transcription, replication errors and genomic 
instability, which are all associated with carcinogenesis (Mamett, 2000; Cooke 
et al., 2003). ROS-induced lipid peroxidation products such as MDA can also 
have detrimental effects on cells as it can react with DNA bases G, C, and A to 
form adducts MiG, MiC, and Mi A respectively (Mamett, 1999). MiG adducts, 
for example, have been detected in breast cancer tissue using P-post-labeling, 
at levels up to 1 . 2  adducts per 1 0 6 nucleotides, which corresponds 
approximately to 6000 adducts per cell (Wang et al., 1996).
Besides the effects lipid peroxidation products have on DNA, ROS can also 
directly affect DNA in the form of the very reactive OH* that can be 
incorporated into the double bonds of DNA bases (Dizdaroglu et al., 2002). 
OH* can abstract a hydrogen atom from the methyl group of thymine, along 
with five carbon atoms of 2’ deoxyribose (Dizdaroglu et al., 2002). An 
additional reaction generates OH-adduct radicals of DNA bases, and the allylic 
radical 8 -hydroxyguanine (8 -OH-G/8 -oxo-G) is derived from thymine and 
carbon-centred sugar radicals through abstraction reactions (Figure 1.6)
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(Mathews et al., 2000; Dizdaroglu et al., 2002). 8 -oxo-G is a biomarker of 
oxidative stress, and as such is perceived as a potential biomarker of 
carcinogenesis (Halliwell & Gutteridge, 1999).
Figure 1.6 Reaction of guanine with OH*.
OH oxidation
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guanine (G) OH-adduct radical 
of guanine
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1.3.2.3 Activation o f  Signalling Path ways
Autophosphorylation or ligand-independent phosphorylation of a number of 
RTKs, including the EGFR family, is known to be enhanced by the pro-oxidant 
H2O2 (Figures 1.4 and 1.5) (King et al., 1989; Knebel et al., 1996; Rao, 1996). 
Indeed, chronic levels of H2O2 can alter gene expression and act as intracellular 
second messenger to activate a wide range of intracellular signalling proteins 
and nuclear transcription factors such as AP-1 (see comprehensive list in 
Appendix I) (Zalba et al., 2001). H2O2 is thought to inactivate phosphatases 
through oxidation of the cysteine active site. It is also considered to activate 
protein kinases by cysteine oxidation, although the exact mechanism by which 
kinase activation by ROS occurs remains elusive (Rhee et al., 2003). H2O2 also 
produced from eNOS uncoupling can also subsequently interact with signal
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transduction pathways (Heinzel et al., 1992; Pou et al., 1992; Vesquez-Vivar et 
al., 1998; Eyries et al., 2004). It has also been documented that under certain 
conditions H2O2 can stimulate the proliferation response via activation of the 
mitogen-activated protein kinase (MAPK) pathway (Ushio-Fukai et al., 1998). 
ROS thus has potential to stimulate growth of cells, assuming cells are able to 
defend sufficiently against the initial assault of excess ROS that could result in 
cell death (Ushio-Fukai et al., 1998).
1.3.3 Antioxidants
Nuclear factor-erythroid-2-related factor 2 (Nrf2) is a basic leucine zipper 
transcription factor and a key element in the transcriptional activation of genes 
encoding both enzymatic and non-enzymatic antioxidants in response to ROS. 
Nrf2 thus plays an essential role in the redox balance of the cell. Under normal 
physiological conditions, it forms an inactive cytoplasmic complex with a 
negative regulator Kelch-like ECH-associated protein 1 (Keapl) that is found 
in the actin cytoskeleton (Zhang et al., 2004; Zhang et al., 2005). Keapl 
controls the subcellular localization and steady state levels of Nrf2 via its 
cysteine residues that act like redox “sensors”. Oxidation of these highly 
reactive cysteine residues under conditions of ROS results in dissociation of 
Nrf2 from Keapl and subsequent nuclear translocation of Nrf2, where it then 
transactivates Antioxidant Response Element (ARE) -  regulated genes (Lee & 
Surh, 2005; Eggler et al., 2008). This occurs following its heterodimeric 
combination with other transcription factors such as small Maf protein, and 
binding to the 5 -upstream cis-acting regulatory sequence, referred to as the
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ARE, located in the promoter region of genes encoding various enzymatic and 
non-enzymatic antioxidant (Itoh et al., 1997). Stress responsive and 
cytoprotective enzymes induced by this mechanism are diverse, including 
SOD, CAT, GPX, TXN, NAD(P)H dehydrogenase, quinine 1 (NQOl), 
Glutathione S-transferase (GST), and heme oxygenase-1 (HO-1) (Chen & 
Kong, 2004; Motohashi & Yamamoto, 2004; Lee & Surh, 2005; Dinkova- 
Kostova & Talalay, 2008; Eggler et al., 2008). Such enzymatic and non- 
enzymatic antioxidants can subsequently go on to quench ROS in the cell to 
limit its diverse, potentially adverse effects (Chen & Kong, 2004; Motohashi & 
Yamamoto, 2004; Lee & Surh, 2005; Dinkova-Kostova & Talalay, 2008; 
Eggler et al., 2008).
1.33.1 Enzymatic Antioxidants
1.3.3.1.1 Superoxide Dismutase (SOD)
SOD is one of the most important intracellular enzymatic antioxidants and is 
the first line of defence induced against ROS. Although this enzyme had been 
isolated in as early as 1939, McCord and Fridovich were the first to discover its 
antioxidant activity and synthesised SOD in 1969. There are three forms of 
SOD in humans: cytosolic Cu/Zn-SOD, mitochondrial Mn-SOD, and 
extracellular SOD (EC-SOD) (Mates et al., 1999; Landis & Tower, 2005). 
More recently, a new class of SOD has been discovered in Streptomyces and 
cyanobacteria containing Nickel (Ni); however, Ni-SOD does not have any 
sequence homology to other SODs (Barondeau et al., 2004). All SODs belong 
to a family of metalloenzymes that catalyse dismutasion reactions, where two
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identical molecules have different fates, as one is oxidised and one is reduced 
(Mathews et al., 2000). SOD thus facilitates the formation of O2 and the less 
reactive ROS H2O2 from the dismutation of the more reactive ROS O2’, at a 
very high reaction rate (Figure 1.4) (McCord & Fridovich, 1969; Kirkman & 
Gaetani, 1984; de Hann, 2004). Below is a typical antioxidant reaction of 
Cu/Zn-SOD:
Cu2+-SOD + 0 2‘ -> Cul+-SOD + 0 2 
Cu,+-SOD + O2" + 2H* -» Cu2+-SOD + H20 2 (3)
The H2O2 generated by total SOD (intracellular Cu/Zn-SOD and Mn-SOD) is 
then further catalysed into water by the further antioxidant enzymes CAT and 
GPX (see below, Kirkman & Gaetani, 1984; de Hann, 2004), thus decreasing 
excess ROS (Figure 1.4). MnSOD has received growing attention as a 
negative modulator of cellular apoptosis and as a survival factor for cancer 
cells by limiting cell death effects of ROS (Housset, 1987; Pani et al., 2004). 
Overexpression of MnSOD found in tumours (at even small amounts) can 
confer resistance to chemotherapy and prevent apoptosis (Housset, 1987; Pani 
et al., 2004). It has therefore been suggested that pharmacological inhibition of 
MnSOD could possibly be an effective strategy to selectively kill cancer cells 
and to circumvent their resistance to chemotherapy (Housset, 1987; Pani et al.,
2004).
33
Chapter 1 -  Introduction
SOD is also of interest in the context of endocrine therapy; interestingly, a 
number of studies have shown that tamoxifen can have an effect on the 
intracellular redox state of the cell, acting as either a pro-oxidant or antioxidant 
depending on the microenvironment of the cell (Nuwaysir et al., 1998; Wei et 
al., 1998; Day et al., 1999). For example, tamoxifen can in some systems be 
activated into reactive electrophilic metabolites causing oxidative stress. 
However, tamoxifen can also protect against lipid peroxidation, and DNA 
damage by inducing phase 1 and II metabolising antioxidant enzymes 
(Nuwaysir et al., 1998; Wei et al., 1998). In 2000, Schiff and colleagues 
investigated growth of an in vivo model of tamoxifen resistance and began to 
explore its association with oxidative stress. They concluded that the 
antioxidant enzyme SOD, and also GST (see below), were significantly up 
regulated in TAMR cells compared to tamoxifen sensitive cells, where ROS 
activation of the AP-1 signalling pathway was also suggested to play a role in 
resistant growth (Schiff et al., 2000).
1.3.3.1.2 Catalase (CA T)
As stated above, the enzyme CAT efficiently promotes the conversion of H2O2 
to water and O2 (Valko et al., 2006), thus reducing ROS levels (figure 1.4).
CAT
2H20 2 ----- ► 2H20  + 0 2 (4)
The significant decrease in the ability of a variety of tumour types to detoxify 
H2O2 has in some instances been linked to a decrease in CAT levels (Valko et
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al., 2006). However, tumour cells were also found to acquire resistance by up 
regulating their CAT activity when exposed to cisplatin in vivo (Spitz et al., 
1993; Suematsu et al., 2002). Interestingly, this resulted in resistance of 
tumour cells to several therapies whose mechanism involves the induction of 
oxidative stress, including chemotherapeutics and radiotherapy (Housset, 1987; 
Szatrowski & Nathan, 1991; Spitz et al., 1993; Toyokuni S, et al., 1994).
1.3.3.1.3 Glutathione Peroxidase (GPX)
The GPX family of peroxidases compete with CAT to scavenge H2O2 as a 
substrate (figure 1.4). GPX is interesting in that it contains an unusual amino 
acid, selenocysteine, an analogue of cysteine (Mathews et al., 2000). There are 
two forms of the GPX enzyme, one of which is the selenium-independent GST, 
and the other selenium-dependent GPX (Mates et al., 1999). There are four 
different selenium-dependent GPXs, all of which add two electrons to 
peroxides forming selenoles (Se-OH) in order to reduce them (Mates et al., 
1999; Valko et al., 2006). These selenoenzymes can therefore neutralise 
peroxides and prevent them from entering the Fenton reaction, thus depleting 
cellular ROS. GPX also works in conjunction with the non-enzymatic 
antioxidant glutathione (GSH) to reduce its substrate H2O2 in the following 
reaction referred to as the glutathione cycle:
GPX
2GSH + H20 2 -----► GSSG + 2 H20  (5)
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GPX thus reduces peroxides to water whilst simultaneously oxidising GSH to 
GSSG (Valko et al., 2006). It remains elusive as to whether these antioxidant 
enzymes play any role in therapeutic resistant states.
1.33.2 Non-Enzymatic Antioxidants
133.2 .1  Thiol Antioxidants -  Glutathione (GSH) Network 
GSH is a multifunctional thiol antioxidant, and it is one of the most important 
of the non-enzymatic antioxidants. GSH is highly soluble and exists 
abundantly in the cytosol (1-11 mM), nuclei (3-15 mM), and mitochondria (5- 
11 mM) (Masella et al., 2005). GSH is able to regenerate further antioxidants 
(e.g. Vitamins C and E) and also acts as a cofactor for several detoxifying 
enzymes that can quench oxidative stress, including glutathione-S-transferase 
A4 (GSTA4), glutathione-S-transferase theta 2 (GSTT2), and (as described 
above) GPX family members. GSH can directly scavenge OH’ and * 0 2  as well 
as detoxifying H2O2 by the catalytic effects of GPX (Masella et al., 2005), and 
is able to acquire resistance to chemotherapy through detoxification pathways 
involving a further enzymatic antioxidant NQOl (Cheng et al., 2009).
Tumour cells have again been reported to be able to acquire resistance to 
chemotherapeutics and radiotherapy by up regulating their GSH activity levels, 
which in turn increases cellular GST and GPX enzyme levels (Housset, 1987; 
Szatrowski & Nathan, 1991; Spitz et al., 1993; Toyokuni S, et al., 1994; 
Suematsu et al., 2002). This is reported to be achieved by the ability of GSH to 
replenish other such antioxidants at the protein level, thus resulting in the
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restoration of their function. This process is termed an “antioxidant network” 
(Sies et al., 2005). The capacity for one antioxidant to regenerate another is 
due to the redox potential of the [Redox/Ox] couple (Valko et al., 2006). Two 
molecules of GSH comprise the reduced form of a major thiol-disulphite redox 
“buffer” that once oxidised forms glutathione disulphite (GSSG) (Figure 1.7). 
The GSH capacity to regenerate other antioxidants is reliant on the redox state 
of this 2GSH/GSSG couple (Jones et al., 2000; Masella et al., 2005). Nuclear 
GSH also maintains the redox state of critical protein sulphydryls that are 
necessary for DNA repair and gene expression. ROS can lead to rapid 
modification of protein sulphydryls (protein-SH), where one electron oxidation 
can yield thiyl radicals (protein-S*), and two electron oxidation can yield 
sulphenic acid (protein-OSH) (Ji et al., 1999). In the absence of GSH, further 
oxidation of protein sulphydryls by ROS would lead to the formation of other 
irreversible oxidised forms including sulphinic (protein-S0 2 H), and sulphonic 
(protein-SOjH) acids therefore leading to cell death by DNA damage (Ji et al., 
1999).
However, GSH reacts with the ROS-promoted thiyl radicals and sulphenic acid 
to form S-glutathiolated proteins (protein-SSG) that are further reduced in the 
glutathione cycle (Equation 5) by glutathione reductase (GLRX) and small 
antioxidant proteins such as thioredoxin in order to restore protein sulphydryls 
(protein-SH) and thus maintain cell viability (Ji et al., 1999).
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Figure 1.7 Structures of reduced (GSH) and oxidised (GSSG) 
glutathione.
-o.
SH
- O
- O
glutamate cysteine glycine
GSH GSSG
GSH homeostasis has been linked to a number of disease states including 
breast cancer (Townsend 2003). Depletion of GSH is known to facilitate 
apoptosis, whereas elevated levels of GSH have been shown to promote cell 
survival (Anderson et al., 1999; Hammond et al., 2001). Interestingly, Craig 
Jordan’s team have shown that their endocrine resistant cell line, MCF-7:2A, 
had elevated levels of GSH (Lewis-Wambi et al., 2009). This promoted 
survival against oestradiol-induced apoptosis. However with the aid of L- 
Buthionine sulfoximine (BSO), a synthetic GSH biosynthesis inhibitor, 
oestradiol-induced apoptosis sensitivity was regained linking GSH clearly with 
endocrine resistant growth in this model (Lewis-Wambi et al., 2009).
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1.3.3.2.2 Thiol Antioxidants -  Thioredoxin (TXN)
TXN is a 12kDa disulphide-containing redox protein, having two redox active 
cysteine residues within a conserved active site (Cys-Gly-Pro-Cys) (Nakanura 
et al., 1997). In its reduced form, TXN contains two adjacent -SH groups that 
once oxidised through redox reactions with proteins are converted to disulphide 
units (Figure 1.8) as follows:
TXN-(SH) 2 + protein-S2 — TXN-S2 + protein-(SH) 2 (7)
TXN can therefore quench the oxidative effects of ROS at the protein level.
Figure 1.8 Reduced and oxidised TXN
SH HS
oxidised TXNreduced TXN
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TXN is restored to its reduced antioxidant form by the catalysis of thioredoxin 
reductase (TXNRD). The source of electrons in this TXN-replenishing 
reaction is NADPH.
TXNRD-S2 + NADPH + H+ —► TXNRD-(SH) 2 + NADP+
TXN-S2 + TXNRD-(SH) 2 -> TXN-(SH) 2 + TXNRD-S2 (8 )
Significant experimental and clinical evidence exists connecting TXN to 
cancer, indicating elevated levels of TXN occur in some forms of cancer such 
as cervical carcinoma, hepatoma, gastric tumours, colorectal and lung 
carcinomas (Sinha et al., 1998; Grogan et al., 2000; Raffel et al., 2003; Hedley 
et al., 2004; Ding et al., 2004; Csiki et al., 2006). Overexpression of TXN has 
been shown to defend cells from pro-oxidant induced apoptosis and thus 
promotes cell survival as well as a growth advantage to tumours (such as in 
colorectal and gastric carcinoma) (Grogan et al., 2000; Raffel et al., 2003). It 
has also again been suggested that an increase in TXN expression in human 
tumours may cause resistance to radiotherapy and to chemotherapeutics that 
induce ROS, such as doxorubicin, cisplatin, mitomycin C, and etoposide 
(Yokomizo et al., 1995; Sinha et al., 1998; Gorgan et al., 2000; Hedley et al., 
2004; Ahmadi et al., 2006). Interestingly, Kim and colleagues have reported 
elevated levels of TXN and PRDX1 (see below) in their acquired tamoxifen 
resistant cells in comparison to control MCF7 cells. They also related this 
increased antioxidant expression to Nrf2/ARE regulation of growth of these 
particular resistant cells (Kim et al., 2008).
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1.3.3.2.3 Peroxiredoxins (PRDX) and their interplay with TXN 
PRDX are a novel group of 25k Da peroxidases containing high antioxidant 
efficiency for peroxides. The mammalian PRDX family has six distinct 
members, PRDX 1-6, which are located in various subcellular locations, such as 
peroxisomes and mitochondria, where oxidative stress is most evident (Noh et 
al., 2001; Karihtala et al., 2003). The non-enzymatic antioxidant TXN acts as 
an electron donor to PRDX, further replenishing its reducing ability for 
peroxides. Thus the redox cycles of TXN and PRDX again form a further 
antioxidant network (Kang et al., 1998; Seo et al., 2000). Karihtala and 
colleagues have found that the expression of PRDX3, 4, and 5 are increased in 
breast malignancy, suggesting the induction of PRDX can occur in response to 
increased production of reactive oxygen species in proliferative carcinoma 
tissue (Ksrihtala et al., 2003).
In addition, PRDX2 is involved in the cellular response to ionizing radiation, 
where it functions to reduce intracellular ROS levels. Interestingly increases in 
PRDX2 resulted in increased resistance of MCF-7 cells to ionizing radiation 
(Wang et al., 2005). A further interesting study comes from Kato and 
colleagues (2005) whereby nearly 50% of patients in a study of 70 patients 
with primary breast cancer or locally recurrent breast cancer (tumor size > 3 cm) 
treated with the chemotherapeutic agent docetaxel failed to respond to 
chemotherapy (Iwao-Koizumi et al., 2005). Kato’s group performed gene 
expression profiling of breast cancer samples to see if a signature could be 
determined that was predictive of a patients’ response/failure to docetaxel.
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Interestingly, they discovered elevated expression of genes controlling the 
cellular redox environment, including PRDX1, TXN and also GST. 
Overexpression of these genes was also able to protect MCF-7 cells from 
docetaxel-induced cell death, suggesting an important role for PRDX/TXN and 
GSH networks in docetaxel resistance (Iwao-Koizumi et al., 2005). These 
results further highlight that a molecular mechanism of chemotherapeutic 
resistance can involve elevation of antioxidant genes.
1.4 Hypothesis and Aims
While there is substantial evidence for a contribution in chemotherapy / 
radiotherapy resistance, and some tentative tamoxifen resistance data as 
described above, it remains largely unexplored as to whether endocrine or anti- 
EGFR agent resistance is associated with changes in redox balance, whereby 
pro-oxidants might play a role in regulating cell growth and death, and in turn 
whether alterations in antioxidants might actively contribute to cell survival 
and as such resistant growth. The initial phase of the investigation for the first 
time therefore aimed to monitor any increased expression in key antioxidants in 
these diverse acquired resistant states in vitro.
These studies examining whether key components that can underlie redox 
balance are altered in acquired resistance, and hence might potentially contribe 
to growth regulation of this state, will employ a panel of in vitro human breast 
cancer models previously-derived in the Tenovus Centre. These cells have 
acquired resistance either to (i) the anti-oestrogens tamoxifen (TAMR cells) or
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faslodex (FASR cells), (ii) to severe oestrogen deprivation (X-MCF cells); or 
(iii) to tamoxifen and subsequently the EGFR inhibitor gefitinib (NEW 
DUBS), where these cells will be compared with their endocrine responsive 
parental cell line w/t MCF7.
The proposed exploration of antioxidants will be achieved through Microarray 
analysis and PCR studies of gene expression, as well as through biochemical 
monitoring of total antioxidant capacity, examining if increases are a feature of 
these acquired resistant models and if any changes identified span multiple 
forms of acquired resistance. Further studies will address if the antioxidants are 
oestrogen-regulated and influenced by initial treatment with antioestrogens in 
endocrine responsive cells, or if any changes observed occur only at the time of 
resistant growth. In addition, the relationship of antioxidants to EGFR 
signalling, a known growth promoting pathway for tamoxifen resistant models, 
will be examined in the resistant cells. These various studies of antioxidants 
will be paralleled by further studies of the redox balance in resistance by 
monitoring ROS level within the acquired resistant models, as well as during 
treatment with antihormones or EGFR pathway inhibition.
If deregulation of antioxidants/ROS is encountered in the acquired endocrine or 
anti-EGFR resistant cells, the following will be performed to further ascertain 
growth relevance of the alterations in redox balance to resistant cells:
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• In the case of elevated levels of antioxidants apparent in the resistant 
models, the impact of inhibitors of the antioxidants of interest will be 
examined, where possible, using a pharmacological approach.
• In the case of deregulated ROS, pro-oxidant level will be manipulated 
to see how further increases impact on resistant cells, addressing if this 
excess is able to overcome the level of antioxidants present and hence 
can be growth inhibitory to resistant cells.
It is hoped that this approach will, for the first time, detail if changes in redox 
balance (including antioxidants) contribute to acquired resistance to diverse 
endocrine agents and also anti-EGFR inhibition in breast cancer, and thus that 
its manipulation could potentially provide new therapeutic avenues to treat 
these various undesirable states.
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2.1 Cell Culture studies
2.1.1 Materials
2.1.1.1 Cell culture reagents and Plasticware
Plasticware including T-25 flasks, T-75 flasks and 96 well plates were 
purchased from Nunc, Roskilde, Denmark, and were supplied by Fisher 
Scientific UK Ltd., Loughborough, Leicestershire, UK. All other components 
required for cell culture including: RPMI 1640 and phenol-red-free RPMI1640 
media, antibiotics (penicillin/streptomycin), Fungizone, L-glutamine and 
Foetal calf serum (FCS) were obtained from Invitrogen Ltd., Paisley, Scotland, 
UK., unless otherwise stated. Activated Charcoal and Tris HCL were 
purchased from Sigma-Aldrich Company Ltd, Poole, Dorset UK. Isoton® II 
azide free balanced electrolyte solution (containing sodium chloride at 7.9g, 
disodium hydrogen orthophosphate at 1.9g., Ethyl diamine tetraacetic acid 
(EDTA) disodium salt at 0.4g., sodium dihydrogen orthophosphate at 0.2g. and 
sodium fluoride at 0.3g.) was purchased from Beckman Coulter Ltd, High 
Wycombe, UK. Eppendorf tubes were purchased from Eppendorf, Hamburg, 
Germany. Micro-centrifuge tubes (0.5ml and 1.5ml) were purchased from 
Elkay Laboratory Products, Basingstoke UK. Bijou tubes were purchased from 
Bibby Sterilin Ltd., Stone, UK. Sterile, disposable serological pipettes (5ml, 
10ml, and 25ml), Falcon tubes (50ml), Coulter Counter lids and caps were 
purchased from Sarstedt AG and Co., Niimbrecht, Germany.
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2.1.1.2 Cell lines, anti-oestrogens, signal transduction inhibitors, and 
drugs impacting on oxidative stress
The wild type (w/t) MCF-7 human breast cancer cell line was originally 
obtained from AstraZeneca Pharmaceuticals, Cheshire, UK. The SERM 4- 
hydroxy-tamoxifen (4-OH-TAM, which is used clinically), referred to as 
tamoxifen in this investigation, was purchased from Sigma-Aldrich Company 
Ltd, Poole, Dorset UK. The pure antioestrogen faslodex, the EGFR Tyrosine 
Kinase Inhibitor (TKI) gefitinib, and the Src kinase inhibitor AZD0530 were 
obtained as gifts from AstraZeneca Pharmaceuticals, Cheshire, UK. The 
oxidative stress-inducer Menadione-Sodium-Bisulfite (MSB), a selective 
inhibitor of GSH synthesis Buthionine Sulphoximine (BSO), the PI3K- 
inhibitor inhibitor Wortmannin (WORT), the NFkB inhibitor Parthenolide 
(PARTH) and the MEK inhibitor U0126 were again obtained from Sigma- 
Aldrich Company Ltd, Poole, Dorset UK.
2.1.1.3 Reagents used fo r MTT growth assays
The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay kit, Phosphate Buffer Solution (PBS) and Triton X-100 used for the 
detection of cellular growth response to different treatments in this study were 
purchased from Sigma-Aldrich Company Ltd, Poole, Dorset UK.
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2.1.1.4 Reagents used fo r  TAC analysis
Total Antioxidant Assay kits was purchased from Sigma-Aldrich Company 
Ltd, Poole, Dorset UK. The antioxidant assay kit contained 30ml of lOx 
concentrated Assay Buffer, 20ml Stop solution, 2 x lmg Myoglobin stock from 
horse heart, 2 x lmg 6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic 
acid (Trolox), 4 x lOmg tablets of 2,2’-azino-bis(3-ethylbenzthiazoline-6- 
sulfonic acid) (ABTS), 4 x phosphate-citrate Buffer tablets at pH 5 and 1ml of 
H2O2 (3%) solution. The kit was sufficient for 200 assays in 96 well plates.
2.1.1.5 Reagents and plasticware used fo r  ROS detection
All reagents for ROS detection analysis including the stock solutions of 2’-7’- 
dihydrodichlorofluorescein diacetate (H2DCFDA) fluorescent dye, and 
delivery agent Dimethyl Sulfoxide (DMSO) were again purchased from 
Sigma-Aldrich Company Ltd, Poole, Dorset UK unless otherwise stated. The 
ROS-inducing internal control, H2O2, and Trypsin used for lysing cells in the 
assay were also purchased from Sigma-Aldrich Company Ltd, Poole, Dorset 
UK. Due to light sensitivity of the fluorescent dye, flat-bottomed black 96 well 
plates were purchased from Invitrogen Ltd., Paisley, Scotland, UK.
2.1.1.6 Reagents and glassware used fo r  Ki67 immuno staining
All reagents for Ki67 proliferation marker immunostaining (including acetone 
for cell fixation, TESPA (3-Aminopropyltriethoxysilane), Methyl green, PBS, 
DPX and ethanol) were purchased from Sigma-Aldrich Company Ltd, Poole, 
Dorset UK unless otherwise stated. The Ki67 Mouse primary antibody, Goat
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anti-Mouse Immunoglobulins secondary antibody, Mouse tertiary peroxidase 
antiperoxidase (PAP) reagent and 3,3' Diaminobenzidine (DAB) chromogen 
were purchased from DakoCytometrics, Carpinteria, California, USA. All 
glassware including coverslips and glass slides were purchased from Nunc, 
Roskilde, Denmark, and were supplied by Fisher Scientific UK Ltd., 
Loughborough, Leicestershire, UK.
2.1.1.7 Reagents used in apoptosis analysis
The ApoAlert mitochondrial membrane sensor kit (MMS) was purchased from 
Clontech Laboratories UK Ltd., Basingstoke, UK. The kit comprised 
Incubation Buffer, and five vials of MitoSensor reagent. All glassware were 
again purchased from Nunc, Roskilde, Denmark, and were supplied by Fisher 
Scientific UK Ltd., Loughborough, Leicestershire, UK.
2.1.2 Methodology
2.1.2.1 Development o f  acquired resistant breast cancer cell models
In this thesis, the wild type (w/t) MCF7 breast cancer cell line was used as the 
endocrine responsive control for comparison with acquired tamoxifen resistant 
(TAMR) and faslodex resistant (FASR) models, cells with acquired resistance 
to severe oestrogen (and growth factor) deprivation (X-MCF), and cells with 
acquired tamoxifen and gefitinib resistance (NEW DUBS). These models were 
developed prior to this project in the Tenovus Centre for Cancer Research Cell
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Culture Unit by continuous drug exposure of the wtMCF7 cells in vitro. In 
brief, to establish the TAMR or FASR cells, w/t MCF7 cells were maintained 
in their experimental medium (comprising Phenol red-free RPMI with 5% 
charcoal-stripped fetal calf serum (csFCS — see Appendix II for charcoal- 
stripping procedure), penicillin (lOiU/ml), streptomycin (lOpg/ml), fungizone 
[2.5pg/ml] and 4mM Glutamine) supplemented with 4-OH Tamoxifen or 
Faslodex respectively at 10‘7M. For derivation of X-MCF cells, experimental 
medium was supplemented with 5% serum which had again been charcoal- 
stripped of steroids and also heat-inactivated at 65°C for 30 minutes (“X”- 
medium). After an initial inhibition of cell growth of approximately 12 weeks 
duration in the presence of Tamoxifen, Faslodex, or X-containing medium, 
cells became able to proliferate in the presence of these treatments indicating 
emergence of acquired resistance.
Cells were subsequently always used for experiments at passage numbers 13- 
18 for w/t MCF7 cells, 37- 52 for TAMR cells, 89-100 for FASR cells, and 66- 
67 for X-MCF cells once the TCCR unit had determined the resistant 
phenotypes had become stable. The acquired TAMR cells were subsequently 
treated with lpM of the EGFR-TKI gefitinib (10'6M in experimental medium, 
maintaining 10'?M tamoxifen) for 6 months until resistance to this additional 
targeted therapy had been acquired. The resultant model (NEWDUBS) was 
subsequently used once stable over passage numbers 39-51 for this thesis.
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2.1,2.2 Maintenance of w/t MCF7 and acquired resistant breast cancer cell 
models
w/t MCF7 breast cancer cells were routinely maintained in phenol red- 
containing RPMI 1640 media supplemented with 5% foetal calf serum (FCS), 
penicillin-streptomycin (lOiU/ml -  lOOpg/ml), and fungizone (2.5pg/ml) in 
either T-25 or T-75 flasks depending on the density of cells required. The 
TAMR, FASR, X-MCF and NEW DUBS breast cancer cell lines were 
routinely maintained in their respective experimental medium i.e. TAMR / 
FASR / NEWDUBS: phenol-red free RPMI media, supplemented with 5% 
charcoal stripped steroid-depleted FCS, penicillin-streptomycin (lOiU/ml -  
lOOpg/ml), fungizone (2.5pg/ml) and glutamine (4mM) with 10'7M tamoxifen, 
faslodex or tamoxifen plus lO^M gefitinib respectively; X-MCF were 
maintained in X medium.
The media was replenished on cells in culture every 4 days and passaging was 
performed every 7 days once cells were in log phase (i.e. -70% confluency). 
To passage, cells were washed three times with PBS and were detached from 
the bottom of the flasks by incubating with Trypsin/EDTA solution 
(0.05%/0.02% w/v) at 37°C for 3-4min. The resultant cell suspension was 
centrifuged at lOOOrpm for 5 minutes, discarding the supernatant, and the 
remaining cell pellet was resuspended in the appropriate medium in fresh 
flasks using a split ratio of 1:10. All cells were maintained at 37°C in a 5% 
CO2 humidified Sanyo MCO-17AIC incubator purchased from Sanyo E&E
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Europe BV, Loughborough, UK., and all reagents for cell culture were pre­
warmed to 37°C before use.
2.1.2.3 Coulter Counting Growth experiment in responsive and 
acquired resistant cell lines
w/t MCF7cell, TAMR cells, FASR cells, X-MCF cells and NEW DUBS cells 
from a T75 flasks were passaged as described in section 2.1.2.2. Cell 
suspensions were diluted to 4xl04 cells/ml and were seeded in 24 well plates 
(1 ml/well). All cell models were incubated for 24 hours prior to 
experimentation in their respective experimental media (phenol red-free RPMI 
supplemented with 5% csFCS, penicillin-streptomycin (lOiU/ml -  lOOpg/ml), 
fungizone (2.5pg/ml) and glutamine (4mM) with 10'7M tamoxifen, faslodex or 
tamoxifen plus lO^M gefitinib respectively; X-MCF were maintained in X 
medium), the medium was replenished every 3-4 days. All cell lines were 
grown over 0 - 1 1  days, counting wells at days 1, 4, 6, 8 and 11 using a 
Beckman Coulter Counter Multisizer II. To record the number of cells per 
well, the medium was initially removed and replaced with 1ml of trypsin 
solution and incubated at 37°C for 3-5 minutes. Using a 5ml syringe with a 
G5/8 0.5 X 16 needle, the detached cells were pipetted up and down twice to 
encourage a single-cell suspension for accurate analysis of cell number. 1ml 
Isoton solution was then added to the well and the solution was again pipette 
up and down twice before being drawn into the syringe. This procedure was 
repeated twice to give a total volume of 4ml. The cell suspensions were 
subsequently transferred to a counting pot containing 6ml of Isoton giving a
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final volume of 10ml. The numbers of cells in each pot were determined in 
duplicate using the Coulter™ Multisizer II set to count the number of cells in 
500|il. Pots were counted twice and duplicate counts for every cell line were 
averaged and multiplied by the dilution factor of 20 to give the average number 
of cells per well. The experiment was preformed three times with significance 
calculated using a student T-test at day 8 compared to the control parental cells 
(w/t MCF7) ± Standard Deviation (SD) with p<0.05 considered significant.
2.1.2.4 M TT assay to evaluate basal growth o f  acquired resistant versus 
responsive cells and in the presence o f  tyrosine kinase inhibitors (TKI), 
signal transduction inhibitors (STIs), Antioxidant inhibitor (BSO), or 
oxidative stress inducer Menadione (MSB)
For MTT growth studies, cell lines were seeded out into 96 well plates at a 
density of approximately 7000 cells per well for w/t MCF7 cells, TAMR, 
FASR, X-MCF or NEW DUBS, subsequently leaving the cells to attach to the 
flask for 24 hours prior to experimentation. To initially seed out cells, T25 or 
T75 flask preparations (depending on number of cells required for multiple 
experimental runs) of the resistant or responsive cell lines at 70% confluency 
were trypsinised and centrifuged as described in section 2.1.2.2. The 
subsequent pellet was then resuspended in 10ml Phenol red-free RPMI with 
5% csFCS.
To ensure equal cell density for each experiment, cells were then counted and 
diluted appropriately prior to plating into the 96 well plate. To count, lOOpl of
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this suspension was added to 10 ml of Isoton and the cell number counted 
twice using a Beckman Coulter counter multisizer n  (from Beckman Coulter 
Ltd, High Wycombe, UK). Calculation of average cell density for each cell 
preparation could then be made from these counts so that the correct cell 
number could then be seeded per well for growth studies. For all MTT assays, 
all resistant cells were subsequently grown in their respective experimental 
media as described in 2.1.2.2, while w/t MCF7 cells were grown in phenol-red 
free, RPMI medium containing 5% csFCS, penicillin-streptomycin (lOiU/ml -  
lOOpg/ml), fungizone (2.5pg/ml) and glutamine (4mM). Cell growth was 
examined under these untreated (basal conditions) or when exposed to different 
treatments added to the media at varying concentrations, as detailed in Table
2.1. Drug concentrations known to be selective for the target and also growth 
inhibitory in further breast cancer models were employed and prepared from a 
stock concentration (made up in ultrapure distilled water in the case of MSB, 
and Ethanol for all other treatments). Literature search enabled determination 
of the optimal dose range for treatment with tamoxifen, faslodex, gefitinib 
(Gee et al., 2003), AZD0503, wortmannin, PARTH, U0126 (Knowlden et al., 
2003; Jordan et al., 2004; Hiscox et al., 2006), the antioxidant inhibitor BSO 
(Lewis-Wambi et al., 2009) and the ROS inducer Menadione-Sodium-Bisulfite 
(MSB; Noto et al., 1989; Nutter et al., 1991; Sun et al., 1997). Cells were 
incubated with/without these various treatments at 37°C in a 5% CO2 
humidified incubator for 7 days, replenishing media after 4 days. The medium 
was then removed and the MTT assay performed within the plates. MTT 
results were obtained in replicates of 8 for each cell line/treatment.
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For the MTT assay, 8.75mg MTT solution was added to 3.5ml phenol-red free 
RPMI medium (without serum, penicillin-streptomycin, fungizone or 
glutamine). This mixture was then filter sterilised through a 0.2pm Supor 
membrane VacuCap 60 filter unit (from Gellman Laboratory Pall, Ann Arbour, 
USA), and diluted 1:5 to produce a final concentration of 0.5mg/ml. 3.2ml of 
this stock solution was added to 12.8ml stripped serum RPMI to give 16ml of 
working solution at 0.5mg/ml, 150pl of which was added to each well in the 
various growth study plates. The plate was incubated at 37°C in a 5% CO2 
humidified incubator for 4 hours. During this time, the MTT was metabolised 
by mitochondrial dehydrogenase enzymes to produce insoluble purple 
formazan crystals. After removing the MTT solution, the cells were lysed 
using lOOpl Triton X-100 (10% in PBS) and left at 4°C overnight. The 
following morning, the plates were allowed to reach room temperature and 
were then gently tapped to mix the solution within the wells, being careful that 
no bubbles were produced. Absorbance of the solution was then read at 540nm 
using an ELISA plate reader (from Biotron diagnostics Inc. California USA.), 
and optical density was plotted on a bar graph with higher optical density 
associated with more formazan crystals formed during growth. Experiments 
were repeated three times and statistical analysis was carried out using Student 
T-test ± SD (p value considered significant <0.05). The half maximal growth 
inhibitory concentrations (IC50), if required, were calculated for treatments by 
obtaining 50% of the maximum effect.
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Table 2.1 Summary of experimental technique and drug concentrations 
used to examine particular cell models in the thesis.
D rug  an d
E x p erim en ta l te c h n iq u e Cell m o d e l
C o n c e n tra tio n TAC R O S MTT Ki 67  A poA lert w /t M CF7 TAM R F A S R  X-M CF N E W  DU B S
Tamoxifen (10*M) v ' v '
Faslodex (10*^) v '
Oe fit nib ✓ >/
AZD0503 (1pM)
Wortmanin (100nM) ✓ v ' ✓ ✓
PARTH (3pM) ✓ v /
U0126 (1 OpM)
BSO(IOOpM) v ''
BSO (100pM) ♦ 
Gefitnto (10^1) ✓ v '
MSB (2-1 SpM) ✓ s
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2.1.2.5 TAC analysis
Using a commercial antioxidant assay kit (Sigma) the resistant breast cancer 
models were assessed for total antioxidant capacity (TAC) in relation to the 
parental endocrine responsive breast cancer cell line w/t MCF7 again under 
basal conditions and following manipulation with antihormones, the EGFR 
TKI, STIs and BSO as in Table 2.1. A water-soluble vitamin E analogue, 
Trolox, was used as an antioxidant assay internal control (Kalinich et al., 
1997). Preparation of all working solutions for TAC analysis from the Total 
Antioxidant kit was carried out using ultrapure water prepared in the Welsh 
School of Pharmacy. The concentrated TAC Assay kit Buffer was diluted lx 
for use and the kit Myoglobin was reconstituted from a Stock Solution by 
addition of 285pi ultrapure water, subsequently diluting 100-fold with the lx 
Assay Buffer to give a Myoglobin Working Solution. The Trolox working 
solution (1.5mM) for TAC assay standard curve construction also required 
reconstitution of kit Trolox in 2.67ml of lx TAC Assay Buffer. One 2,2’- 
azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) tablet and one 
Phosphate-Citrate Buffer tablet from the kit were mixed well with 100ml 
ultrapure water to obtain an ABTS Substrate working solution for the assay.
The principle of the antioxidant assay is that oxidation of the ABTS substrate 
produces a radical cation ABTS*+’ which is a soluble green colour chromogen 
that can be detected spectrophotometrically at 405 nm. Antioxidants naturally 
occurring within the cell suppress the production of the radical cation ABTS*+ 
in a concentration dependent manner, and the colour intensity decreases
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proportionally to the level of antioxidants present. By combining with ABTS 
Substrate working solution (150pl) containing H2O2 (25pi of a 3% solution), 
Myoglobin working solution (20pl), and lx Assay kit buffer (500pl), 
increasing volumes of the 1.5mM Trolox antioxidant standard were used to 
create a standard curve (concentrations in the standard ranging 0-0.42mM). 
Antioxidant concentration (mM) of the test breast cancer models could then be 
calculated using equation (a) in Figure 2.1(a) which uses the linear regression 
of the Trolox standard curve obtained also as shown in Figure 2.1(b). To 
perform the assay on the test cell lines, these were seeded down at an optimised 
10,000 cells per well of a 96 well plate in preparation for the experiment, and 
allowed to grow for 24hours, 7days and lOdays (changing media at day 4) 
before being measured for TAC. Assays were performed in duplicates. As for 
the Trolox internal control, ABTS Substrate Working Solution was prepared by 
adding 25pl of 3% H2O2 solution to 10ml ABTS stock solution, 150pl of which 
was added to lOpl of Trolox standard and 20pl Myoglobin Working Solution 
in the 96 well plate. 150pl ABTS Substrate Working Solution and 20pl 
Myoglobin Working Solution was again added to the cell lines in each of the 
wells in the 96 well plates. Plates were incubated for 5min before the reaction 
was stopped using 100pl kit Stop Solution and final absorbance was read at 
405nm using a plate reader. Absorbance values were used to subsequently 
calculate approximate antioxidant capacity for each cell model. Experiments 
were repeated three times with data plotted on a bar graph and statistical 
analysis was carried out using Student T-test ± SD (p value considered 
significant <0.05), as demonstrated by Rice-Evans, 2000.
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Figure 2.1 Determining Total Antioxidant Capacity (TAC) of test 
samples
(a) Calculation for determining TAC of a test sample:
X (mM) =
y(A405) -  Intercept
Slope
(b) Example of Trolox Standard Curv e obtained in this study:
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Total Antioxidant capacity o f  the test samples (e.g. resistant model versus w/t 
MCF7 cells) was calculated using equation (a) as shown above, obtained from 
the linear regression o f  the Trolox standard curve (see example b achieved in 
this thesis in Figure 2.1 above). X (mM) refers to the antioxidant concentration 
in mM, calculated relative to the Trolox internal control. y(A 4 os) is the average 
absorbance o f  the test sample at 405nm. Intercept is the intercept o f  the Y axis 
by the standard curve shown here as 0.6611 in Figure 2.1 (b), and the Slope 
refers to the slope o f  the standard curve, a negative value shown here as-1.4878 
in Figure 2.1(b). The standard curve was duplicated for accuracy and the 
experiment was repeated three times with duplicates again for each sample for 
accuracy. Final data was represented in a bar graph with statistical analysis 
using a Student T-test ± SD.
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2.1.2.6 ROS detection
Cells for ROS experimentation according to Table 2.1 were seeded down as for 
TAC at i.e. 10,000 cells per well of a 96 well plate in preparation for the 
experiment, allowing the cells to grow for 24 hours, 7 days and 10 days and 
subsequently measuring total ROS. In this assay a cell-permeable non- 
fluorescent probe 2’-7’-dihydrodichlorofluorescein diacetate (H2DCFDA) is 
de-esterified intracellularly and becomes the highly fluorescent 2',7'- 
dichlorofluorescin (DCF) dye upon oxidation. H2DCFDA thus provides a 
sensitive and rapid quantitation of ROS in response to oxidative metabolism 
(Wan et al., 2003), and was therefore used in this thesis for the detection of 
ROS.
H2DCFDA was used to detect ROS using lOpl/ml of stock solution in 
combination with a delivery agent, Dimethyl Sulfoxide (DMSO) at lpl/ml, 
both made up in phenol-red free, RPMI medium (without serum, penicillin- 
streptomycin, fungizone or glutamine). Cells were incubated in the wells with 
150pl dye (i.e. H2DCFDA and DMSO) for 30 minutes at 37°C followed by 
draining off their media. The ROS detection assay also required further wells 
prepared from the various cell models under control conditions but treated with 
ImM H2O2 (from a 0.03% stock solution) for 10 minutes as an internal positive 
control for oxidative stress in the assay. In addition, wells treated with DMSO 
alone at 1 pl/ml of stock solution in phenol-red free, RPMI medium without 
serum, penicillin-streptomycin, fungizone or glutamine were used as a negative 
assay control. Following incubation with dye, all cells were lysed using lOOpl
60
Chapter 2 -  Methodology
Trypsin (0.05%) and transferred to black 96 well plates in which the intensity 
of fluorescence was measured from 8 wells for each model (per treatment/per 
time point) at 420nm excitation and 580nm emission using a FlouroStar 
absorbance reader (from BMG LabTech, Aylesbury, UK). The FlouroStar 
compared the “gain” (highest reading from each 96 well plate) of each 
experimental design against its replicates in order to produce comparable 
results. Results were taken for each cell model and treatment in triplicate. 
Mean absorbance readings were presented in a bar graph with statistical 
analysis using a Student T-test ± SD (p value considered significant <0.05).
2.1.2.7 Ki67 immunostaining fo r  proliferation
The Ki67 proliferation marker detects all cells in cell cycle, while resting cells 
(in GO) remain unstained (Gerdes et al., 1983). w/t MCF7 cells and TAMR 
cells were seeded down at lxlO6 cells onto TESPA coated glass coverslips 
(22x22mm) and grown to log phase (7 days) before evaluation of proliferation 
under basal conditions in their respective experimental media. Treatment of 
TAMR cells with 10"^ gefitinib for 7days was also examined in parallel 
versus the untreated TAMR cells. Cells growing on the coverslips were fixed 
using acetone for 10 minutes at room temperature and then allowed to air-dry 
for 30 minutes. A single wash of the coverslips was carried out using PBS (pH
7.2, 0.01M) for 5 minutes, before a blocking step with 10% normal goat serum 
prepared in PBS for 10 minutes. Excess blocking reagent was then wiped off 
before the addition of Dako Ki67 monoclonal primary antibody (80mg/L) at 
1/100 in PBS for 45 minutes. Negative control coverslips omitted the primary
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antibody step, were incubated with the PBS carrier for 45 minutes. All 
coverslips were then washed three times for 4 minutes using PBS before the 
application of the secondary antibody, Dako Goat anti-Mouse 
Immunoglobulins. This was applied at 1/25 prepared in PBS for 30 minutes 
and then washed three times using PBS for 4 minutes. A Tertiary reagent, 
Dako Mouse PAP was then added at 1/250 in PBS for 30 minutes and again 
washed three times for 4 minutes using PBS. The chromagen Dako DAB 
chromogen (1 drop DAB to 1ml Substrate Buffer as provided by manufacturer) 
was then applied for 8 minutes followed by three washes for 4 minutes using 
distilled water. Coverslip preparations were then counterstained using 0.5% 
methyl green (aqueous) for 5 minutes followed by two 2 minute washes with 
distilled water, dehydration through graded ethanols, and then mounting on 
glass slides using DPX mountant when dry. Assessment of staining was 
carried out on an Olympus BH-2 microscope, where cells were counted in 10 
square fields for positive (brown) or negative (blue/green) staining and given 
an average percentage positivity score. Representative photographs of staining 
were also taken using an Olympus DP 12 digital camera (X40 magnification).
2.1.2.8 ApoAlert assay (MMS) fo r  apoptosis
The ApoAlert mitochondrial membrane sensor kit (MMS) uses a Mitosensor 
reagent to detect cells in early apoptosis. MitoSensor reagent forms red 
fluorescent mitochondrial aggregates in non-apoptotic cells, however in early 
apoptosis MitoSensor remains in a monomeric green fluorescent cytoplasmic 
form due to altered mitochondrial membrane permeability (Green & Reed
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1998; Gee et al., 2003). Apoptosis is therefore evaluated by the percentage of 
green fluorescent cells. The MMS kit comprised an Incubation Buffer 
(100ml), and five vials (20pl) of MitoSensor reagent (5mg/ml).
w/t MCF7 and TAMR cells were seeded at lx l06onto TESPA-coated glass 
coverslips and grown to log phase (7 days) in their experimental media before 
analysis of apoptosis. Treatment with lO^M gefitinib was also examined in 
parallel versus the untreated TAMR cells. Assays also included an internal 
positive control comprising w/t MCF-7 grown for 7 days and then exposed to 
UV light for 20 minutes followed by a 4 hour incubation period at 37°C prior 
to assay. Each coverslip was then washed with 1ml of phenol-red free, RPMI 
medium (without serum, penicillin-streptomycin, fungizone or glutamine) that 
was pre-warmed to 37°C. MitoSensor assay solution was then prepared 
immediately prior to use by addition of lpl stock Mitosensor reagent per 1ml 
of kit Incubation Buffer to give a final Mitosensor concentration of 5pg/ml. 
lml of this MitoSensor solution was then added to every coverslip and 
incubated for 20 minutes at 37°C in a 5% CO2 incubator, foil-covering the 
coverslips to protect the Mitosensor from light. Subsequently the MitoSensor 
solution was removed and the coverslip gently rinsed with lml of serum-free 
media (pre-warmed to 37°C) and viewed immediately under a fluorescence 
microscope at x40 magnification. The average apoptotic cell percentage for 
each coverslip was estimated by counting, green-stained cells (versus red cells) 
over nine fields per coverslip.
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2.2 Affymetrix microarray analysis
2.2.1 Materials
2.2.1.1 Cell culture reagents andplasticware fo r  microarrays
All plasticware and reagents employed for the initial generation of 
experimental material from the wtMCF-7 cells and the acquired resistant, 
TAMR, FASR, MCF-7X and NEWDUBS models for microarraying were as 
described above in section 2.1.1.1. Lysis of cell preparations for RNA 
preparation used TRI-Reagent from Sigma-Aldrich Company Ltd, Poole, 
Dorset UK.
2.2.1.2 RNA purification kits
Deoxyribonuclease 1 was purchased from Sigma-Aldrich Company Ltd, Poole, 
Dorset UK. RNeasy columns for RNA cleanup and the RNeasy mini kit were 
purchased from Qiagen House Fleming Way, Crawley, West Sussex, UK. 
Chloroform and isopropanol were purchased from Sigma-Aldrich Company 
Ltd, Poole, Dorset UK, and agarose gel was purchased from Bioline Ltd. 
London UK.
2.2.2 Methodology
Initial RNA extraction, and Microarray preparation from w/t MCF7, TAMR, 
FASR, X-MCF and NEW DUBS cells and the subsequent expression database 
construction for triplicate preparations of each of these cell lines was
64
Chapter 2 -  Methodology
performed prior to the commencement of this thesis by Mr. RA McClelland 
(Tenovus Centre for Cancer Research) and by the Affymetrix-approved 
commercial microarray facility Central Biotechnology Services (Wales College 
of Medicine, Cardiff University). The methodology that was employed for 
these steps is briefly provided for clarity in sections 2.2.2. J and 2.2.2.2. Since 
this thesis focussed around performing subsequent analysis of the antioxidant 
gene probe sets represented within this expression database, this analysis is 
provided in detail in the subsequent sections 2.2.2.3 onwards.
2.2.2.1 RNA extraction from cell lines
RNA was initially isolated from triplicate experimental cultures of w/t MCF7, 
TAMR, FASR and NEW DUBS cells (maintained in their respective 
experimental medium and containing 10'7M tamoxifen, faslodex, or 10'7M 
tamoxifen with lO^M gefitinib for TAMR, FASR and NEW DUBS 
respectively). Cells were seeded at 1x10 cells/80-cm flask and harvested 
during log phase growth at day 7 (with a media change at day 4). Equivalent 
preparations were made for X-MCF cells maintained in X medium. Further 
preparations were made from w/t MCF7 cells harvested at day 10 in their 
experimental medium supplemented throughout with oestradiol (10'9M), in the 
absence of oestradiol, or in the presence of the antihormones tamoxifen or 
faslodex (at 10'7M). All cell preparations were then lysed in situ in the 
presence of phenol-based TriReagent, scraped into 1.5 ml microcentrifuge 
tubes and stored at -80°C overnight. Total RNA was isolated according to the 
TriReagent kit protocol, including chloroform extraction and isopropanol
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precipitation of RNA which produced a precipitation of a pink protein layer, a 
cloudy DNA layer and a clear RNA supernatant that was removed, washed 
using 75% ethanol and re-dissolved in RNase free water. This was quantified 
at 260nm and purity assessed by analysis of the spectrophotometric ratio of 
260/280nm to give acceptable optical density levels of >1.7 using UV 
spectrophotometry (using a UV Transilluminator from Alpha Innotech Corp. 
California, USA). Assessment of RNA integrity was then made by horizontal 
2% agarose gel electrophoresis followed by DNase 1 treatment (for 30minutes 
at 37°C) of RNA to ensure absence of genomic DNA, and subsequent RNA 
clean-up using RNeasy Mini Columns. RNA samples were eluted in sterile 
RNase free water and then re-quantified, with RNA integrity again determined 
by spectrophotometry and electrophoresis.
2.2.2.2 Hybridisation to Affymetrix Chips and expression database 
construction fo r  expression studies in the cell lines
RNA samples at >lpg/pl were transferred on dry ice to the specialist Cardiff 
University Central Biotechnology Services (CBS) Microarray facility for initial 
Agilent RNA chip analysis to check suitability of the RNA for subsequent 
Affymetrix U133A GeneChip hybridisation analyses. All samples satisfied 
CBS quality control parameters, and so the triplicate RNA samples from each 
cell line were then used to generate biotinylated cRNA which was then 
hybridised to cDNA oligonucleotides on Affymetrix Genechips, using one 
Affymetrix HG U133A Genechip for each sample. This microarray 
encompasses probes representing 22800 genes as well as array controls.
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Hybridised arrays were then scanned and fluorescence data output per probeset 
generated using Microarray Suite 5.0 (MAS5.0) software (Affymetrix, UK). 
This software interprets the laser-generated intensity scores for each probe, 
subtracts non-specific signal obtained from parallel single-band mismatch 
controls for each, and unifies and reports the expression signal for each “probe 
set” by combining the n=l 1-14 individual values as a single “probe set” value. 
A “probe set” for each individual RNA species thus represents the data from a 
set of different oligonuclotides (often 11-14, overlapping / adjacent) spanning a 
region towards the poly A terminals of the RNA of interest. MAS 5.0 also 
statistically produces a likely expression call of present (P), absent (A), or 
marginal (M) based on specific/non-specific signal ratios.
Data files detailing the Affymetrix HG-U133A GeneChip-determined 
expression levels of individual RNA species in each sample were then recorded 
on CD-ROM and returned in an Excel file format to the Tenovus Centre to 
enable comparative analysis across the various cell models. The triplicate 
expression data for each cell line were uploaded into the online software 
package GeneSifter™ (www.genesiffer.net), creating an expression database 
encompassing each cell line to perform microarray analysis. The data were 
then normalised and log transformed within the software, creating “projects” 
(see below) for comparative analysis of gene expression across groups of 
particular cell models, in this instance ultimately allowing interrogation of 
expression of individual oxidative stress-related genes.
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2.2.2.3 Creating new projects fo r  expression analysis
Once logged on to GeneSifter, the online Homepage displayed a control panel 
by which existing projects could be analysed or inventoried, or new projects 
could be created (Figure 2.2). For this thesis, the first new project created in 
GeneSifter was to analyse expression in wtMCF-7 cells versus the resistant 
models TAMR, FASR, X-MCF or NEW DUBS. This was achieved by 
clicking on the ‘create new: project’ option in the control panel (Figure 2.2) on 
the left o f  the homepage screen, and the U133A:HG-U133A array option was 
then selected (Figure 2.3) as this was the microarray chip format used in this 
investigation. The conditions o f  this array were subsequently displayed in the 
‘common conditions’ text box (Figure 2.3), and it was then possible to 
‘continue’ on to page 2 o f  3 for ‘create new: project’.
Figure 2.2 GeneSifter Homepage at http://gs41.genesifter.net/users/
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Figure 2.3 Creating a new project in GeneSifter, page 1 of 3.
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Subsequent to creating a new project, a group name describing the cell model 
used was designated in the description text box on page 2 (Figure 2.4: “w/t 
vs.resistant models”). As recommended in Genesifter, median normalization 
of the U133A array data was chosen using the ‘All Median’ option (Figure 
2.4), and data log transformed prior to choosing the experimental conditions 
for comparative analysis. The first cell line chosen is automatically treated as 
control, which for these studies was the w/t MCF7 cell line, for comparison 
with the resistant models TAMR, FASR, X-MCF, or NEW DUBS (referred to 
as NEW TAMR/TKIR in the database). Once the desired conditions were 
chosen, it was possible to ‘create group’ (Figure 2.4), and go into the final page 
of “create new project” (Figure 2.5) where all experimental replicates were 
selected for each condition, thus allowing new project creation to be completed 
ready for analysis (Figure 2.5). Other projects created included exploring if 
antioxidant genes were hormone/antihormone regulated, where w/t MCF7 cells 
were run in GeneSifter as the control alongside oestradiol treated w/t MCF7 
cells (+E2, 10*9M), tamoxifen treated w/t MCF7 cells (+TAM, 10"7M), or 
faslodex treated w/t MCF7 cells (+FAS, 10'7M) (lOdays treatment).
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Figure 2.4 Creating a new project in GeneSifter, page 2 of 3.
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2.2.2.4 Initial interrogation of gene of known expression profile (quality 
control step)
The expression profile of the oestrogen/ER-regulated gene pS2 (Affymetrix 
probe no. 205009_at), a gene of known expression in the responsive and 
resistant models and during oestrogen/antihormone manipulation (Henry et al., 
1991; Hutcheson et al., 2003; Staka et al., 2005), was then interrogated to 
initially check the quality of the arrayed samples, ensuring the expression 
database was likely to subsequently permit robust interrogation of genes of 
unknown expression profile (in this instance, antioxidant genes).
2.2.2.5 Interrogation of antioxidant gene expression profile
A set of 39 antioxidant genes were chosen (through extensive literature 
searches using references from Medline: http://www.ncbi.nlm.nih.gov/pubmed/ 
and using the GeneCards® online database, a database of genomic, proteomic, 
transcriptomic, genetic and functional information on all known human genes), 
as listed in Results Table 3.1, to interrogate expression across the responsive 
and resistant models.
Their gene names were also individually entered into the web-based computer 
programme GeneCards® (http://genecards.org/index.shtml) in order to obtain 
the Affymetrix probe set ID number(s) for each of the genes under 
investigation. Initially 200 oxidative stress related genes were found and probe 
set numbers obtained for each gene were listed in an Excel worksheet, along 
with the gene name, aliases, reported function, and gene accession number.
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However this thesis focussed on Antioxidant genes (n=39, Table 3.1) and in 
order to analyse these genes, the ‘analysis: projects’ option on the GeneSifter 
homepage was selected (Figure 2.2). The project of interest for analysis (e.g. 
resistant and responsive cells) was opened and its group information checked 
(Figure 2.6). As shown in Figure 2.6, this new project could then be used to 
analyse the desired genes via the ‘Analyze this project’ option and their 
Affymetrix probe set ID numbers.
To analyze the project (containing triplicate experimental arms) for antioxidant 
gene expression (Figure 2.7), Affymetrix probe set ID numbers for each of the 
oxidative stress related genes were placed in the identifiers box ( * ). If 
statistical analysis was required to compare two (or more) experimental arms in 
the group (e.g. Student t-test or ANOVA), these were selected in the 
“statistics” box in Figure 2.7. A search was then initiated and resultant 
heatmap diagram of relative gene expression produced, choosing to sort the 
results by relative expression (and significance). A sample Heatmap of a 
selection of antioxidant genes up regulated (red -  representing at least 2 fold 
increase) and down regulated (green -  representing at least 2 fold decrease) in 
TAMR or FASR cells versus w/t MCF7 cells (Black -  for control) is shown in 
Figure 2.8. If statistical analysis was again required to compare two (or more) 
experimental arms in the group (e.g. Student t-test or ANOVA), these were 
selected in the “statistics” box in Figure 2.8. Each gene represented by a line on 
the resultant heatmap diagram had hyperlinks to information regarding that 
antioxidant gene and also the option to click for a graphical display of the mean
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log intensity values (+/- SEM) profile for that gene across the analysed samples 
(Figure 2.9). The log intensity data were accompanied by likely absent (no or 
low expression), marginal or present (high expression) calls for the gene at the 
mRNA level for each replicate. Results of the statistical analyses, if selected, 
were also displayed enabling the identification of significant gene expression 
changes (Figure 2.8).
Of the 39 antioxidant genes investigated, 23 gene showed evidence of up- 
regulation across at least two forms of resistance and 15 genes were ANOVA 
significant and of potential interest for PCR verification. The strongest overall 
ontological and expression profiles (Results Tables 3.2 and 3.3), were 
designated by their present call at the RNA level, above described ontological 
selection, and heatmap significant patterns in resistance. Of the strong profiles 
chosen, 11 antioxidant genes were thus chosen for analysis by PCR.
2.2.2.6 Multiple probe analysis for antioxidant genes (quality control)
Of the 39 antioxidant genes investigated by project analysis, some (e.g. the 
antioxidant gene UDP glycosyltransferase 1 family polypeptide A6 
[UGT1A6]) had up to 5 Affymetrix probe set representations on the array so 
that there was a total of 61 Affymetrix probe IDs representing the 39 genes 
under test. Using Genesifter, all probes for significant differentially expressed 
genes were examined to investigate if the multiple probes exhibited 
reproducible expression profiles using heatmaps. In the absence of known 
splice variants for these genes, such a finding would further re-enforce
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confidence in the use o f  GeneSifter as a tool for robustly analysing expression 
data derived from Affymetrix HG-U133A chips (see Results section 3.2, 
Figure 3.8).
Figure 2.6 Details of Project selected in GeneSifter for expression analysis
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Figure 2.7 Expression analysis of genes of interest (using Affymetrix 
Probeset IDs entered in box *) in selected project
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Figure 2.8 Resultant Heatmap of a selection of antioxidant genes
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Log intensity profile for antioxidant gene GSTA4 is shown as an example 
where this gene is generally called absent (A) in w/t MCF7 cell preparations 
but significantly present (P) in TAMR and FASR cells.
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2.3 RT-PCR studies of selected antioxidant gene expression
2.3.1 Materials
2.3. L I Cell culture reagents and plasticware fo r  PCR studies 
All plasticware and reagents employed for the initial generation of 
experimental material and RNA extraction from the w/t MCF7 cells and the 
acquired resistant, TAMR, FASR, MCF-7X and NEWDUBS models for PCR 
was as described above in section 2.2.
2.3.1.2 Enzymes and inhibitors
The enzyme Taq DNA polymerase, MMLV-Reverse Transcriptase, the 
RNasin™ RNase inhibitor and dNTP mix was purchased from Invitrogen Ltd., 
Paisley, Scotland UK. Random hexamer oligonucleotide mix was purchased 
from Promega UK, Southampton, UK.
2.3.1.3 PCR reagents
All chemicals and buffers used in this RT-PCR investigation were purchased 
from Sigma-Aldrich Company Ltd, Poole, Dorset UK, unless otherwise stated. 
Dithiothreitol (DTT) and 10 x concentration of PCR buffer used in reverse 
transcription (RT) and the further polymerase chain reaction (PCR) reactions 
were purchased from Invitrogen Ltd., Paisley, Scotland UK. Molecular biology 
grade multipurpose agarose used for PCR gel electrophoresis was obtained 
from Bioline Ltd, Humber Road, London, UK. Standard size (range of lOObp
79
Chapter 2 -  Methodology
to lOOObp) DNA molecular weight marker (Hyperladder IV 100-Lanes) used to 
estimate nucleic acid was obtained from Bioline Ltd, Humber Road, London, 
UK. Large molecular weight p-actin Primers (380bp) were purchased from 
MWG Biotech AG, Anzinger Str.7, D-85560 Ebersberg, Germany. All other 
PCR primers used in this thesis were synthesised by Invitrogen Ltd., Paisley, 
Scotland UK.
23.1.4 Equipment
The PTC-100™ Programmable thermal controller (PCR machine) was 
purchased from MJ Research Global Medical Instrumentation, Inc., Bunker 
Lake Boulevard, Ramsey, Minnesota U.S.A. The microcentrifuge was 
purchased from Heraeus instruments, Inc., South Plainfield, NJ. The BioRad 
Power Pac p i000 and BioRad gel electrophoresis tank were purchased from 
BioRad Laboratories Ltd, Hemel Hempstead, Hertfordshire, UK. PCR 
products were photographed using an AlphaDigiDoc® RT Olympus camera, 
and images were obtained and analysed using the Alpha DigiDoc™ computer 
software, all purchased from Alpha Innotech Corporation, Merced St., San 
Leandro, U.S.A.
2.3.2 Methodology
w/t MCF7, TAMR and FASR cells were seeded and cultured to log phase for 
RNA preparation as in section 2.2.2. J in their respective experimental media, 
w/t MCF7 RNA preparations treated with oestradiol (10'9M), tamoxifen (10" 
?M), or faslodex (10"7M) for lOdays, and TAMR cells treated with gefitinib
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(lO^M) for 7days were also prepared following the same RNA preparation 
procedure as in section 2.2.2.1.
2.3.2.1 Polymerase Chain Reaction (PCR)
PCR is an in vitro method of nucleic acid synthesis by which a particular 
segment of deoxyribonucleic acid (DNA) can be specifically replicated for 
evaluation. This technique has become an increasingly useful tool in molecular 
biology for its inherent speed, simplicity, specificity, and sensitivity. Due to 
this sensitivity, all components of the PCR reaction are required to be 
ribonucleic acid (RNA) and DNase free, as any traces of such nucleases in the 
PCR reaction mixture would result in degradation of the RNA or DNA 
templates. All reagents for this technique were therefore prepared in 
RNA/DNAse-free solutions. All plasticware and tips used was autoclaved 
before use in the PCR procedure. As skin is a major potential contaminant, 
gloves were worn at all time when handling any equipment or performing the 
experiment.
2.3.2.1.1 Reverse transcription (RT) o f  cDNA templates
PCR is used to amplify messenger RNA (mRNA) using the retroviral enzyme 
reverse transcriptase. mRNA sequences are transcribed by the enzyme into 
double stranded complimentary DNA (cDNA), a more stable form, in first 
strand cDNA synthesis. First strand cDNA was accomplished in this thesis 
using the method described by O’Brian et al., (1991). A typical RT reaction 
was performed in a total volume of 20pl in 10 x PCR buffer (lOmM Tris-HCl
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pH 8.3, 50mM KC1, 1.5mM MgCh 0.001% w/v gelatine), and the reaction 
mixture comprised the following reagents made up in a 0.5ml microcentrifuge 
tube on ice:
Total RNA* (lpg/pl) lpl
dNTP mix (0.625mM each of dCTP, dATP, dGTP, & dTTP) 5 pi
Random hexamer oligonucleotide mix (1 OOpM) 2pl
DTT(O.IM) 2pl
1 Ox concentration of PCR buffer 2 pi
Sterile nuclease free water to a final volume of 20pl
*Total RNA was from the various cell preparations generated as described in 
section 2.1.2.1
In order to check for contamination, a “minus RNA” sample was also included 
as a negative RT control. A denaturation step at 95°C for 5 minutes in a PTC- 
100™ Programmable Thermal Controller was initially performed in order to 
break up any aggregates or secondary RNA structures that could inhibit 
subsequent primer annealing. The reaction mixture was then rapidly cooled on 
ice for another 5 minutes followed by a pulse spin in a microfuge to collect the 
solution, and then placed back on ice. 10 Weiss units (1 pi) of MMLV-Reverse 
Transcriptase and 25 Weiss units (0.5pl) of RNasin™ RNase inhibitor were 
added to the reaction. The PTC-100™ Programmable Thermal Controller was 
then used to perform the RT reaction using the following parameters:
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incubation at room temperature for 10 minutes to facilitate primer annealing; 
heating to 42°C for 42 minutes as the RT extension time; and subsequent 
denaturing of samples at 95 °C for 5 minutes that terminated the reaction by 
separating cDNA/RNA hybrids and inactivating the reverse transcriptase. The 
cDNA templates resulting from RT were rapidly cooled on ice for an additional 
5 minutes and were either used immediately for PCR, or stored at -20°C until 
required.
2.3.2.1.2 Oligonucleotide primer design and PCR amplification from  
cDNA
The oligonucleotide primer pairs (Table 2.3) used for the PCR were designed 
manually from DNA sequences for the antioxidant genes of interest (master 
sequences were provided by Clonetech®) using the web based package 
Primer3 (Rozen & Skaletsky, 2000), following the general guidelines listed in 
Table 2.2. 20fiM primer stock solution was then prepared in nuclease free 
water for use in subsequent PCR reactions. Annealing conditions used 
subsequently for all primers was 60 seconds at 55°C, using variable cycle 
numbers following optimisation (to generate a robust, non-saturated, specific 
signal) as shown in Table 2.3. The cycle number to begin optimisation was 
chosen according to the likely abundance of the 11 antioxidant genes of interest 
subsequent to microarray analysis that generated expression call within the cell 
lines. The genes/sequences examined with product sizes, are presented in Table
2.3, including B-actin controls, and also pS2 primers for normalisation and 
quality control purposes respectively.
83
Chapter 2 -  Methodology
Table 2.2 General guidelines used for PCR Primer design
Parameter General Guidelines
Length: 18-30 nucleotides
G/C content: 40-60%
Cone.: 0.1-0.5|iM (0.2pM)
Tm: Similar melting temperature (I’m) for both primer pairs
Tm = 2°C x (A+T) + 4°C x (G+C) (Suggs et al., 1981) 
Sequences: Avoid a run of 3 or more G or C bases at the 3’-terminal as it
may stabilise non-specific annealing of the primer, and avoid a 
T at the 3’ end as it is more prone to mis-priming than other 
nucleotides (Kwok et al., 1990).
Avoid mismatches between the 3’ end and the target sequence, 
as well as avoiding complimentary sequences within and 
between primers that would reduce primer dimer formation 
(Sommer & Tautz, 1989; Kwok et al., 1990).
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Table 2.3 Primer Sequences, expected product size and PCR cycle number
Primer Sequences
Product Optimised 
Size Cycle
number
5’ p-actin 5’-GGA GCA ATG ATC TTG ATC TT-3’
3’ p-actin 5’-CCT TCC TGG GCA TGG AGT CCT-3’
204bp 27
5* p-actin 5’-CTA CGT CGC CCT GGA CTT CGA GC-3’
3* p-actin 5’-GAT GGA GCC GCC GAT CCA CAC GG-3’
380bp 27
5* pS2 
3* pS2
5’-CATGGAGAACAAGGTGATCTG-3’
5’-CAGAAGCGTGTCTGAGGTGTC-3’
380bp 24
5’ CAT 
3’ CAT
5’-AGC TTA GCG TTC ATC CGT G-3’
5’-TCC AAT CAT CCG TCA AAA C-3’
220bp 30
5’ GLRX 5’-AAC GGT GCC TCG AGT CTT T-3’
3’ GLRX 5’-CTT GGT GTA GGG GGC T-3’
180bp 36
5 ’ GPX2 5’-CAA GCG CCT CCT TAA AGT T-3 ’
3 * GPX2 5’-GAG GGT TGG GAG AGG AAA A-3 ’
380bp 30
5’ GSTA4 5’-TCC GTG AGA TGG GTT TTA G-3’
3* GSTA4 5’-TGC CAA AGA GAT TGT GCT T-3’
200bp 30
5* NQOl 5’-TTA CTA TGG GAT GGG GTC C-3’
3’ NQOl 5’-TCT CCC ATT TTT CAG GCA A-3’
250bp 24
85
Chapter 2 -  Methodology
5’ SOD1 5 ’-CG ATGTGTCTATTGAAG ATTCTGTG-3 ’
3’ SOD1 5’-ACAGCTAGCAGGATAACAGATGAGT-3’
180bp 24
5’ PRDX1 5’-CAA CTG CCA AGT GAT TGG TG-3’
3’ PRDX 1 5’-TGA TCT GCC GAA GAA TAC CC-3’
220bp 27
5* PRDX6 5’-CGT GTG GTG TTT GTT TTT GG-3’
3’ PRDX6 5’-CTG ACA TCC TCT GGC TCA CA-3’
350bp 24
5’ TXN
3’ TXN
5’-CTG CTT TTC AGG AAG CCT TG-3’ 
5’-ACC CAC CTT TTG TCC CTT CT-3’
250bp 27
5’ TXNRD1 5’-GGT CAC ACA AAG CTT C-3’
3 ’ TXNRD1 5’-TCA GGG CCG TTC ATT T-3’
200bp 27
5’ TXNRD2 5’-AGCTTCAGGACAGAAAAGTCAAGTA-3’
3 ’ TXNRD2 5’-GTCATCACTTGTGATTCCATATTCC-3’
200bp 27
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The PCR procedure carried out in this investigation was adopted from that 
developed for use in breast cancer cells by Knowlden et al., (1997). PCR for 
each gene was performed on cDNA templates, in the first instance using p— 
actin (204bp) primers to initially verify the recovery and check for any 
degradation of the RNA, as well as to verify sample-to-sample uniformity 
under RT-PCR conditions. For each PCR reaction 0.5|il of template DNA (i.e. 
0.5|il of RT product) was added to the following reagents on ice in a 0.5ml 
microcentrifuge tube:
lOx concentration of PCR buffer 2.5|il
dNTP mix (2.5mM stock) 2.0pl
5’ Primer (20pM stock) 0.625pl
3’ Primer (20pM stock) 0.625pl
Taq DNA polymerase (5 Weiss units/pl) 0.2pl
Sterile nuclease free water to a final volume of 25pl
A “minus cDNA” sample was also incubated as a negative PCR control. 
Assembled reactions were all amplified in a PTC-100™ Programmable 
thermal controller, the standard thermal cycling conditions of which are 
tabulated in Table 2.4. The optimised cycle number was varied according to the 
gene of interest (see Table 2.3) at the “Remaining Cycles” step in Table 2.4.
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Table 2.4 Standard thermal cycling conditions for PCR
Cycle Cycle conditions
Initial Cycle: Cycle number 1
• Denaturation 2 minutes at 95°C
• Annealing 1 minutes at 55°C
• Extension 10 minutes at 72°C
Remaining Cycles: Cycle number 24-36
• Denaturation 30 seconds at 94°C
• Annealing 1 minute at 55°C
• Extension 1 minute at 72°C
Final Cycle: Cycle number 1
• Denaturation 1 minute at 94°C
• Annealing 1 minute at 55°C
• Extension 10 minutes at 60°C
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2.3.2.1.3 Visualisation o f  PCR Products
Following PCR, the PCR products were analysed by size separation using 2% 
agarose gel electrophoresis and visualised using ethidium bromide (EtBr) 
staining of agarose gels under ultra violet (UV) light illumination. The p-actin 
product was also added to the appropriate wells for each gene sample to allow 
normalisation.
In order to prepare the 2% agarose gel, 2g of molecular biology grade 
multipurpose agarose was added to 100ml of 1 x Tris acetate buffer pH 8.3 
(TAE) (made as a 50 x concentration stock using 242g/L Trizma® base, 
57.1ml/L glacial acetic acid and 18.2g/L disodium salt EDTA). TAE 
containing the agarose was brought to the boil using a microwave oven, and 
left to cool before addition of lpl of EtBr (5mg/ml stock) to the gel. The gel 
was then poured into a gel casting tray with the appropriate well former (20pl 
comb spaces) inserted at the top end. The gel was allowed to polymerise for at 
least 40 minutes on a flat surface before use. Once set, the gel was placed in a 
BIORAD electrophoresis tank filled with 1 x TAE. Samples were loaded using 
RNA loading buffer (containing 6g sucrose and 10ml distilled water filtered 
through a 0.2pM filter), loading each well with 3 pi loading buffer, 3 pi P-actin 
PCR product, and 11.5pl gene Primer PCR product, alongside a standard size 
molecular weight marker (Hyperladder IV 100-Lanes). The products on the gel 
were set to run at 70 volts for 40 minutes.
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The PCR products were then visualised under UV and photographed using an 
AlphaDigiDoc® RT Olympus camera, and images obtained and analysed using 
Alpha DigiDoc™ computer software. Intensity of each band was estimated by
•TW
the Alpha DigiDoc computer software, which normalised to |3-actin signal. 
Results obtained were subsequently standardised to the control preparation for 
the experiment (e.g. in treated w/t MCF7 cells) and plotted onto a graph. Error 
bars were added according to standard deviation and statistical significance 
was measured using a two tailed Student T-test (p value considered significant 
<0.05).
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Chapter 3 — Results
Antioxidants and Oxidative stress in Resistant and 
Responsive Breast Cancer Cells
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3.1 Total Antioxidant Capacity (TAC) measured in ER+ 
Tamoxifen resistant versus Endocrine responsive MCF-7 breast 
cancer cells, and further antihormone and anti-EGFR resistant 
models
Recent literature indicates that an excess of antioxidants may be detrimental to 
the effectiveness of some chemotherapeutics in cancer which rely on the 
induction of ROS as part of their antitumour mechanism. As such, antioxidants 
released subsequent to chemotherapeutic-induced ROS can inevitably confer 
therapeutic resistance. Interestingly, blockade of such antioxidants can in turn 
enforce chemotherapeutic response (Spitz et al., 1993). The relationship 
between antioxidants and response and failure with antihormones remains 
largely unknown in breast cancer. Equally it remains unexplored in the context 
of growth factor inhibitor resistance, for example anti-erbB inhibitors (such as 
the anti-EGFR agent gefitinib) that are under evaluation in patients with breast 
cancer who have failed on endocrine therapy. Measurement of TAC in our 
antihormone resistant (and gefitinib resistant) breast cancer models could thus 
provide important biological information as to whether increased antioxidants 
may play a role in resistance to these various targeted therapies. In turn this 
could begin to determine if antioxidants may have relevance as a new 
therapeutic target to limit resistance.
Basal measurement of TAC was first undertaken using an Antioxidant assay kit 
following 24 hours seeding down of tamoxifen resistant versus responsive
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cells. There was an elevated level of basal TAC within the TAMR cells, with a 
significant 12 fold increase in TAC (p=0.005) in comparison to the parental w/t 
MCF-7 models (Figure 3.1). Approximately 10 fold difference was maintained 
throughout the subsequent growth of these cell models for both 7 and 10 days 
with significantly increased TAC levels (p=0.001 and p=0.0005 respectively) 
versus w/t MCF7 cells (Figure 3.1).
With the observation that significantly increased levels of TAC appeared to 
exist in the therapeutic resistant breast cancer model TAMR in comparison to 
the w/t MCF-7, it was explored whether this relationship extended to other 
antihormone resistant cells and also to the acquired tamoxifen and EGFR 
inhibitor resistant breast cancer model. These comprised the Faslodex resistant 
FASR cells, oestrogen deprivation resistant X-MCF cells and the tamoxifen 
and gefitinib resistant NEW DUBS model. Growth curve analysis of these 
models in their experimental media was performed in parallel in order to 
confirm that any increase in TAC detected in the various resistant models was 
not a result of increased proliferative capacity in the resistant cells (Figure 3.2). 
There was no significant difference in growth rate in any of the resistant 
models TAMR, FASR, X-MCF or NEW DUBS cells versus untreated w/t 
MCF7 cells (Figure 3.2).
93
Chapter 3 -  Results
Figure 3.1 Total Antioxidant Capacity examination of TAMR resistant
model versus w/t MCF-7 cell line at 24 hours, 7 days and 10 days
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Basal TAC levels in TAMR and w/t MCF-7 cells were measured using the 
Total Antioxidant Assay Kit from Sigma-Aldrich Company Ltd. The 
antioxidant assay measures the oxidation o f  the ABTS substrate to ABTS’+ 
which is a soluble green colour chromogen that can be detected 
spectrophotometrically at 405nm. Antioxidants naturally occurring within the 
cell suppress this reaction in a concentration dependent manner, with the colour 
intensity decreasing proportionally to the increased levels o f  antioxidants 
present. TAMR cells were tested against the parental MCF-7 cell line at 24 
hours, 7 days and 10 days and were significant by Student T-test compared to 
the parental cells with *p=0.005, **p=0.001, ***p=0.0005 respectively. These 
data represent a typical example o f n=3 experiments ± SD.
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Figure 3.2 Growth curve for resistant models TAMR, FASR, X-MCF and 
NEW DUBS versus w/t MCF-7 cells
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Cell models w/t MCF-7, TAMR, FASR, X-MCF, and NEW DUBS were 
grown in phenol red-free RPMI supplemented with 5% csFCS, 
penicillin/streptomycin (lOiU/ml -  lOOpg/ml), fungizone (2.5100pg/ml), and 
glutamine (4mM) over 0-1 ldays, counting wells at days 1,4,6,8 and 11 using a 
Beckman Coulter Counter Multisizer II. Cells were initially seeded at an 
equivalent density (4 x l0 4cells/well) on 24 Well Coming Co-star plates. 
Significance was calculated using Student T-test (on day 8) compared to the 
control parental cells (w/t MCF7) with TAMR at p=0.321, FASR at p=0.987, 
X-MCF at p=0.0558 and NEW DUBS at p=0.067. These data represent a 
typical example o f  an experiment performed three times ± SD.
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There was again, however, an increase in TAC in the FASR versus the w/t 
MCF-7 model. Indeed, the elevated level of TAC appeared even greater in 
FASR models, with differences of up to 22 fold increase shown at 24 hours and 
21 fold increase at 7 and 10 days in comparison to the w/t MCF-7 (p=0.0003, 
p=0.006 and p=0.0005 respectively) (Figure 3.3). In oestrogen deprived X- 
MCF cells, an even more prominent elevation of TAC was present with 50 fold 
difference shown in X-MCF models versus the w/t MCF-7 model by day 10 
(p=0.0006) (Figure 3.4). This was again similar to the 24 hour and 7 day level, 
which gave a 48 fold and 40 fold increase respectively compared to the w/t 
MCF-7 models (p=0.003 and p=0.01 respectively) (Figure 3.4). When 
detection of TAC was extended to the tamoxifen and anti-EGFR inhibitor 
resistant model NEW DUBS, again significant upregulation of TAC was 
apparent (Figure 3.5). Thus there were significantly elevated levels of TAC 
present at 24 hours, 7 days and 10 days, which were at 14 fold, 11 fold, and 16 
fold difference in comparison to the w/t MCF-7 model (p=0.007, p=0.03 and 
p=0.0006 respectively) (Figure 3.5).
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Figure 3.3 Total Antioxidant Capacity examination of FASR resistant 
model versus w/t MCF-7 cell line at 24 hours, 7 days and 10 days.
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Basal TAC levels in FASR and w/t MCF-7 cells were measured using the Total 
Antioxidant Assay Kit from Sigma-Aldrich Company Ltd. FASR cells were 
tested against the parental MCF-7 cell line at 24 hours, 7 days and 10 days and 
were significant by student T-test compared to the parental cells with 
*p=0.0003, **p=0.006, ***p=0.0005 respectively. These data represent a 
typical example o f  n=3 experiments ± SD.
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F ig u re  3.4 T o ta l A n tio x id a n t C a p a c ity  e x a m in a tio n  o f X -M C F  re s is ta n t
m odel v e rsu s  w /t M C F -7  cell line a t 24 h o u rs , 7 days a n d  10 days.
Basal TAC levels in X-MCF and w/t MCF-7 cells were measured using the 
Total Antioxidant Assay Kit from Sigma-Aldrich Company Ltd. X-MCF cells 
were tested against the parental MCF-7 cell line at 24 hours, 7 days and 10 
days and were significant by student T-test compared to the parental cells with 
*p=0.003, **p=0.01, ***p=0.0006 respectively. These data represent a typical 
example o f  n=3 experiments ± SD.
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F ig u re  3.5 T o ta l A n tio x id an t C a p a c ity  ex am in a tio n  o f N E W  DUBS
re s is ta n t  m odel v e rsu s  w /t M C F -7  cell line a t 24 h o u rs , 7 days an d  10 days.
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Basal TAC levels in NEW DUBS and w/t MCF-7 cells were measured using 
the Total Antioxidant Assay Kit from Sigma-Aldrich Company Ltd. NEW  
DUBS cells were tested against the parental MCF-7 cell line at 24 hours, 7 
days and 10 days and were significant by student T-test compared to the 
parental cells with *p=0.007, **p=0.03, ***p=0.0006 respectively. These data 
represent a typical example o f  n=3 experiments ± SD.
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3.2 Affymetrix Microarray mRNA profiling to determine 
Antioxidant gene expression in antihormone resistance
Given that TAC increased in all the acquired resistant cell models, mRNA 
profiling of antioxidant (and other oxidative stress-related) genes was 
performed using Affymetrix HG-U133A microarray data available for these 
models. The web-based microarray data analysis software Genesifter™ was 
used to analyse and compare the expression data for the antioxidant genes 
derived from triplicate Affymetrix HG-U133A chips for each cell model. The 
project created for this investigation in GeneSifter was that of w/t MCF-7 cells 
as a control versus the various resistant cell lines i.e. TAMR, FASR, X-MCF, 
and NEW DUBS. For confidence in array performance prior to the antioxidant 
expression interrogation, the trefoil factor 1 (breast cancer, oestrogen-inducible 
sequence) or pS2 gene was initially profiled using heatmapping in GeneSifter 
to see if it exhibited the expression pattern already known for such models 
(Henry et al., 1991; Hutcheson et al., 2003; Staka et al., 2005) (Figure 3.6). On 
the heatmaps, green represented down regulated genes versus the w/t MCF-7 
model, and red represented up regulation of the gene versus the w/t MCF-7 
model, where black indicates no change. As expected, expression of the gene 
was down regulated in TAMR and FASR models versus w/t MCF-7 cells. 
Equally pS2 was up regulated in X-MCF and NEW DUBS models where there 
are known to be high levels of this ER regulated gene. These findings give 
confidence of the arrayed sample performance for subsequent antioxidant gene 
interrogation.
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F ig u re  3.6 T refo il  F a c to r  1 o r  pS2 gene (A ffym etr ix  p ro b e  no. 205009_at)
expression heatmap profile from GeneSifter across acquired resistant
versus responsive breast cancer models
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3.2.1 GeneSifter analysis of antioxidant gene expression on the arrays
Initially through extensive literature search, 200 oxidative stress related genes 
were identified for study, 39 of which were antioxidant genes, comprising 
n=61 Affymetrix probes in total. Of note, analysis of individual genes and their 
multiple probes confirmed that multiple probes in general exhibited the same 
trend of expression across the cell models. For example, it was revealed that 
the multiple probes exhibited highly comparable expression profiles for the 
antioxidant gene UDP glycosyltransferase 1 family, polypeptide A6 (UGT1A6) 
(Figure 3.7a). The intensity of the colour red on the heatmaps indicated 
approximately the increase in expression of the gene for each model, where 
bright red indicated high expression and a dark red/brown shade was indicative 
of a more modest increase in expression versus the MCF-7 model (in black). 
The five probes of this gene exhibited down regulation in three resistant 
models and up regulation in the FASR cells only versus the w/t MCF-7 model, 
with small error bars from the triplicate results for each probe’s log intensity 
plot (Figure 3.7b). This finding gave confidence in individual antioxidant 
probe profiles revealed by Genesifter, and thus in its potential usefulness as a 
tool for analysing expression data derived from Affymetrix HG-U133A chips 
for antioxidant genes.
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Figure 3.7a GeneSifter heatmaps showing mRNA profiles for the 
multiple probes of the antioxidant gene UGT1A6 across acquired resistant 
versus responsive cell lines
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(b) Log intensity profile o f  expression as shown by GeneSifter™ for
representative probe no. 215125_s_at (mean +/- SEM) for gene UGT1A6
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3.2.2 GeneSifter analysis of antioxidant gene category
As indicated above, of the 200 oxidative stress related genes originally 
collected, 39 genes were antioxidants that could potentially defend against pro­
oxidant assaults on the cell. These 39 antioxidant genes which could have a 
potential role in contributing to therapeutic resistant growth are displayed in 
Table 3.1. In order to subsequently begin to find if any of these antioxidant 
genes are up regulated in two or more forms of resistance, GeneSifter heatmap 
profiles were initially examined across all the acquired endocrine and anti- 
EGFR resistant cell lines to monitor for any associated trends, examining for 
increases in resistant models TAMR, FASR, X-MCF, and NEW DUBS versus 
w/t MCF-7 cells. Of these 39 antioxidant genes, 59% (n=23 genes) showed up 
regulation to some degree in at least two forms of resistance in comparison to 
the w/t MCF-7 and their typical probe profiles are displayed in Figure 3.8. It 
was subsequently explored using statistical testing if any of these up regulated 
antioxidant genes were significantly-induced in the endocrine and anti-EGFR 
resistant models versus w/t MCF-7 cells. Testing using ANOVA across the 
cell lines showed that 15 of the antioxidant genes showed evidence of 
significant (p<0.05) up regulation, and for these that the up regulation spanned 
at least two forms of resistance. Of these antioxidant genes, 9 displayed 
upregulation shared across all forms of antihormone and anti-EGFR resistance 
(Figure 3.9), with 6 antioxidant genes displaying upregulation in two or three 
forms of resistance (Figure 3.9). These GeneSifter profile findings are further 
clarified in the Venn diagram for the various models in Figure 3.10.
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Table 3.1 Antioxidant genes (n=39) examined using GeneSifter
Alias Name
AFAR3 Aldehyde reductase 3
CAT Catalase
EPHX2 Epoxide hydrolase 2, cytoplasmic
EPX Eosinophil peroxidase
FMOl Flavin containing monooxygenase 1
FM05 Flavin containing monooxygenase 5
G6PD Glucose-6-phosphate dehydrogenase
GPX1 Glutathione peroxidase 1
GPX2 Glutathione peroxidase 2 (gastrointestinal)
GPX3 Glutathione peroxidase 3 (plasma)
GPX4 Glutathione peroxidase 4 (phospholipid hydroperoxidase)
GRX Glutaredoxin (thioltransferase)
GSR Glutathione reductase
GST2 Glutathione S-transferase A2
GSTA4 Glutathione S-transferase A4
GSTM1 Glutathione S-transferase Ml
GSTM3 Glutathione S-transferase M3 (Brain)
GSTT2 Glutathione S-transferase theta 2
HMOX1 Heme oxygenase (decycling) 1
HMOX2 Heme oxygenase (decycling) 2
LPO Lactoperoxidase
MGST1 Microsomal glutathione S-transferase 1
MPO Myeloperoxidase
NQOl NAD(P)H dehydrogenase, quinone 1
PON1 Paraoxonase 1
PRDX1 peroxiredoxin 1
PRDX2 peroxiredoxin 2
PRDX3 peroxiredoxin 3
PRDX4 peroxiredoxin 4
PRDX5 peroxiredoxin 5
PRDX6 peroxiredoxin 6
SOD1 Superoxide dismutase 1, soluble
SOD2 Superoxide dismutase 2, mitochondrial
SOD3 Superoxide dismutase 3, extracellular
TXN Thioredoxin
TXN2 Thioredoxin 2
TXNRD1 Thioredoxin reductase 1
TXNRD2 Thioredoxin reductase 2
UGT1A6 UDP glucuronosyltransferase 1 family, peptide A6
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Figure 3.8 GeneSifter heatmaps displaying mRNA expression profiles for 
23 genes showing upregulation in at least 2 acquired resistant model 
versus w/t MCF-7 cells.
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GeneSifter heatmap expression profiles were derived from Affymetrix HG- 
U133A chips for each cell model (from triplicate preparations). O f the 39 
antioxidant genes, these 23 genes showed visual evidence on the heatmaps o f  
up regulation (different shades o f red/brown) in at least 2 resistant models 
versus w/t MCF-7 cells.
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Figure 3.9 GeneSifter profile analysis for antioxidant genes with a 
significant increase in expression (ANOVA p<0.05) in the resistant cell 
lines versus the w/t MCF-7 model (n=15)
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Heatmaps were derived from Affymetrix HG-U133A chips for each cell model 
in triplicate using GeneSifter for these genes that were ANOVA significant. 9 
genes show a trend o f upregulation (different shades o f  red) across all resistant 
models, shown in yellow. The remaining 6 genes are shared by two or more 
forms o f  resistance versus the w/t MCF-7 model, shown in orange.
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Figure 3.10 Venn diagram of patterns of up regulated antioxidant gene 
changes shared across multiple resistant models (ANOVA p<0.05)
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This four-way Venn diagram was designed to show the ANOVA significant 
upregulated antioxidant genes for each resistant model. Where resistant 
models overlap, the antioxidant genes were shared across those forms o f  
resistance.
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Of the 15 antioxidant genes that showed evidence of up-regulation across at 
least two forms of resistant models, the 9 genes shared by all forms of 
resistance were PRDX6, PRDX1, PRDX4, NQOl, EPHX2, GPX2, GSTA4, 
TXNRD1, and SOD1 (Figure 3.9 and 3.10). In addition, GLRX, and G6PD 
were upregulated in TAMR cells, FASR cells, and NEW DUBS models. CAT 
is upregulated in TAMR cells, FASR cells, and X-MCF models. TXN and 
PRDX3 antioxidant genes are upregulated in FASR and X-MCF models, and 
the antioxidant gene TXNRD2 is upregulated in TAMR cells, NEW DUBS and 
X-MCF models (Figure 3.9 and 3.10). Although there were also genes that 
were upregulated specific to individual forms of resistance, they are not the 
main focus of this thesis since they are unlikely to contribute to a generic 
resistance mechanism, and are therefore not displayed in Figures 3.9 and 3.10.
Along with expression increases in multiple forms of resistance, to select the 
final resistant antioxidant gene-set for further investigation by PCR verification 
priority was also given to genes that were linked together in specific pathways. 
This included the antioxidant networks of the PRDX family that regulates 
intracellular H2O2, and TXN, TXNRD1, TXNRD2 that can react with oxygen 
free radicals and help to replenish depleted PRDX that can be inactivated upon 
over-oxidation by H2O2 (GeneCards™). Not all genes of the PRDX family 
were chosen as two were considered to suffice to examine if there was a trend 
of involvement for this pathway. Both PRDX1 and PRDX4 were very similar 
in expression profile, therefore only PRDX1 was chosen for further analysis. 
PRDX6 was upregulated significantly (T-test p<0.05) across all resistant
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models, and was therefore chosen above PRDX3 that was induced in only two 
forms of resistance and only T-test significantly up regulated in FASR cells.
Montano et al. had previously reported that anti-oestrogens could activate 
NQOl that can protect cells against the toxic and tumour promoting effects of 
carcinogens in early onset of disease (Montano et al., 2005). NQOl was of 
interest since it would be of value to see if this protection also extended to 
promotion of growth in multiple resistant states. GLRX, GSTA4 and GPX2 
are all glutathione dependant antioxidant genes, although each have their own 
unique redox function within the cell. With the availability of a glutathione 
inhibitor, buthionine sulfoximine (BSO), all these genes in the glutathione 
network were thus deemed important for further verification by PCR to tiy to 
determine if there is an importance of glutathione in resistance. SOD1 and 
CAT are also high priority for verification by PCR since they not only 
conveyed a strong profile but also comprise a common first line defence 
against ROS, whereby SOD1 destroys intracellular free radicals and CAT 
protects against toxic effects of the peroxides formed within the cell. EPHX2 
mainly targets xenobiotics and G6PD plays a more important role in the 
pentose phosphate pathways and therefore were deemed ontologically of less 
interest at this stage of the investigation in the context of progression to 
antioxidant verification at the mRNA level.
The 15 shared antioxidant genes of potential interest for PCR verification were 
also further analysed using GeneSifter software capabilities and also intensity
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profiles, along with literature searches (including available inhibitors for 
further future study), in order to compile comprehensive data for each “shared” 
gene as presented in Table 3.2, and for genes up regulated in two or three forms 
of resistance in Table 3.3. Along with intensity profiles, GeneSifter also 
reported likely mRNA expression level for each gene from the Affymetrix 
data. These “present” (high expression), “absent” (low/no expression) and 
“marginal” calls indicated relative expression abundance. Individual models in 
which the increase of expression reached levels that were also T-test significant 
versus w/t MCF-7 cells (p<0.05), across triplicate cell preparations for each 
model were also noted. In addition, it was noted by examination of the w/t 
MCF7 Affymetrix database that some of the genes were also induced early by 
10 day tamoxifen and/or faslodex treatment, while others were potentially 
unique to acquired resistance (Table 3.2 and 3.3)
The strongest overall ontological and expression profiles in Tables 3.2 and 3.3, 
were designated by their present call at the RNA level, above described 
antioxidant pathway and ontological selection, and heatmap significant patterns 
in resistance. 11 antioxidant genes were thus chosen for analysis by PCR with 
a strong overall profile.
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Table 3.2 ANOVA Significant antioxidant genes (n=9) with expression profiles 
upregulated in all resistant models
G ene nam e Call at 
mRNA level
T -test
Significance
Antihormonal 
up-regulation in 
w/t MCF7 cells
Drugs to  target 
m echanistic link
Ontological 
and Drug 
R eference
Overall
Strong
profile
PRDX1 Present FASR 
X-MCF 
NEW DUBS
Anti-hormone induced AW464 Wells et al.. 2003, 
Berry et al.. 2005
y
PRDX4 Present FASR 
X-MCF 
NEW DUBS
Anti-hormone induced AW464 Wells et al.. 2003; 
Berry et al., 2005
PRDX6 Present All models Specific to resistance AW464 Wells et al., 2003; 
Berry et al.. 2005 y
NQ01 Present TAMR
FASR
NEW DUBS
Anti-hormone induced dicoumarol Lien et al . 2008
y
EPHX2 Absent X-MCF 
NEW DUBS
Anti-hormone induced AUDA Motoki et a l . 2008
TXNRD1 Present TAMR
FASR
TAM and FAS anti- 
hoimone induced
PX-916 Powis et a l , 2006 y
OPX2 Mixed present & 
Absent
TAMR 
NEW DUBS
Specific to resistance BSO Lewis-Wambi et 
al.. 2009 y
SOD1 Present FASR
X-MCF
Anti-hormone induced Disulfiram
(DSF)
Marikovsky et al., 
2003 y
OSTA4 Present TAMR
FASR
NEW DUBS
TAM and FAS anti- 
hoimone induced
BSO Lewis-Wambi et 
al.. 2009 y
Table 3.3 ANOVA significant antioxidant genes (n=6) with expression profiles 
upregulated in two or three forms of resistance
G ene nam e Call at mRNA level
T-test
Significance
Antihormonal 
up-regulation in 
wA MCF7 cells
D rugs to target 
m echanistic link
Ontological 
and Drug 
R eference
Overall
Strong
profile
GLRX Mixed present & 
absent
TAMR
FASR
FAS anti-hormone 
induced BSO
Lewis-Wambi et 
al.. 2009 y
G6PO Present TAMR only Specific to resistance DHEA Okouchi et al., 
2005
CAT Mixed present & 
Absent
FASR
X-MCF
Specific to resistance Copper sulfate, 
3-amino-1,2,4- 
triazole
Margoliash & 
Novogradsky, 1958 y
TXN Present FASR
X-MCF
Specific to resistance AW 464 Wells et al., 2003. 
Berry e ta l .  2005 y
PRDX3 Present FASR only Specific to resistance AW464 Wells etal., 2003, 
Berry et al., 2005
TXNRD2 Present TAMR 
NEW DUBS
Specific to resistance 1-Chloro-2.4-
dinitrobenzene
A m 6ret al..1995 y
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3.3 PCR Verification studies for the 11 induced Antioxidant 
genes increased in resistance
The 11 antioxidant genes PRDX1, PRDX6, TXN, TXNRD1, TXNRD2, GPX2, 
GSTA4, GLRX, NQOl, SOD1, and CAT were chosen for verification by PCR 
in triplicate mRNA preparations from resistant cells, focusing on TAMR and 
FASR cells, versus the parental w/t MCF-7 model. An RNA free sample was 
also run as a negative control and this always failed to give a spurious signal. 
Densitometric results obtained for each model were subsequently normalised to 
p actin expression, and presented graphically in relation to the w/t MCF7 
model. Statistical analysis was performed for each resistant model against the 
w/t MCF7 model using a Student's paired t-Test. Again for confidence in PCR 
and the mRNA samples, the trefoil factor 1 (pS2) gene was first examined in 
these mRNA samples to see if it exhibited the expression change that would be 
expected (Figure 3.11), where the additional use of 10 day oestradiol (E2 (10- 
9M)) -  treated w/t MCF7 cell mRNA samples confirmed this is behaving as an 
E2 -  regulated gene in this system. As in Affymetrix, small but significantly 
detectable decreases were shown in TAMR and FASR respectively versus w/t 
MCF7 cells, with the expected significant E2 increase in expression.
The following genes were readily detectable, in keeping with the “present” call 
by Affymetrix (Tables 3.2 and 3.3): (i) GSTA4 -  The antioxidant gene
GSTA4 was shown by microarray gene analysis profiling to be up regulated 
across all forms of resistance, with particular significance (by t-Test) in TAMR
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and FASR cells (Figure 3.12). PCR verified this, with over a 50% significant 
increase in mRNA expression achieved in the TAMR model (p = 0.012), and 
FASR models (p = 0.047) versus the w/t MCF7 model (Figure 3.12). (ii) 
TXNRD1 -  the antioxidant gene TXNRD1 had been shown by gene analysis 
profiling to be up regulated across all forms of resistance, again with particular 
significance (by t-Test) in TAMR and FASR cells. Again, PCR verified these 
increases in TAMR and FASR cells increasing approximately 80% in both 
models (p = 0.028 and p = 0.033 respectively, Figure 3.13). (iii) NQOl -  the 
antioxidant gene NQOl had also been shown by gene analysis profiling to be a 
resistant gene significantly up regulated in both TAMR and FASR models 
(Figure 3.14). However, mRNA analysis by PCR was only able to confirm a 
significant (t-Test) elevation of NQOl expression in TAMR cells with a 
substantial (over 100%) increase in expression versus w/t MCF7 cells (p = 
0.02) (Figure 3.14).
(iv) GLRX -  equating with its mixed present and absent call at mRNA level 
using Affymetrix, GLRX required a higher PCR cycle number of 36. 
Affymetrix analysis for GLRX also showed higher expression levels of this 
resistant gene particularly in TAMR and FASR models. PCR analysis verified 
these gene changes, with over 50% increase shown in the TAMR model 
(p=0.006) and over 80% increase in GLRX shown in the FASR model 
(p=0.037) versus w/t MCF7 cells (Figure 3.15).
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(v) CAT -  Again like GLRX, equating with its mixed present and absent call at 
mRNA level using Affymetrix, CAT required a higher PCR cycle number of 
30 cycles. The antioxidant gene CAT had again been shown by gene analysis 
profiling to be up regulated in all endocrine resistant models with particular 
significance in the FASR model (Figure 3.16). mRNA analysis by PCR was 
able to detect a small yet significant (t-Test) increase in CAT expression of 
20% in TAMR models (p=0.049) and over 40% increase in FASR models 
(p=0.016) consistent with the Affymetrix profile obtained for that gene (Figure 
3.16).
(vi) TXN -  This gene was more easily detectable, in agreement with the 
present call by Affymetrix using 27 cycles for PCR. TXN was shown by 
Genesifter log intensity profiles to be a resistance gene significantly (by t-Test) 
up regulated in FASR (and in X-MCF model not displayed here). PCR analysis 
of mRNA expression was able to reveal significant increase in FASR 
expression by 80% (p=0.028), and also suggested this could extend to TAMR 
cells with over 70% increase (p=0.015) in comparison to w/t MCF7 control 
(Figure 3.17).
(vii) TXNRD2 was a resistant gene giving a present call equating with a lower 
cycle number of 27 cycles. It was shown to be slightly upregulated in TAMR 
models but down regulated in FASR model (in contrast to other resistant 
models) by Affymetrix gene analysis. This profile was verified by PCR, with a
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50% increase in TAMR models (p=0.042) and over 30% decrease in FASR 
cells (p=0.042) versus w/t MCF7 cells (Figure 3.18).
(viii) GPX2 had been shown by gene analysis profiling to be up regulated to 
some degree in all resistant models, with particular significance in the TAMR 
model (Figure 3.19). However, with a mixed present and absent call at mRNA 
level and thus 30 PCR cycles required, mRNA analysis by PCR was only able 
to detect the significant (t-Test) increase in the TAMR model with over 300% 
up regulation compared to the w/t MCF7 model (p=0.0009), and no significant 
increase in FASR cells (Figure 3.19). Although the remaining SOD1, PRDX1 
and PRDX6 called present and showed upregulation by Affymetrix gene 
analysis in the resistant models, PCR results detected expression but failed to 
verify the increases in antioxidant genes’ mRNA expression in both TAMR 
and FASR models versus w/t MCF7 cells (Figures 3.20). There was thus some 
evidence of upregulation in resistance by both Affymetrix and PCR for 8 out of 
the 11 genes, with GSTA4, TXNRD1, GLRX, CAT, and TXN proving to be 
“shared” genes upregulated in both TAMR and FASR cells.
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Figure 3.11 Verification of PCR samples (versus Affymetrix heatmap 
data) for TAMR and FASR samples versus the w/t MCF7 model (and 
oestradiol treated w/t MCF7 cells) by monitoring the Trefoil Factor 1 gene 
(pS2)
w/t MCF7 w/t MCF7 TAMR
+ E2
FASR
Affymetrix data:
PCR data: 
pS2 (380bp) 
(3-actin (204bp)
d-o £ 
<u c
V i —
oZ
dw-o
4 0 0
3 5 0
3 0 0
2 5 0
200
1 5 0
100
5 0
0
J-i-J
**
_ _ _ _ _
**★
□ i■
Negative
Control
w /t M C F 7 w/t MCF7
+ E2
T A M R F A S R
Affymetrix profile data were obtained using GeneSifter heatmaps for w/t MCF7 cells 
treated with 10'9M E2, TAMR and FASR models versus w/t MCF7 cells for pS2. 
These intensity changes were verified by PCR analysis and the mean expression ± SD 
are displayed in a histogram as shown above. Normalised PCR densitometry results 
were represented relative to 100% for w/t MCF7 cells for the E2 treatment, TAMR 
and FASR cells and these were statistically significant using a Student T-test 
(*p=0.004, **p=0.022, and ***p=0.015 respectively) using triplicate preparations 
versus untreated w/t MCF7 cells. The same analysis approach was carried out in 
resistant models versus w/t MCF7 cells for all antioxidant genes in the following 
Figures (3.12 -  3.20)
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F ig u re  3.12 P C R  profi le  fo r  G S T A 4  gene (versus  A ffym etr ix  h e a tm a p
d a ta )  in T A M R  a n d  F A S R  cell lines v e rsu s  w /t  M C F -7  cells
w/t MCF7 TAMR FASR
Asymetrix data:
p actin (380bp) 
GSTA4 (200bp)
w/t MCF7 TAMR FA SR
Affymetrix profile data were obtained using GeneSifter heatmaps for TAMR and 
FASR models versus w/t MCF7 (day 7) cells for GSTA4. These expression changes 
were verified by PCR analysis and the mean ± SD are displayed in a histogram as 
shown above. Normalised PCR densitometry results were represented relative to 
100% for w/t MCF7 cells for TAMR and FASR cells and these were statistically 
significant using a Student T-test (*p=0.012 and **p=0.047 respectively) using 
triplicate preparations.
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F ig u re  3.13 P C R  profile  fo r  TX N RD 1 gene (versus  A ffym etrix  h e a tm a p
d a ta )  in T A M R  a n d  F A S R  cell lines ve rsu s  w /t  M C F -7  cells
w/t MCF7 TAMR FASR
Affymetrix data:
P actin (380bp)
TXNRD1
(200bp)
w/t M C F7 TAMR F A S R
Affymetrix profile data were obtained using GeneSifter heatmaps for TAMR and 
FASR models versus w/t MCF7 (day 7) cells for TXNRD1. These expression changes 
were verified by PCR analysis and the mean ± SD are displayed in a histogram as 
shown above. Normalised PCR densitometry results were represented relative to 
100% for w/t MCF7 cells for TAMR and FASR cells and these were statistically 
significant using a Student T-test (*p=0.028 and **p=0.033 respectively) using 
triplicate preparations.
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F igu re  3.14 P C R  profile  fo r  N Q O l  (versus  A ffym etrix  h e a tm a p  d a ta )  in
T A M R  a n d  FA SR  cell lines versus  w /t  M C F -7  cells
w/t MCF7 TAMR FASR
Affymetrix data:
PCR data:
(i actin (380bp) 
NQOl (250bp)
d-o 3
s a  
■5 b
E © 
o E Z. 2*s
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250
200
150
100
50
0
w/t MCF7 TAMR FASR
Affymetrix profile data were obtained using GeneSifter heatmaps for TAMR and 
FASR models versus w/t MCF7 (day 7) cells for NQOl. These expression changes 
were verified by PCR analysis and the mean ± SD are displayed in a histogram as 
shown above. Normalised PCR densitometry results were represented relative to 
100% for w/t MCF7 cells for TAMR and FASR cells and only TAMR cells were 
statistically significant using a Student T-test (*p=0.02) using triplicate preparations.
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F ig u re  3.15 P C R  profile  fo r  G L R X  gene (versus  A ffym etr ix  h e a tm a p
d a ta )  in T A M R  a n d  FA SR  cell lines ve rsu s  w /t  M C F -7  cells
w/t MCF7 TAMR FASR
Affymetrix data:
PCR data:
(i actin (380bp) 
GLRX (180bp)
& 2 5 0
T3
B<U 2 0 0
<U cl“ l 1 5 0
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6■o 0
* *
w/t M C F7 TAM R F A S R
Affymetrix profile data were obtained using GeneSifter heatmaps for TAMR and 
FASR models versus w/t MCF7 (day 7) cells for GLRX. These expression changes 
were verified by PCR analysis and the mean ± SD are displayed in a histogram as 
shown above. Normalised PCR densitometry results were represented relative to 
100% for w/t MCF7 cells for TAMR and FASR cells and these were statistically 
significant using a Student T-test (*p=0.006 and **p=0.037 respectively) using 
triplicate preparations.
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F ig u re  3.16 P C R  profile  fo r  C A T  gene (versus  A ffym etrix  h e a tm a p  da ta )
in T A M R  a n d  F A S R  cell lines ve rsus  w /t  M C F -7  cells
w/t MCF7 TAMR FASR
Affymetrix data:
PCR data:
3 actin (380bp) 
CAT (220bp)
1803c 160
■T36
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E
b
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Z o 60t/5c 40<u“O 20
0
* *
wA M C F 7 TAMR FASR
Affymetrix profile data were obtained using GeneSifter heatmaps for TAMR and 
FASR models versus w/t MCF7 (day 7) cells for CAT. These expression changes were 
verified by PCR analysis and the mean ± SD are displayed in a histogram as shown 
above. Normalised PCR densitometry results were represented relative to 100% for 
w/t MCF7 cells for TAMR and FASR cells and these were statistically significant 
using a Student T-test (*p=0.049 and **p=0.016 respectively) using triplicate 
preparations.
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F igu re  3.17 P C R  profile  fo r  TX N  gene (versus  A ffym etrix  h e a tm a p  d a ta )
in T A M R  a n d  F A S R  cell lines versus  w /t M C F -7  cells
w/t MCF7 TAMR FASR
Asymetrix data:
PCR data:
P actin (380bp) 
TXN (250bp)
C/3
c■o 2
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100
5 0
w /t M C F 7 T A M R F A S R
Affymetrix profile data were obtained using GeneSifter heatmaps for TAMR and 
FASR models versus w/t MCF7 (day 7) cells for TXN. These expresion changes were 
verified by PCR analysis and the mean ± SD are displayed in a histogram as shown 
above. Normalised PCR densitometry results were represented relative to 100% for 
w/t MCF7 cells for TAMR and FASR cells and these were statistically significant 
using a Student T-test (*p=0.015 and **p=0.028 respectively) using triplicate 
preparations.
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F ig u re  3.18 P C R  profile  fo r  T X N R D 2 gene (versus  A ffym etrix  h e a tm a p
d a ta )  in T A M R  a n d  F A S R  cell lines v e rsu s  w / t  M C F -7  cells
w/t MCF7 TAMR FASR
Affymetrix data:
PCR data: 
p actin (380bp) 
TXNRD 2 (200bp)
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Affymetrix profile data were obtained using GeneSifter heatmaps for TAMR and 
FASR models versus w/t MCF7 (day 7) cells for TXNRD2. These expression changes 
were verified by PCR analysis and the mean ± SD are displayed in a histogram as 
shown above. Normalised PCR densitometry results were represented relative to 
100% for w/t MCF7 cells for TAMR and FASR cells and these were statistically 
significant using a Student T-test (*p=0.042 and **p=0.042 respectively) using 
triplicate preparations, TAMR expression increasing and FASR expression decreasing 
respectively.
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F ig u re  3.19 P C R  profile  fo r  G P X 2  gene (versus  A ffym etr ix  h e a tm a p  d a ta )
in T A M R  a n d  F A S R  cell lines ve rsus  w /t  M C F -7  cells
w/t MCF7 TAMR FASR
Affymetrix data:
PCR data:
GPX2 (380bp) 
{3-actin (204bp)
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Affymetrix profile data were obtained using GeneSifter heatmaps for TAMR and 
FASR models versus w/t MCF7 (day 7) cells for GPX2. These expression changes 
were verified by PCR analysis and the mean ± SD are displayed in a histogram as 
shown above. Normalised PCR densitometry results were represented relative to 
100% for w/t MCF7 cells for TAMR and FASR cells and these were only statistically 
significant in TAMR cells using a Student T-test (*p=0.0009) using triplicate 
preparations.
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F ig u re  3.20 P C R  profile  fo r  PR D X 1, P R D X 6, a n d  SOD1 genes in T A M R
a n d  F A S R  cell lines ve rsu s  w /t M C F -7  cells
w/t MCF7 TAMR FASR
p actin (380bp)
PRDX1 (200bp)
p actin (380bp)
PRDX6 (350bp)
P actin (380bp)
SOD1 (180bp)
PCR expression profiles were obtained for TAMR and FASR models versus w/t 
MCF7 (day 7) cells for PRDX1, PRDX6, and SOD1 genes. Results were not 
statistically significant in TAMR and FASR cells using a student T-test (p>0.05) using 
triplicate preparations.
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3.4 TAC and Antioxidant gene expression during initial 
treatment o f w /t MCF7 cells with anti-hormonal agents
Total antioxidant capacity had been shown earlier in the project to be elevated 
significantly in all the anti-hormone and anti-EGFR resistant models versus the 
w/t MCF7 cell line. Gene profiling analysis by Affymetrix also revealed 
significant upregulation of 15 genes across at least two forms of resistance 
versus w/t MCF7 cells with 9 potentially spanning all resistant states. In total 
11 antioxidant genes were chosen for their strong profiles and potential role in 
the antioxidant pathways, and these underwent verification studies at the 
mRNA level using RT-PCR on the TAMR and FASR versus w/tMCF7 cells. 
Of these, 11 antioxidant genes, 8 showed significant upregulation in at least 
one of the antihormone resistant breast cancer models with 5 spanning both 
states. However, a question arises as to whether the increase occurring in the 
verified antioxidant genes and TAC actually begins early in w/t MCF-7 cells 
during their treatment with endocrine agents such as tamoxifen (TAM) or 
faslodex (FAS), or if such increases are a feature only associated with the 
resistant state.
In order to address this, TAC analysis of triplicate w/t MCF7 cell preparations 
were treated with the growth inhibitory dose of 0.1 pM tamoxifen or faslodex. 
TAC measurement was performed after 10 days anti-hormone treatment to 
ensure cells are undergoing a growth inhibitory response and to allow 
comparison with further available Affymetrix, day 10 expression data, and
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subsequently PCR. Results showed an elevated level of TAC in w/t MCF7 
cells in the presence of tamoxifen (p=0.008) and in the presence of faslodex 
(p=0.001) versus untreated control w/t MCF7 cells (Figure 3.21). Levels 
achieved approximated 0.022mM and 0.042mM for TAMR and FASR cells 
respectively at 10 days (Figures 3.1 and 3.3). Thus, the elevated TAC appeared 
to be instigated early during initial exposure to endocrine agents.
The 11 selected antioxidant genes were then explored during 10-day anti­
hormone treatment of w/t MCF7 cells with tamoxifen or faslodex by PCR 
analysis. The untreated parental w/t MCF-7 model and w/t MCF-7 treated with 
10‘9M oestradiol (E2) were used as controls to run against w/t MCF7 cells 
treated with the anti-hormonal agents to learn more about the ER regulation of 
these genes. To initially check the quality of the mRNA samples and for 
confidence in PCR performance, the pS2 gene was again examined using the 
mRNA samples +/- anti-hormone treatment to see if the expected expression 
change was observed (Henry et al., 1991). An RNA free sample was also 
included as a negative control (Figure 3.22). As expected, PCR analysis of the 
oestrogen regulated pS2 gene revealed it was significantly upregulated in w/t 
MCF7 cells treated with E2, and significantly decreased in the presence of 
tamoxifen and particularly faslodex treatment versus untreated w/t MCF7 cells, 
indicating the samples were representative of behaviour of w/t MCF7 cells 
during endocrine response (Figure 3.22), and thus appropriate to examine 
antioxidant genes during this phase.
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The 11 antioxidant genes were not E2 induced versus w/t MCF7 cells. Thus, 
PCR results showed no significant changes for the antioxidant genes for E2 
treated w/t MCF7 cells versus control w/t MCF7 cells also with an acceptable 
mRNA free negative control shown for all (Figure 3.23). However in contrast, 
there was evidence of gene regulation by the growth inhibitory antihormones 
tamoxifen and/or faslodex in w/t MCF7 cells as had been observed by 
Affymetrix (referring to Table 3.2), whereby 8 of the 11 Antioxidant genes 
PRDX6, NQ01,TXNRD1, GPX2, GSTA4, GLRX, TXN, and TXNRD2 all 
correlate at the PCR level with the Affymetrix day 10 profiles. Only CAT, 
SOD1, and PRDX1 did not correlate.
Thus, the antioxidant gene GSTA4 was upregulated in both the presence of 
tamoxifen by over 80% (p=0.033) and faslodex by approximately 140% 
(p=0.026) compared to E2 treated w/t MCF7 cells (Figure 3.24), equating with 
Affymetrix findings (Table 3.2), where (as shown in Figure 3.12) this 
antihormone induced increase was subsequently retained by PCR in both the 
resistant TAMR and FASR cells versus w/t MCF7 cells.
TXNRD1 also had a similar profile to GSTA4 as it was again upregulated in 
w/t MCF7 cells treated with tamoxifen (by over 80%, p=0.027) and faslodex 
(by 145%, p=0.034) (Figure 3.25) again equating with Affymetrix profiles 
(Table 3.2) and again with increases retained within resistance by PCR (Figure 
3.13). NQOl was also upregulated in w/t MCF7 cells treated with tamoxifen 
(by 65%, p=0.015) or faslodex (by over 100%, p=0.003) as shown in Figure
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3.26, equating with Affymetrix profiles (Table 3.2), although this upregulation 
was only subsequently retained in the TAMR model by PCR (Figure 3.14).
Although both antioxidant genes GLRX and CAT were upregulated in both 
resistant models TAMR and FASR by PCR (Figures 3.15 and 3.16), they were 
only significantly upregulated by 10 day faslodex treatment and not by 
tamoxifen in w/t MCF7 cells (Figures 3.27 and 3.28 respectively). GLRX was 
upregulated by faslodex by over 100% (p=0.036) (Figure 3.27), and CAT by 
over 140% (p=0.016) (Figure 3.28). The GLRX profile thus equated with 
Affymetrix findings, although some discrepancies are with CAT (Table 3.3).
Despite a lack of E2 induction, GPX2 was found to be significantly down 
regulated in w/t MCF7 cells in the presence of either tamoxifen or faslodex 
suggesting this may be a classically ER regulated gene (contrasting all other 
antioxidant genes examined). Thus w/t MCF7 cells treated with tamoxifen 
showed approximately 50% reduction (p=0.00074) in GPX2 expression, and a 
100% reduction (p=0.0017) in the presence of faslodex treated (Figure 3.29). 
Lack of upregulation during treatment equates with the Affymetrix profile 
(Table 3.2), but was clearly different to the increase that subsequently appeared 
to arise later in TAMR cells as verified by PCR (Figure 3.19).
Finally, the antioxidant genes TXN, TXNRD2, PRDX6, PRDX1 and SOD1 
were found to not be significantly changed in expression by 10 days tamoxifen 
or faslodex treatment in w/t MCF7 cells versus E2 treated w/t MCF7 cells
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(Figures 3.30 -  3.34 respectively). Any changes displayed during treatment did 
not reach significance, equating with Affymetrix data for TXN, TXNRD2, and 
PRDX6 (Tables 3.2 and 3.3) that were confirmed by Affymetrix expression 
profiling as specific to resistance and subsequently PCR verified for TXN and 
TXNRD2 only (Figures 3.17 and 3.18), PRDX1 and SOD1 showed no 
regulation at PCR level in response (Figures 3.33 and 3.34 respectively) or 
resistance (Figure 3.20).
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Figure 3.21 TAC analysis of w/t MCF7 cells treated with 10'7M Tamoxifen 
or Faslodex for 10 days
* *
0.06
~  0.05cTO ^
3  c  0.04
x -S
|  0.03
n  o.o23  TOO (_)
F- 0.01
w/t MCF7 w/t MCF7 w/t MCF7 
+ TAM + FAS
TAC levels were measured using the Total Antioxidant Assay Kit from Sigma-Aldrich 
Company Ltd. TAC for w/t MCF-7 cells treated with 10'7M Tamoxifen (TAM) or 
Faslodex (FAS) for 10 days was significant by Student T-test compared to the parental 
cells (*p=0.042, **p=0.005 respectively). These data represent a typical example of an 
experiment performed three times ± SD.
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Figure 3.22 pS2 gene verification of PCR samples for the w/t MCF-7 
model treated with 10'9M E2 , 10'7M Tamoxifen or Faslodex for 10 days
pS2 (380bp) 
3-actin (204bp)
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+ E,
w/t MCF7 
+ TAM
w/t MCF7 
+ FAS
pS2 PCR expression results were obtained from a densitometer and normalised to 
readings obtained for (3 actin in triplicate. Statistical analysis was performed for each 
model against the w/t MCF-7 model using a Student's paired t-Test ±SD (*p=0.004, 
**p=0.004, and ***p=0.027).
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F ig u re  3.23 Effect o f  10 day  E 2 t r e a tm e n t  o f  w /t  M C F 7  cells on
a n t io x id a n t  gene expression
w/t MCF7 Negative 
w/t MCF7 + E2 Control
(3 actin (380bp)
GSTA4 (200bp)
& actin (380bp)
TXNRD1 (200bp)
& actin (380bp) 
NQ01 (250bp)
B actin (380bp) 
GLRX (180bp)
B actin (380bp) 
CAT (220bp)
B actin (380bp) 
TXN (250bp)
B actin (380bp) 
TXNRD2 (200bp)
GPX2 (380bp) 
P-actin (204bp)
B actin (380bp) 
PRDX6 (350bp)
B actin (380bp) 
PRDX1 (200bp)
B actin (380bp) 
SOD1 (180bp)
PCR analysis of the 11 antioxidant genes for 10'9M E2 treated w/t MCF7 cells versus 
control w/t MCF7 cells, together with (3 actin. Negative control comprises loading 
buffer only.
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F ig u re  3.24 a) T h e  effect o f  t r e a tm e n t  w ith  10 day  T am ox ifen  ve rsus  E 2
t r e a tm e n t  o f  w /t  M C F 7  cells on G S T A 4 gene expression
ft actin (380bp) 
GSTA4 (200bp)
& 2 5 0
T5
c
s
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w AMCF7 + E2 w /tMCF7 + TAM
b) The effect of treatment with 10 day Faslodex versus E2 treatment of 
w/t MCF7 cells on GSTA4 gene expression
& actin (380bp)
GSTA4 (200bp)
w/tMCF7 + E2 WAMCF7 + FAS
a & b) PCR for GSTA4 gene expression following treatment with 10‘7M Tamoxifen or 
Faslodex (*p = 0.033 and **p = 0.026 respectively) compared to treatment of w/t 
MCF7 cells with 10'9M E2 Results are from triplicate preparations and were 
statistically compared using the Student T-test ± SD.
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F igu re  3.25 a) T h e  effect o f  t r e a tm e n t  w ith  10 day  T am ox ifen  ve rsus  E 2
t re a tm e n t  o f  w /t  M C F 7  cells on TX N RD 1 gene expression
3 actin (380bp)
TXNRD1 (200bp)
*  300
I 250
T3 22 
|   ^ 200
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C /5
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b) The effect of treatment w ith 10 day Faslodex versus E2 treatment of w/t 
MCF7 cells on TXNRD1 gene expression
B actin (380bp)
TXNRD1 (200bp)
w/tMCF7 + E2 w/tMCF7 + FAS
a & b) PCR analysis for TXNRD1 gene expression following treatment with 10'7M 
Tamoxifen or Faslodex (*p = 0.027 and **p = 0.034 respectively) compared to 
treatment of w/t MCF7 cells with 10'9M E2 Results are from triplicate preparations 
and were statistically compared using the Student T-test ± SD.
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F igu re  3.26 a) T h e  effect o f  t re a tm e n t  w ith  10 day  T am ox ifen  ve rsus  E 2
t r e a tm e n t  o f  w /t M C F 7  cells on N Q O l  gene express ion
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b) the effect of treatment w ith Faslodex versus E2 treatment of w/t MCF7 
cells on NQOl gene expression
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a & b) PCR analysis for NQOl gene expression following treatment with 10'7M 
Tamoxifen or Faslodex (*p = 0.015 and **p = 0.003 respectively) compared to 
treatment of w/t MCF7 cells with 10‘9M E2 Results are from triplicate preparations 
and were statistically compared using the Student T-test ± SD.
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F igu re  3.27 a) T h e  effect o f  t r e a tm e n t  w ith  10 day  T am oxifen  ve rsus  E 2
t re a tm e n t  o f  w /t  M C F 7  cells on G L R X  gene expression
P actin (380bp)
GLRX (180bp)
T3
w /tMCF7 + E2 w /tMCF7 + TAM
b) The effect of treatment with 10 day Faslodex versus E2 treatment of w/t 
MCF7 cells on GLRX gene expression
3 actin (380bp)
GLRX (180bp)
w/tMCF7 + E2 w/tMCF7 + FAS
a & b) PCR analysis for GLRX gene expression following treatment with 10'7M 
Tamoxifen or Faslodex (p = 0.57 and *p = 0.036 respectively) compared to treatment 
of w/t MCF7 cells with 10‘9M E2 Results are from triplicate preparations and were 
statistically compared using the Student T-test ± SD.
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F ig u re  3.28 a) T h e  effect o f  t r e a tm e n t  w ith  10 day  T am ox ifen  ve rsus  E 2
t r e a tm e n t  o f  w /t  M C F 7  cells on C A T  gene express ion
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b) The effect of treatment w ith 10 day Faslodex versus E2 treatment of w/t 
MCF7 cells on CAT gene expression
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a & b) PCR analysis for CAT gene expression following treatment with 10‘7M 
Tamoxifen or Faslodex (p = 0.26 and *p = 0.016 respectively) compared to treatment 
of w/t MCF7 cells with 10'9M E2 Results are from triplicate preparations and were 
statistically compared using the Student T-test ± SD.
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Figure 3.29 a) The effect of treatment with 10 day Tamoxifen versus E2 
treatment of w/t MCF7 cells on GPX2 gene expression
GPX2 (700bp)
& actin (380bp)
*
w/tMCF7 + TAM
b) The effect of treatment with 10 day Faslodex versus E2 treatment of w/t 
MCF7 cells on GPX2 gene expression
GPX2 (700bp)
13 actin (380bp)
120
* *
w/tMCF7 + FAS
a & b) PCR analysis for GPX2 gene expression following treatment with 10'7M 
Tamoxifen or Faslodex (*p = 0.00074 and **p = 0.0017 respectively) compared to 
treatment of w/t MCF7 ceils with 10'9M E2 Results are from triplicate preparations 
and were statistically compared using the Student T-test ± SD.
■o 2
J  -  80
| t  60
Z  0  40
= 20
w /tMCF7 + E2
£  120
c/)
100
.8  -  80
E s  60
o E
Z 2 40
S 20
w/tMCF7 + E2
140
Chapter 3 -  Results
F ig u re  3.30 a) T h e  effect of t re a tm e n t  w ith  10 day  T am oxifen  ve rsus  E 2
t r e a tm e n t  o f  w /t  M C F 7  cells on TX N  gene expression
P actin (380bp) 
TXN (250bp)
w/tMCF7 + E2 w/tMCF7 + TAM
b) The effect of treatment w ith 10 day Faslodex versus E2 treatment of w/t 
MCF7 cells on TXN gene expression
8 actin (380bp) 
TXN (250bp)
w /tMCF7 + E2 w /tMCF7 + FAS
a & b) PCR analysis for TXN gene expression following treatment with 10'7M 
Tamoxifen or Faslodex (p = 0.134 and p = 0.118 respectively) compared to treatment 
of w/t MCF7 cells with 10’9M E2 Results are from triplicate preparations and were 
statistically compared using the Student T-test ± SD.
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F ig u re  3.31 a) T h e  effect o f  t re a tm e n t  w ith  10 day  T am oxifen  ve rsu s  E 2
t r e a tm e n t  o f  w /t  M C F 7  cells on T X N R D 2 gene expression
B actin (380bp) 
TXNRD2 (200bp)
w/tMCF7 + E2 w/tMCF7 + TAM
b) The effect of treatment w ith 10 day Faslodex versus E2 treatment of w/t 
MCF7 cells on TXNRD2 gene expression
B actin (380bp) 
TXNRD2 (200bp)
w/tMCF7 + E2 w/tMCF7 + FAS
a & b) PCR analysis for TXNRD2 gene expression following treated with 10'7M 
Tamoxifen or Faslodex (p = 0.253 and p = 0.249 respectively) compared to treatment 
of w/t MCF7 cells with 10'9M E2 Results are from triplicate preparations and 
statistically significant using the Student T-test ± SD.
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F ig u re  3.32 a) T h e  effect o f  t r e a tm e n t  w ith  10 day  T am ox ifen  v e rsu s  E 2
t r e a tm e n t  o f  w / t  M C F 7  cells on P R D X 6 gene expression
B actin (380bp)
PRDX6 (350bp)
& 1508m
■ 0  I.8 s 100
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w/tMCF7 + E2 w/tMCF7 + TAM
b) The effect of treatment w ith 10 day Faslodex versus E2 treatment of w/t 
MCF7 cells on PRDX6 gene expression
B actin  (380bp) 
PR D X 6 (350bp)
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a & b) PCR analysis for PRDX6 gene expression following treatment with 10'7M 
Tamoxifen or Faslodex (p = 0.836 and p = 0.852 respectively) compared to treatment 
of w/t MCF7 cells with 10'9M E2 Results are from triplicate preparations and were 
statistically compared using the Student T-test ± SD.
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F ig u re  3.33 a) T h e  effect o f  t re a tm e n t  w ith  10 day  T am oxifen  ve rsus  E 2
tre a tm e n t  o f  w /t  M C F 7  cells on PRDX1 gene expression
B actin (380bp) 
PRDX1 (200bp)
w/tMCF7 + E2 w/tMCF7 + TAM
b) The effect of treatment w ith 10 day Faslodex versus E2 treatment of w/t 
MCF7 cells on PRDX1 gene expression
B actin (380bp) 
PRDX1 (200bp)
T3
w/tMC F7 + E2 w/tMC F7 + FAS
a & b) PCR analysis for PRDX1 gene expression following treatment with 10 M 
Tamoxifen or Faslodex (p = 0.177 and p = 0.595 respectively) compared to treatment 
of w/t MCF7 cells with 10'9M E2 Results are from triplicate preparations and were 
statistically compared using the Student T-test ± SD.
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F ig u re  3.34 a) T h e  effect o f  t re a tm e n t  w ith  10 day  T am oxifen  ve rsu s  E 2
tr e a tm e n t  o f  w /t  M C F 7  cells on SOD1 gene expression
ft actin (380bp) 
SOD1 (180bp)
w /tMCF7 + E2 w /tMCF7 + TAM
b) The effect of treatment w ith 10 day Faslodex versus E2 treatment of w/t 
MCF7 cells on SOD1 gene expression
ft actin (380bp) 
SOD1 (180bp)
w /tMCF7 + E2 w /tMCF7 + FAS
a & b) PCR analysis for SODl gene expression following treatment with 10'7M 
Tamoxifen or Faslodex (p = 0.064 and p = 0.274 respectively) compared to treatment 
of w/t MCF7 cells with 10'9M E2 Results are from triplicate preparations and were 
statistically compared using the Student T-test ± SD.
145
Chapter 3 -  Results
3.5 Impact of EGFR inhibitor Gefitinib on antioxidant gene
expression in TAMR cells
Colleagues at the Tenovus Centre for Cancer Research and further groups, 
have previously linked increased EGFR signalling to acquired TAM resistance 
in vitro and this pathway can be deregulated in further resistant cell models, 
including some cell lines resistant to faslodex (McClelland et al., 2001; 
Knowlden et al., 2003; Gee et al., 2003; Hiscox et al., 2004; Jones et al., 2004; 
Gee et al., 2005; Jones et al., 2005;). Thus in the TAMR model, targeting of 
EGFR using a selective Tyrosine Kinase Inhibitor (TKI), gefitinib, at 1 pM had 
been shown to promote approximately 60% inhibition of TAMR models, 
illustrating that EGFR signalling is dominant in their growth (Knowlden et al., 
2003). It was thus investigated here whether the 11 antioxidant genes, that also 
could be growth-relevant, were regulated by EGFR in TAMR cells by 
monitoring the genes by PCR in mRNA samples prepared from TAMR cells 
+/-1 pM TKI treatment for 7 days.
Of the genes that had been shown to be increased in TAMR by PCR, the 
antioxidant genes GSTA4, TXNRD1, NQOl, GLRX, CAT, TXN, and 
TXNRD2 were all downregulated in the presence of TKI treatment. GSTA4 
was inhibited in TAMR cells treated with TKI by over 40% (p=0.041) (Figure 
3.35), TXNRD1 was inhibited by over 90% (p=0.002) (Figure 3.36), NQOl 
was inhibited by over 50% (p=0.006) (Figure 3.37), GLRX was inhibited by 
approximately 20% (p=0.005) (Figure 3.38), CAT was inhibited by
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approximately 45% (p=0.014) (Figure 3.39), TXN was inhibited by 
approximately 40% (p=0.005) (Figure 3.40), and TXNRD2 was inhibited by 
approximately 45% (p=0.02) (Figure 3.41) compared to the untreated control 
TAMR cells. In contrast, the gene GPX2 was shown to be further upregulated 
in the presence of the TKI gefitinib by over 130% (p=0.005) compared to the 
untreated TAMR cells (Figure 3.42). Antioxidant genes that were not 
confirmed by PCR as increased in resistance, PRDDX6 and SOD1, were also 
not regulated by TKI treatment (Figures 3.43 and 3.44 respectively), although 
PRDX1 was again slightly decreased by 10% (p=0.001) compared to untreated 
TAMR cells (Figure 3.45). Table 3.4 represents this PCR information in 
summary form, alongside the expression of these 11 antioxidant genes in the 
resistant models TAMR and FASR and whether they are induced by 
antihormone treatments tamoxifen and faslodex at the PCR level.
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F ig u re  3.35 Im p a c t  o f  gefitin ib  on G S T A 4 gene expression  in T A M R  cells
& act in (380bp)
G S TA 4  (200bp)
T A M R  T A M R + T K I
PCR analysis was performed and the specific mRNA band measured for 
intensity by a densitometer, normalised to p actin, and presented as TAMR + 
lpM  TKI (gefitinib, 7 days) compared to untreated TAMR which was 
normalised to 100%. Experiments were performed three times and statistical 
analysis was carried out using a Student T-test ± SD (*p=0.041). The same 
experimental design was carried out for all antioxidant genes examined in 
TAMR +/- TKI over Figures 3.36 -  3.45.
Figure 3.36 Impact of gefitinib on TXNRD1 gene expression in TAMR 
cells
B act in (380bp)
TXNRD1 ( 200bp)
TAMR T AMR+ T KI
Experiments were performed three times and statistical analysis was carried out
using a Student T-test ± SD (*p=0.002).
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F ig u re  3.37 Im p a c t  o f  gefitinib on N Q O l  gene expression  in T A M R  cells
& actin (380bp) 
N Q 0 1 (250bp)
TAMR TAMR+TKI
Experiments were performed three times and statistical analysis was carried out 
using a Student T-test ± SD (*p=0.006).
Figure 3.38 Impact of gefitinib on GLRX gene expression in TAMR cells
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Experiments were performed three times and statistical analysis was carried out
using a Student T-test ± SD (*p=0.005).
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F ig u re  3.39 Im p a c t  of gefitinib on C A T  gene expression  in T A M R  cells
B ac t in  ( 3 8 0 b p )  
C A T  ( 2 2 0 b p )
TAMR TAMR+TKI
Experiments were performed three times and statistical analysis was carried out 
using a Student T-test ± SD (*p=0.014).
Figure 3.40 Impact of gefitinib on TXN gene expression in TAMR cells
B actin (380bp) 
TXN (250bp)
TAMR TAMR+TKI
Experiments were performed three times and statistical analysis was carried out
using a Student T-test ± SD (*p=0.005).
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Figure 3.41 Impact of gefitinib on TXNRD2 gene expression in TAMR 
cells
B a c t i n  ( 3 8 0 b p )  
T X N R D 2  ( 2 0 0 b p )
T AMR T A MR + T K I
Experiments were performed three times and statistical analysis was carried out 
using a Student T-test ± SD (*p=0.02).
Figure 3.42 Impact of gefitinib on GPX2 gene expression in TAMR cells
GPX2 (700bp)
(3 actin (380bp)
TAMR TAMR + TKI
Experiments were performed three times and statistical analysis was carried out
using a Student T-test ±  SD (*p=0.005).
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Figure 3.43 Impact of gefitinib on PRDX6 gene expression in TAMR cells
B actin (380bp)
PRDX6 (350bp)
TAMR TAMR + TKI
Experiments were performed three times and statistical analysis was carried out 
using a Student T-test ± SD (p=0.08).
Figure 3.44 Impact of gefitinib on SOD1 gene expression in TAMR cells
& ac t in  ( 3 8 0 b p )  
S O D 1  ( 1 8 0 b p )
52 C
a6"O
120
100
80
60
40
20
0
TAM R TAM R +TKI
Experiments were performed three times and statistical analysis was carried out
using a Student T-test ± SD (p=0.09).
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Figure 3.45 Impact of gefitinib on PRDX1 gene expression in TAMR cells
B a c t i n  ( 3 8 0 b p )  
P R D X 1  ( 2 0 0 b p )
T A M R  T A M R + T K I
Experiments were performed three times and statistical analysis was carried out 
using a Student T-test ± SD (p=0.001).
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Table 3.4 Summary of PCR results for 11 antioxidant genes in resistant 
models, as well as their regulation by antihormones in w/t MCF7 cells and 
by anti-EGFR TKI treatment in TAMR cells
Gene name Upregulated Upregulated TAM FAS TKI
in TAM R in FASR Induced Induced Supressed
cells cells
GSTA4 y y > / Y
TXNRD1 y y Y
NQ01 y X Y
GLRX y y X v'' Y
CAT y y X v'' Y
TXN Y y X X Y
TXNRD2 Y * X X Y
GPX2 Y X * * * * 'k'k'k
PRDX6 X X X X X
PRDX1 X X X X y
S0D1 X X X X X
*TXNRD2 is suppressed in FASR cells. **GPX2 is suppressed in Tamoxifen
or Faslodex treated w/t MCF7 cells, and unlike the other antioxidant genes
***GPX2 is further TKI induced in TAMR cells.
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3.6 Impact of EGFR inhibitor gefitinib and further growth 
factor signalling inhibitors on TAC in TAM R cells
The PCR findings indicated a number of the antioxidant genes that increased in 
TAMR cells were positively regulated at the expression level by the EGFR 
pathway and thus inhibited by EGFR TKI gefitinib at 7 days. To further 
explore the relationship between EGFR and antioxidant regulation in TAMR 
cells, the growth and TAC levels in the TAMR cell line with and without TKI 
treatment for 24 hours, 7 days and 10 days were investigated, compensating for 
TKI growth inhibitory effect. Thus, MTT growth analysis of TAMR cells with 
TKI treatment revealed approximately 30% growth inhibition after 24 hours 
(p=0.008), approximately 60% inhibition after 7 days and 50% inhibition after 
10 days (p=0.042 and p=0.017 respectively) as shown in Figure 3.46. There 
was an 18 fold drop in total antioxidant capacity in TAMR cells with TKI 
treatment after 24 hours (Figure 3.47a). Surprisingly, however by 7 and 10 
days there was a further increase in the level of TAC in TAMR cells with TKI 
treatment by 9 fold (p = 0.0148) and 4 fold (p = 0.007) respectively (Figure 3.47b 
and c), contrasting the decrease seen with this agent for most antioxidant genes 
here investigated by PCR (Figures 3.35 -  3.45), and implying TAC may be 
driven by EGFR independent mechanisms.
In order to further investigate TAC regulation by other growth factor pathway 
signalling elements in TAMR cells, the impact of further signal transduction 
inhibitors were examined after 7 days treatment. TAMR cells were monitored
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for growth impact during treatment with 1 pM TKI (gefitinib), a Src inhibitor 
AZD0530 at lpM, a PI3K inhibitor Wortmannin (WORT) at lOOnM, an NFkB 
pathway inhibitor Parthenolide (PARTH) at 3pM and a MEK 1/2 inhibitor 
U0126 at lOpM (Figure 3.47). As indicated in the Methods, dosages were 
chosen from the group’s previous studies monitoring pathway targeting and 
growth impact of these various compounds. MTT assay results showed that the 
inhibitors gefitinib, AZD, PARTH and U0126 all were partially inhibitory of 
growth of TAMR cells (Figure 3.48). TAMR cells treated with lpM gefitinib 
for 7 days showed the 60% inhibition, TAMR cells treated with lpM 
AZD0530 or lOpM U0126 showed over 70% inhibition (p=0.0212 and 
p=0.005 respectively), and treatment with 3pM PARTH showed approximately 
50% inhibition (p=0.0183). Treatment with lOOnM WORT showed no change 
in growth (p=0.88, Figure 3.48).
Parallel TAC analysis results with these inhibitors (compensated for cell 
number decreases obtained in the MTT analysis) (Figure 3.49) again revealed 
significant increases in TAC levels after 7 days. Thus, TAMR cells treated 
with 1 pM GEF for 7 days showed a 6 fold increase in TAC (p=0.003), TAMR 
cells treated with lpM AZD0530 showed a 7.4 fold increase (p=0.005), 
treatment with 3pM PARTH showed a 4 fold increase (p=0.013) and treatment 
with lOpM U0126 showed a 2 fold increase (p = 0.01). There was no 
significant change in TAC level in response to lOOnM WORT (p=0.06).
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F igu re  3.46 M T T  g ro w th  analysis  o f  T A M R  cells t re a te d  w ith  the T K I
gefitin ib  fo r  24 hours ,  7 days o r  10 days
a)
C/3c<L>Q
13
■— >Q.
o
1000
800
600
400
200
0
TAMR TAMR + TKI
b)
C/3a
a>Q
73
C.O
1000
800
600
400
200
0
TAMR
*
eh
TAMR + TKI
c)
C/3ti
Q
KJO
cL
o
1000
800
600 I
400
200
0
*
E * |
TAMR TAMR + TKI
MTT analysis o f growth for TAMR cells treated with/without lpM  TKI 
gefitinib for (a) 24 hours (p=0.008) (b) 7 days (p=0.042), or (c) 10 days 
(p=0.017). All results are representative o f  an experiment performed three 
times and statistical analysis was carried using a Student T-test ± SD.
157
Chapter 3 -  Results
Figure 3.47 Total antioxidant capacity of TAMR cells treated with the TKI 
gefitinib for 24 hours, 7 days and 10 days
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TAMR cells treated with/without lpM  TKI gefitinib for (a) 24 hours 
(p=0.0068) (b) 7 days (p=0.0148), or (c) 10 days (p=0.007). These data are 
presented after compensation for the TKI growth inhibitory effects shown in 
Figure 3.46(a, b and c). All results are representative o f  an experiment 
performed three times and statistical analysis was carried using a Student T-test 
± SD.
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F igu re  3.48 M T T  g row th  analysis o f  T A M R  cells t re a te d  w ith  gefitinib,
A ZD 0530, w o r tm a n n in ,  pa r th en o lid e ,  o r  U0126 fo r  7 days
10C0 
90D 
>> 800 
g 700 
q  000 
13 500
•3 400
o  300 
200 
100 
0
TAMR TAMR+ TAMR+ TAMR+ TAMR+ TAMR+
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TAMR cells were treated with/without lpM  GEF (*p=0.0171), lpM  AZD0503 
(**p=0.0212), lOOnM WORT (p=0.88), 3pM PARTH (***p=0.018) or lOpM 
U0126 (****p=0.005) for 7 days. Cells were exposed to the MTT reagent for 
4hours, and refrigerated overnight in Triton X-100. Absorbances were read the 
following day using a plate reader at 570nm from multiple wells. Statistical 
analysis was carried out using a Student T-test ± SD versus untreated TAMR 
cells, and results shown are representative o f n=3 experiments.
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F ig u re  3.49 T A C  analysis o f  T A M R  cells t re a te d  w ith  g row th  fac to r
signalling  inh ib ito rs  gefinitib, A ZD 0530, w o r tm a n n in ,  p a rtheno lide ,  o r
U0126 fo r  7 days
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TAMR cells were treated with/without lpM  GEF (*p=0.003), lpM  AZD0530 
(**p=0.005), lOOnM WORT (p=0.06), 3pM PARTH (***p=0.013) or lOpM 
U0126 (****p=0.01) for 7 days. TAC analysis was carried out as described in 
the Sigma-Aldrich kit protocol. These data are presented after compensation 
for the growth inhibitory effects shown in Figure 3.48. Results are 
representative o f  n=3 experiments and statistical analysis was carried using a 
Student T-test ± SD versus untreated TAMR cells.
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3.7 Impact of glutathione (GSH) pathway depletion using 
BSO +/- EGFR blockade in TAMR cells
It has been shown here that the tyrosine kinase inhibitor gefitinib can inhibit 
TAMR cell growth by approximately 60% inhibition. However, in parallel 
with this anti-tumour effect, TAMR cells showed an increased level of TAC 
that may feasibly be contributing to cell survival in the presence of TKI, 
subsequently maintained at high levels into resistance (NEW DUBS). Of the 
11 antioxidant genes examined, only GPX2 was upregulated (complementing 
the TAC data) in the presence of gefitinib at 7 days. The glutathione 
(GSH)/GPX system is reported to be essential for maintaining the redox 
balance and defending against elevated levels of oxidative stress, where cells 
may develop a conditional GSH-dependent GPX reduction system that confers 
stronger resistance against oxidative challenge (Fu et al., 2007). GSH is a 
naturally occurring tripeptide whose reducing properties enable it to play a 
central role in antioxidant pathways. GSH is essential for the survival of many 
cell systems and its depletion by the GSH biosynthesis inhibitor BSO has been 
proven to lead to cell death and highly sensitise tumor cells to apoptosis 
induced by chemotherapy and in an endocrine resistant model to pro-apoptotic 
effects of E2 (Lewis-Wambi et al., 2009).
To further examine the role of GSH/GPX in TAMR cells, including during 
TKI treatment, experiments were performed in TAMR cells with BSO, and 
with BSO in combination with gefitinib. lOOpM BSO was able to significantly
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inhibit TAMR growth by 48% (p=0.001) (Figure 3.50). TAMR treated with 
GEF + BSO gave an inhibition of 66% (p=0.0005), with 60% for GEF alone 
(p=0.0006) (Figure 3.50). However, there was no significant increase in 
inhibition of the combination treatment versus GEF alone at 7 days. Parallel 
TAC analysis in TAMR cells again demonstrated that treatment with lpM 
GEF for 7 days increased total antioxidant capacity. Surprisingly, treatment of 
TAMR cells with the glutathione antioxidant inhibitor BSO (lOOpM) for 7 
days showed a 5 fold increase in TAC in TAMR (p=0.0009) (Figure 3.51). 
Combination treatment of GEF + BSO showed a higher increase of 8 fold in 
TAC (p=0.0001 versus untreated TAMR) that was also more significantly 
increased versus GEF alone (p=0.03) (Figure 3.51).
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Figure 3.50 MTT analysis of TAMR cells monitoring impact of BSO, 
gefitinib, and combined treatment at 7 days
1200 i
TA M R  TA M R  + BSO TA M R  + G E F  TA M R  + G E F
+ BSO
MTT analysis was carried out for TAMR cells treated with lOOpM BSO 
(*p=0.001), lpM  GEF (**p=0.0006), or combination treatment (***p=0.0005) 
for 7 days. Results are from triplicate preparations and statistical testing was 
carried out using a Student T-test ± SD versus untreated TAMR cells.
Figure 3.51 TAC analysis of TAMR cells following treatment with BSO, 
gefitinib or gefitinib + BSO for 7 days
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TAC analysis was carried out for TAMR cells treated with lOOpM BSO 
(p=0.0009), lpM  GEF (p = 0.0009), or combination treatment (p=0.0001) for 7 
days. These data are presented after compensation for the growth inhibitory 
effects for shown in Figure 3.50. Results are from triplicate preparations and 
statistical testing was carried out using a Student T-test ± SD versus untreated 
TAMR cells.
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3.8 Oxidative stress (ROS) measured in TAMR cells versus 
w/tMCF-7 cells
Antioxidant levels in acquired endocrine or anti-EGFR resistant models have 
been shown here to be elevated in comparison to untreated endocrine 
responsive w/t MCF7. However it remains elusive as to whether these 
antioxidants are upregulated in response to elevated levels of ROS, or are 
independent of this in resistant models. In order to more fully understand the 
redox balance in the resistant models, total oxidative stress was measured in 
each of these models in relation to the endocrine responsive cells over a 24hour 
to 10 day time course using a ROS fluorescence assay (H2DCFDA).
ROS measurements taken 24hours after seeding allowed monitoring of the 
basal levels of ROS that existed within the various cell lines before they 
entered exponential growth. Results showed significantly elevated levels of 
basal ROS existed within TAMR cells (65% increase, p=0.034) compared to 
the parental w/t MCF-7 model (Figure 3.52). After 7 days growth there was an 
even greater increase (110% increase, p=0.036) with ROS levels further 
increasing to 190% (p=0.01) in TAMR cells compared to the w/t MCF-7 cells 
by 10 days (Figure 3.52).
Along with previous growth curve data (Figure 3.2), in order to address if ROS 
was paralleled by any changes in cell proliferation or cell survival in the 
TAMR versus w/t MCF7 cells, staining for the Ki67 protein and an ApoAlert
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kit were employed respectively at day 7. TAMR cells were 100% positive for 
Ki67 versus 80% positive in w/t MCF7 models, while apoptosis was 7% versus 
11% respectively (Figure 3.53). Thus the increased ROS (and associated 
increased TAC) was paralleled by very modestly increased cell proliferative 
capacity and cell survival in TAMR cells versus w/t MCF7 cells at day 7 (a 
time that both cell lines are in log phase growth). Although this does not 
appear to translate out into a significant increase in overall growth profile in 
TAMR versus w/t MCF7 cells (Figure 3.2), equivalent growth rates to 
untreated w/t MCF7 had clearly been acquired by the TAMR cells despite the 
elevated ROS.
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Figure 3.52 H2DCFDA fluorescent examination of ROS levels in TAMR 
cells at 24 hours, 7 days, and 10 days in comparison to the w/t MCF7 cell 
line
<u(/) CJ 
C  C <u u
c &
2<L> O > 3
140000
120000
100000
80000
60000
40000
20000
0
* *
w/t MCF7 
24hours
TAMR 
24 hours
i f i
w/t MCF7 
7days
TAMR
7days
w/t MCF7 
1Odays
TAMR 
1Odays
ROS analysis using H2DCFDA fluorescent dye was carried out for TAMR 
cells at 24hours (*p=0.034), 7 days (**p=0.036), and 10 days (***p = 0.01) 
versus the w/t MCF7 model. Results are o f  triplicate preparations and 
statistical analysis was by Student T-test ± SD.
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Figure 3.53 Ki 67 staining and ApoAlert MMS staining to identify level of 
proliferation and apoptosis respectively in w/t MCF-7 cell line versus 
TAMR cells at 7 days.
a) Ki67 staining b) ApoAlert KIT
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Ki67 immunostaining and ApoAlert MMS assays were carried out in 
accordance to the manufacturers’ protocol for detection o f proliferation and 
apoptosis respectively. For Ki67 staining (a), the brown signal represents cells 
in proliferation (versus blue/green counterstain o f  non-proliferating cells) and 
the absence o f  a secondary antibody was used as a negative control. In the 
ApoAlert assay (b), green signal represents cells undergoing early apoptosis 
with exposure to UV being used as a positive control (representative o f  n=3 
experiments, X40 magnification).
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3.9 ROS measurements in other acquired resistant models 
versus w/t MCF7 cells
Total ROS was also examined using the H2DCFDA assay in the further 
resistant breast cancer models FASR, X-MCF and NEW DUBS versus the w/t 
MCF7 breast cancer model.
3.9.1 ROS measurement in FASR cells versus w/tMCF7
ROS measurements for FASR following 24hours after seeding and after 7 days 
growth again showed significant increases in ROS levels at 135% and 140% 
(p=0.0021 and p=0.023 respectively) compared to parental w/t MCF-7 models, 
with ROS after 10 days also substantially elevated versus w/t MCF7 cells 
(175%, p=0.025) (Figure 3.54).
3.9.2 ROS measurement in X-MCF cells versus w/tMCF7
ROS measurements taken from the oestrogen deprived resistant cell line X- 
MCF showed the greatest increase in ROS elevation versus w/t MCF7. 
Following 24hours after seeding, X-MCF cells showed a significant 160% 
increase (p=0.0008) in ROS levels compared to the parental w/t MCF-7 models 
(Figure 3.55). At 7 days for the X-MCF model, ROS increase was 170% 
(p=0.022) and 190% (p=0.0023) after 10 days (Figure 3.55).
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3.93 ROS measurement in NEW DUBS cells versus w/tMCF7 
There was a 110% increase of ROS (p=0.019) after 24hours compared to the 
parental w/t MCF-7 model (Figure 3.56). Results after 7 days for the NEW 
DUBS model again showed an increase in ROS levels compared to the w/t 
MCF-7 cells at 150% (p=0.036) (Figure 3.56). At 10 days there was a more 
prominant increase in ROS at 170% (p=0.009) (Figure 3.56).
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Figure 3.54 H2DCFDA fluorescent analysis of ROS in FASR cells at 24 
hours, 7 days, and 10 days in comparison to the w/t MCF7 cell line
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ROS analysis using H2DCFDA fluorescent dye was carried out for FASR cells 
at 24hours (*p=0.0021), 7 days (**p=0.023), and 10 days (***p=0.025) versus 
the w/t MCF7 model. Results are o f  triplicate preparations and statistical 
analysis was by Student T-test ± SD.
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Figure 3.55 H2DCFDA fluorescent analysis of ROS in X-MCF cells at 24 
hours, 7 days and 10 days in comparison to the w/t MCF7 cell line
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ROS analysis using H2DCFDA fluorescent dye was carried out for X-MCF 
cells at 24hours (*p=0.0008), 7 days (**p=0.022), and 10 days (***p=0.0023) 
versus the w/t MCF7 model. Results are o f  triplicate preparations and 
statistical analysis was by Student T-test ± SD.
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Figure 3.56 HnDCFDA fluorescent analysis of ROS in NEW DUBS cells at 
24 hours, 7 days, and 10 days in comparison to w/t MCF7 cells
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ROS analysis using H2DCFDA fluorescent dye was carried out for NEW  
DUBS cells at 24hours (*p=0.019), 7 days (**p=0.036), and 10 days 
(***p=0.009) versus the w/t MCF7 model. Results are o f  triplicate 
preparations and statistical analysis was by Student T-test ± SD.
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3.10 Examination of ROS in w/t MCF7 cells during initial 
treatm ent with antihorm onal agents
Since total ROS was elevated significantly in all acquired resistant models 
versus the w/t MCF7 cell line, as for TAC the project again investigated 
whether these increases begin early in w/t MCF-7 cells during initial treatment 
(10 day) with the endocrine agents tamoxifen or faslodex (10'7M). Results 
showed no change in ROS levels in w/t MCF7 cells in the presence of  
tamoxifen (p=0.949) or faslodex (p=0.961) (Figure 3.57).
Figure 3.57 H2DCFDA fluorescent examination of ROS in w/t MCF-7 cells 
treated with tamoxifen or faslodex for 10 days
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w/t MCF7 models in Phenol free RPMI medium with 5% charcoal-stripped 
serum were treated with 0.1 pM tamoxifen or 0.1 pM faslodex. ROS analysis 
using H2DCFDA fluorescent dye was carried out after 10 days, comparing 
with untreated w/t MCF7 cells (p=0.949 and p=0.961 respectively). Results 
were o f  triplicate preparations and statistical analysis was by Student T-test ± 
SD.
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3.11 Impact of Inhibitors of growth factor signalling pathways
on ROS level in TAMR cells
To again explore regulation of the elevated ROS in TAMR cells by EGFR and 
further growth factor signalling pathways, we investigated ROS levels in the 
TAMR cell line with/without treatment with the EGFR TKI gefitinib over 24 
hours, 7 days and 10 days. There was an increase in ROS of approximately 2 
fold at 24hours (p = 0.0008) (Figure 3.58) and 10 days (2 fold, p=0.001) 
(Figure 3.60) and 4 fold at 7 days with gefitinib (p=0.0009) (Figure 3.59). A 
further experiment was prepared to compare impact of lpM TKI (gefitinib) 
and the further STIs Src inhibitor AZD0530 (AZD) at lpM, PI3K inhibitor 
Wortmanin (WORT) at lOOnM, NFkB inhibitor Parthenolide (PARTH) at 3pM 
or a MEK 1/2 inhibitor U0126 at lOpM in TAMR cells, measuring ROS at 7 
days and again compensating for the various growth inhibitory effects seen 
with these agents as in Figure 3.48. Gefitinib, AZD0530, PARTH and U0126 
all increased ROS in TAMR cells, with over a 3-4 fold increase with such 
treatments (p=0.038, p=0.0036, p=0.0005, and p=0.0005 respectively) (Figure 
3.61). Treatment with WORT showed no change in ROS level (p=0.425).
In addition to the overall growth data with MTT (Figure 3.48), Ki67 staining 
and the ApoAlert kit was again used to monitor level of proliferation and 
apoptosis respectively, in parallel with ROS, in TAMR cells during treatment 
with the EGFR-TKI gefitinib (lpM) at 7 days (Figure 3.62). As shown in 
Figures 3.62a, there was 60% reduction in proliferation in TAMR cells treated
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with GEF, and a 10% increase in early apoptosis (Figure 3.62b), equating with 
the significant growth inhibition (Figure 3.48) but contrasting the increase in 
ROS induced by this agent.
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Figure 3.58 Impact of gefitinib on ROS level in TAMR cells at 24 hours
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ROS analysis using H2DCFDA fluorescent dye was carried out in TAMR cells 
treated with/without the EGFR TKI lpM  GEF for 24hours (p=0.0008). 
Results were for triplicate preparations and statistical analysis was by Student 
T-test ± SD. These data are compensated for cell number from MTT data 
shown in Figure 3.46.
Figure 3.59 Impact of gefitinib on ROS level in TAM R cells at 7 days
350000
300000o
.1 ?  o  250000C/3 O
3  % 200000
.2 1/3
<U § 150000
.> 3
^  100000
50000
TAMR TAMR + GEF
ROS analysis using H2DCFDA fluorescent dye was carried out in TAMR cells 
treated with/without the EGFR TKI lpM  GEF for 7 days (p=0.0009). Results 
were for triplicate preparations and statistical analysis was by Student T-test ± 
SD. These data are compensated for cell number from MTT data shown in 
Figure 3.46.
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Figure 3.60 Impact of gefitinib on ROS level in TAMR cells at 10 days
q-lo
>> dj’55 oa a<L> u«->C 3s.. .—i
<L> q> 3'-3
13cti
300000
250000
200000
150000
100000
50000
0
*
- i -
TAMR TAMR + GEF
ROS analysis using H2DCFDA fluorescent dye was carried out in TAMR cells 
treated with/without the EGFR TKI lpM  GEF at 10 days (p=0.001). Results 
were for triplicate preparations and statistical analysis was by Student T-test ± 
SD. These data are compensated for cell number from MTT data shown in 
Figure 3.46.
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ROS analysis using H2DCFDA fluorescent dye was carried out in TAMR cells 
treated with/without lpM  GEF (p=0.038), lpM  AZD0530 (p=0.0036), lOOnM 
WORT (p=0.425), 3pM PARTH (p=0.0005), or 10(iM U0126 (p = 0.0005) at 7 
days. Results were for triplicate preparations and statistical analysis was by 
Student T-test ± SD versus untreated TAMR cells. These data are 
compensated for cell number from MTT data shown in Figure 3.48.
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Figure 3.62 Ki 67 and ApoAlert MMS Staining of TAMR cells during 
treatment with gefitinib
a) Ki67 staining b) ApoAlert KIT
TAMR: 100% Ki67+ TAMR: 7% apoptosis
TAMR + TKI 1 uM: 40% Ki67+ TAMR + TKI 1 uM: 17% apoptosis
Ki67 and ApoAlert MMS assays were carried out in accordance to the 
manufacturer’s protocol for detection o f proliferation and apoptosis 
respectively. For Ki67 staining (a), the brown signal represents cells 
proliferating, and the absence o f  a secondary antibody was used as a negative 
control. In the ApoAlert assay (b), a green signal represents cells undergoing 
early apoptosis, with exposure to UV being used as a positive control. Results 
are representative o f  n=3 experiments, X40 magnification.
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3.12 TAMR growth sensitivity to excess oxidative stress
With significantly increased levels of ROS in the acquired resistant models 
versus the w/t MCF7 cell line, but also with further increased ROS in gefitinib 
treated TAMR cells under growth inhibitory conditions, it remained to be 
explored if induction of more substantial levels of oxidative stress could be 
growth inhibitory in resistant models versus responsive cells. The oxidative 
stress inducing agent Menadione (MSB) was used for this investigation, as it is 
reported to work similarly to H2O2 in promoting ROS but is easier to 
manipulate experimentally (Noto et al., 1989). MSB is reported to promote 
substantial ROS within cell, and the pM dose range used was chosen for use in 
TAMR (versus w/t MCF7 cells) by extensive literature search (Noto et al., 
1989; Nutter et al., 1991; Sim et al., 1997).
MTT analysis of w/t MCF7 cells treated with different doses of MSB for 7 
days showed a dose dependent decrease in growth with increased exposure to 
MSB (Figure 3.63). There was a 23% significant reduction in growth at lOpM 
MSB (p=0.02), with a calculated IC50 (50% growth inhibitory concentration) of 
15.4pM (Figure 3.63). The greatest reduction in w/t MCF7 growth (64%, 
p=0.001) was achieved with the highest MSB concentration examined at 
18jiM. In TAMR cells there was also a reduction in cell growth at 7 days by 
MSB at lOpM, but this was more substantial than in w/t MCF7 cells (Figure 
3.64). Indeed, the IC50 was reached at this concentration (p=0.002), suggesting
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increased sensitivity to this oxidative stress inducer in the acquired resistant 
versus w/t MCF7 cells.
Parallel ROS measurements for w/t MCF7 cells and TAMR cells treated 
with/without lOpM MSB were subsequently taken after 7 days treatment. 
Basal ROS levels in TAMR cells were 2.7 fold higher than in w/t MCF7 cells, 
as previously observed in the project. MSB increased ROS levels in w/t MCF7 
cells by 3.9 fold (p=0.005) and by 2.9 fold in TAMR cells at lOpM MSB 
(p=0.036) (Figure 3.65), reaching substantially higher levels in the TAMR than 
w/t MCF7 cells in the presence of this agent.
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MTT analysis was carried out for w/t MCF7 cells treated with 10pM 
(*p=0.02), 12pM (**p=0.01), 14pM (***p=0.003), 16pM (****p=0.004) or 
18pM (*****p= 0.001) MSB for 7 days. Results were for triplicate 
preparations and statistical analysis was by Student T-test ± SD versus 
untreated w/t MCF7 cells.
Figure 3.64 MTT analysis of TAMR cells treated with MSB for 7 days
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MTT analysis was carried out for TAMR cells treated with lOpM (*p=0.006), 
12fiM (**p=0.003), 14pM (***p=0.001), 16pM (****p=0.005) or 18pM 
(*****p= 0.002) MSB for 7 days. Results were for triplicate preparations and 
statistical analysis was by Student T-test ± SD versus untreated TAMR cells.
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ROS analysis using H2DCFDA fluorescent dye was carried out in w/t MCF7 
cells and TAMR cells treated with and without lOpM MSB (*p=0.005, and 
**p=0.036 respectively) for 7 days. Results for cell models were compensated 
for growth inhibitory effect o f  lOpM MSB in Figures 3.63 and 3.64 and for 
triplicate preparations with statistical analysis by Student T-test ± SD versus 
the respective untreated models.
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3.13 Growth sensitivity of further acquired resistant models to 
excess oxidative stress
Monitoring of growth sensitivity to excess oxidative stress induced by MSB 
was also examined in the further acquired endocrine or anti-EGFR resistant 
models FASR, X-MCF and NEW DUBS. Initial MTT analysis of FASR, X- 
MCF and NEW DUBS models with doses above lOfiM MSB revealed such 
concentrations were markedly inhibitory in these resistant models, thus the 
impact of lower doses of 2pM, 4pM, 6pM, 8pM and lOpM MSB was explored 
over 7 days in these models. Results showed that FASR, X-MCF and NEW 
DUBS were all highly sensitive to MSB in a dose dependent manner. FASR 
models were significantly growth inhibited from 8pM MSB (p=0.017) with an 
IC50 of 8.3pM (Figure 3.66). X-MCF cells exhibited a greater sensitivity to 
growth inhibition by MSB, significantly inhibited from 2pM MSB (p=0.02) 
with an IC50 of 7.3pM (Figure 3.67). NEW DUBS approximated to TAMR 
cells in their sensitivity to MSB significantly inhibited from 8pM (p=0.022) 
with an IC50 of 9.3 pM (Figure 3.68). All the resistant models thus had an IC50 
of lOpM MSB or below, and thus significantly increased sensitivity to this 
agent versus w/t MCF7 cells.
ROS measurements for w/t MCF7 cells versus the resistant models FASR, X- 
MCF and NEW DUBS treated with or without growth inhibitory lOpM MSB 
were also made at 7 days (Figure 3.69). Basal ROS levels in all these resistant 
models were again increased versus w/t MCF7 cells, as seen earlier in this
184
Chapter 3 -  Results
project. FASR cells treated with lOpM MSB displayed a 2.5 fold increase in 
ROS (p=0.023). X-MCF cells treated with MSB showed a 3 fold increase in 
ROS (p=0.022), and NEW DUBS with MSB displayed a 2.1 fold increase 
(p=0.036) compared to their respective untreated controls (Figure 3.69). In all 
resistant models, although showing approximately similar/lower fold induction 
in ROS with MSB than w/t MCF7 cells, the resistant cells all displayed 
substantially higher overall ROS levels than their w/t MCF7 counterpart after 
MSB treatment, which may underlie the more effective growth inhibitory 
effects seen with this compound in the resistant cells if a threshold for tolerable 
oxidative stress has been reached in the various acquired resistant cell lines. Of 
note, therefore, we were successful in promoting cell death in all acquired 
resistant models by manipulation of redox balance through use of the oxidative 
stress inducer MSB.
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Figure 3.66 MTT analysis of FASR cells treated with MSB for 7 days
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MTT analysis was carried out for FASR cells treated with MSB at 2pM 
(p=0.351), 4pM (p=0.132), 6pM (p=0.113), 8pM (*p=0.017) and lOpM 
(**p=0.011) for 7 days. Results for cell models were from triplicate 
preparations with statistical analysis by Student T-test ± SD versus untreated 
FASR cells.
Figure 3.67 MTT analysis of X-MCF cells treated with MSB for 7 days
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MTT analysis was carried out for X-MCF7 cells treated with MSB at 2pM  
(*p=0.022), 4pM (**p=0.004), 6pM (***p=0.01), 8pM (****p=0.0006) and 
10pM (*****p=0.003) for 7 days. Results for cell models were from triplicate 
preparations with statistical analysis by Student T-test ± SD versus untreated 
X-MCF cells.
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MTT analysis was carried out for NEW DUBS treated with MSB at 2pM  
(p=0.314), 4pM (p=0.164), 6pM (p=0.137), 8pM (*p=0.022) and lOpM 
(**p=0.002) for 7 days. Results for cell models were from triplicate 
preparations with statistical analysis by Student T-test ± SD versus untreated 
NEW DUBS cells.
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ROS levels were measured using the H2DCFDA fluorescent dye in w/t MCF7 
cells (+MSB, *p=0.046) versus FASR (+MSB, **p=0.023), X-MCF (+MSB, 
***p=0.022) and NEW DUBS (+MSB, ****p=0.036) with/without lOpM 
MSB for 7 days. Results for cell models were compensated for any growth 
inhibitory effects o f lOpM MSB as in Figures 3.66 -  3.68. Results for cell 
models were also from triplicate preparations with statistical analysis by 
Student T-test ± SD versus each cell line’s respective untreated control.
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4.1 Discussion & future studies
Chemotherapy and radiotherapy can induce ROS as part of their growth 
inhibitory mechanism, but it is understood that subsequent induction of 
antioxidants, can ultimately promote development of chemotherapy or 
radiotherapy resistance in tumour cells (Housset, 1987; Szatrowski & Nathan, 
1991; Spitz et al., 1993; Toyokuni S, et al., 1994; Pani et al., 2004; La Torre et 
al., 1997; Kim et al., 2008). However it remains unexplored as to whether the 
acquisition of endocrine or anti-EGFR agent resistance is similarly associated 
with changes in redox balance, where alterations in antioxidants might again 
actively contribute to such resistant growth. Treating such resistance to 
targeted therapies remains an area of unmet clinical need in breast cancer since 
this state can confer a poorer patient outlook (Schiff et al., 2001); hence 
research in this area is important since it may reveal means of improving in 
treatment or even preventing resistance, and thereby confer better patient 
prognosis. This thesis therefore tested the hypothesis that there is an altered 
antioxidant state, and changes in oxidative stress in acquired resistance, using 
the various Tenovus acquired resistant breast cancer cell models in vitro 
including cell lines resistant to anti-oestrogen therapy (TAMR, FASR) 
(Knowlden et al., 2003), severe oestrogen deprivation (X-MCF) (Staka et al.,
2005) or the anti-EGFR agent gefitinib (NEW DUBS) (Jones et al., 2004), 
versus the endocrine responsive parental cell line w/t MCF7. This approach 
may reveal a new biology of resistance and thus potentially new therapeutic 
approaches, perhaps which could be extended to multiple resistant states if 
common changes in redox balance are encountered.
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The above models are reported to mirror the relapse that commonly occurs 
during treatment of clinical breast cancer, in that they emerged following an 
initial response period, with the resultant resistant cells having 
re-instated their proliferation and in some instances having gained invasive 
behaviour (Hiscox et al., 2004). In keeping with this concept, growth curve 
analysis of the TAMR, FASR, X-MCF and NEW DUBS models in this thesis 
was equivalent to untreated w/t MCF7 cells. These data showed the models 
had indeed become resistant to therapy, in that their growth was re-instated 
despite the presence of the respective treatment regime, giving confidence that 
the cells under test were truly reflective of the acquired resistant state in the 
thesis. The growth data also implied that any differences shown subsequently 
in redox balance (i.e. in TAC or ROS production) were unlikely to be merely 
due to a grossly-elevated growth rate in resistant cells, which would make any 
redox data difficult to interpret, but was likely to be an inherent feature of 
these cells. Moreover, any changes in redox balance that were subsequently 
encountered in resistant cells clearly were not giving an overall adverse impact 
on acquired resistant growth rate. Indeed, there was a small increase in 
proliferation and cell survival detected in TAMR resistant cells versus the 
responsive w/t MCF7 cells using ApoAlert MMS and Ki67 staining 
respectively.
Schiff, and Osborne had previously shown that resistance in their TAMR cell 
line was associated with increased oxidative stress and also an increase in the 
antioxidants SOD and GST (Osborne et al., 1991; Schiff et al., 2000), while
191
Chapter 4 -  Discussion
Besada and colleagues (2006) more recently noted using proteomics that their 
tamoxifen resistant model was also associated with altered oxidative stress 
processes (amongst changes in other processes such as the mitochondrial 
respiratory chain, apoptosis, signal transduction, and DNA and protein 
synthesis machinery). Given these limited tamoxifen resistance data and 
previous findings linking antioxidants to chemotherapy resistance (Szatrowski 
& Nathan, 1991; Spitz et al., 1993; Toyokuni S, et al., 1994), the initial phase 
of this investigation therefore aimed to examine if there was an increase in total 
antioxidant capacity, and also antioxidant gene expression, not only in the 
Tenovus antihormone resistant TAMR cells but importantly extending such 
studies to further resistant models spanning endocrine strategies and an EGFR 
inhibitor.
TAC was found to be significantly increased in TAMR cells versus w/t MCF7 
cells from the basal level measured at 24hours through to 7 and lOdays. Of 
note, the further resistant models FASR, X-MCF, and NEW DUBS all 
displayed a similar trend of significantly upregulated TAC at these timepoints 
in comparison to w/t MCF7 cells. It is possible therefore that this elevated 
level of TAC could be an important feature of acquired resistance that is shared 
by multiple resistant states. Global oxidative stress-related gene expression, 
and within this antioxidant enzyme gene expression analysis, was also 
undertaken using an Affymetrix microarray database of the various cell lines. 
The web-based technology GeneSifter was used, with careful initial pS2 
verification of samples and Affymetrix performance, as well as monitoring of
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multiple probes (using the UGT1A6 antioxidant gene as an example). This 
gave confidence in the individual gene expression profile changes exhibited. 
The system proved to have considerable power as a tool for analysing 
expression data derived from Afiymetrix HG-U133A chips for oxidative stress 
related genes.
200 oxidative stress related genes were compiled of which 39 genes were 
antioxidants that could potentially defend against pro-oxidant assault on the 
cell, comprising n=61 Afiymetrix probes. Antioxidants exhibited large 
increases in expression, with 59% of these probes up regulated versus w/t 
MCF7 cells (n=23/39 genes) that in some instances, spanned multiple forms of 
resistance. This was further supportive of the concept that prominent increases 
in antioxidant capacity occur in such resistant cells that may potentially be 
important in promoting cell survival and therapeutic resistance (Housset, 1987; 
Szatrowski & Nathan, 1991; Osborne et al., 1991; Spitz et al., 1993; Toyokuni 
S, et al., 1994; Pani et al., 2004). With elevated levels of antioxidant genes 
occurring within all four resistant cell lines, it is possible that oxidative stress is 
a common feature associated with endocrine resistant and anti-EGFR resistant 
breast cancer cells. These antioxidant gene changes may feasibly contribute to 
the increased TAC detected in the resistant models.
Subsequent statistical analyses by ANOVA (p<=0.05) identified that 15 
significant antioxidant gene expression changes occurred across the endocrine 
and anti-EGFR resistant models TAMR, FASR, X-MCF and NEW DUBS
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versus the w/t MCF7 model. This testing showed that all 15 of the antioxidant 
genes had upregulation spanning at least two forms of resistant models, 
confirming that significant gene expression changes related to oxidative stress 
could be detected that occurred across all endocrine and anti-EGFR resistant 
models. 9 of the antioxidant genes showed evidence of up-regulation across all 
4 endocrine and anti growth factor resistant models, whilst 6 antioxidant genes 
were up regulated in 2 or 3 forms of resistance. Ontological and literature 
searches using GeneCards and Entrez PubMed revealed that o f the 9 “generic” 
shared antioxidant genes, the vast majority had previously been implicated in 
protecting cells against intracellular oxidative stress promoted by H2O2 (Spitz 
et al., 1993; Suematsu et al., 2002), 02*(Kirkman & Gaetani, 1984; de Hann,
2004) and other ROS, thus potentially preventing against oxidative DNA 
damage (Dizdaroglu et al., 2002) and cell membrane damage by lipid 
peroxidation (Biemond et al., 1986). As these events could be detrimental to 
the cell, sometimes resulting in death if significant oxidative stress is 
unchecked, it may be that resistant cells have adapted to using antioxidants as a 
cell survival mechanism in the presence of therapy-induced oxidative stress, 
where an increase in antioxidants may thus be an advantage to emergence of 
such resistant growth as previously described for chemotherapy (Szatrowski & 
Nathan, 1991; Spitz et al., 1993; Toyokuni S, et al., 1994).
The 9 genes increased in all forms of antihormone and anti-EGFR resistance 
included: (a) Genes within the PRDX/TXN antioxidant network i.e. PRDX6, 
PRDX1 and PRDX4, three members of the peroxiredoxin (PRDX) family that
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regulate intracellular H2O2 , short chain organic fatty acids and phospholipid 
hydroperoxides, protecting cells against injury to the cell membrane and 
associated signal transduction pathways leading to apoptosis (Kang et al., 
1998; Seo et al., 2000; Noh et al., 2001; Karihtala et al., 2003). In addition, 
TXNRD1 was induced, an antioxidant that can react with oxygen free radicals 
and helps to replenish depleted PRDX if the latter is inactivated upon over­
oxidation by H2O2 (Amer et al., 1995; Powis et al., 2006); (b) Genes involved 
in the glutathione cycle i.e. GPX2 that also regulates intracellular H2O2 and 
GSTA4 that defends the cell against lipid peroxidation by-products such as 4- 
hydroxynonenal (4-HNE) (Yang et al., 2003); (c) SOD1 (Cu/Zn-SOD) that 
destroys free radicals such as O2 ’ that in excess can be toxic to biological 
systems, NQOl, a gene involved in the detoxification pathway, and EPHX2 
that degrades potentially toxic epoxides (McCord & Fridovich, 1969; Kirkman 
& Gaetani, 1984; de Hann, 2004; Cheng et al., 2009).
The 6 antioxidant genes that were shared by at least two forms of resistance 
versus the w/t MCF-7 model comprised: (a) PRDX3, another member o f the 
PRDX family and hence potentially again within the PRDX/TXN network that 
can be involved in redox regulation of the cell, protecting radical-sensitive 
enzymes from oxidative damage by a radical- generating system (Kang et al., 
1998; Seo et al., 2000; Noh et al., 2001; Karihtala et al., 2003), as well as TXN 
that participates in various redox reactions through the reversible oxidation of 
its active centre dithiol sites and TXNRD2, that like TXNRD1 reacts with 
oxygen free radicals and helps replenish depleted PRDX that can be inactivated
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by over-oxidation with H2O2 ; (b) a further glutathione mechanism-related gene, 
GLRX, shared by TAMR, FASR and NEW DUBS that as a member of the 
glutathione cycle reduces low molecular weight proteins (Ji et al., 1999; Valko 
et al., 2006) and (c) CAT, that protects against the toxic effects of peroxide and 
G6PD which is involved in the pentose phosphate pathway and is the main 
producer o f NADPH reducing power (Valko et al., 2006).
Given the potential role in cell survival in multiple forms of resistance and 
according to their strong profiles (with present call at mRNA level and 
ontology taken into consideration), 11 of the 15 antioxidant genes up regulated 
in at least two forms of resistance were prioritised for subsequent verification 
by PCR. The 11 antioxidant genes were the glutathione-related genes GSTA4, 
GLRX, GPX2; the PRDX/TXN related genes TXNRD1, TXN, TXNRD2, 
PRDX1 and PRDX6; as well as SOD1, CAT and NQOl in TAMR and FASR 
cells versus the parental w/t MCF7 model. It was found that there was some 
evidence of upregulation in resistance by both Affymetrix and PCR for 8 of 
these 11 genes, and that these genes again encompassed at least two potential 
antioxidant networks (TXN/PRDX; glutathione cycle). These antioxidant 
networks could feasibly contribute to the elevated TAC in resistant cells, and 
potentially to cell survival and acquired resistant growth. As such, this could 
even indicate that such antioxidants might comprise potential new targets for 
resistance, in some instances spanning resistant states.
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Among these, the antioxidant gene GSTA4 was up regulated across all forms 
of resistance by gene analysis profiling with particular significance (by t-Test) 
in TAMR and FASR cells, and was similarly shown to be significantly up 
regulated in both TAMR and FASR models by over 50% at the mRNA level by 
PCR. This finding is in agreement with the data of Schiff and colleagues who 
discovered statistically significantly increased GST (twofold; p=0.004) activity 
in their TAMR models, using an antioxidant enzyme assay kit (Schiff et al., 
2000), although this thesis was able to also show that GSTA4 gene 
upregulation extended at the mRNA level to FASR cells. In agreement with the 
mixed present and absent call at mRNA level using Affymetrix, the gene 
GLRX required a high cycle numbers o f 36 for PCR indicating minimal 
expression o f this gene, albeit increased in resistant cells. Affymetrix analysis 
for GLRX had showed up regulation in all endocrine resistant models with 
particular significance in TAMR and FASR and PCR analysis again verified 
these gene changes, with over 50% and 80% increases for GLRX in TAMR 
and FASR models respectively. Finally, GPX2 shown to be predominantly 
upregulated in TAMR models by Affymetrix gene analysis, was verified by 
PCR with over a 300% increase in the TAMR model. In total, these various 
gene changes further indicate that the glutathione cycle may be important in 
such resistant states.
Potentially part of a PRDX/TXN antioxidant network within resistant cells, the 
antioxidant gene TXNRD1 has been shown by gene analysis profiling here to 
be up regulated across all forms of resistance, again with particular significance
197
Chapter 4 -  Discussion
(by t-Test) in the TAMR and FASR models. In agreement, PCR verified 
significant increases in both TAMR and FASR cells by approximately 80%. 
TXNRD2 was also shown to be up regulated predominantly in TAMR models 
by Afiymetrix gene analysis and this was verified by PCR with a significant 
50% increase in the TAMR model. The potential importance of this network to 
the resistant states was further verified by PCR for TXN (whose reducing 
ability o f TXN can be replenished by TXNRD1; Valko et al., 2006). This gene 
was shown by Genesifter log intensity profiles to be significantly (by t-Test) up 
regulated in FASR cells and PCR analysis o f mRNA expression verified 
significant increases in FASR cells by 80%, as well as a 70% increase in 
expression in TAMR cells in comparison to the w/t MCF-7 control. Significant 
experimental and clinical evidence exists suggesting elevated levels o f TXN 
occur in some forms of cancer such as cervical carcinoma, hepatoma, gastric 
tumours, colorectal and lung carcinomas (Sinha et al., 1998; Grogan et al., 
2000; Raffel et al., 2003; Hedley et al., 2004; Ding et al., 2004; Csiki et al.,
2006).
Overexpression of TXN has also been shown to defend cells against pro­
oxidant induced apoptosis and thus can promote cell survival as well as 
conferring a growth advantage to tumours (Gorgan et al., 2000; Raffel et al., 
2003). Kim and colleagues (2008) have also previously found significantly 
elevated levels of TXN in tamoxifen resistant cells in comparison to control 
MCF7 cells, where they were able to relate increased antioxidant expression to 
an NF-E2-related factor2 (Nrf2)/ARE mechanism. A further gene potentially
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in this network, PRDX1, was also increased in the Kim et al. (2008) study; 
although PRDX1 and also PRDX6 showed upregulation by Affymetrix gene 
analysis in the present project in all resistant models, PCR failed to verify such 
increases in the TAMR and FASR models versus w/t MCF7 cells. 
Nevertheless, these latter antioxidants were still detected in all cells and may 
thus still be relevant within this network to such cells.
The antioxidant gene NQOl had also been shown by gene analysis profiling in 
the project to be a resistant gene significantly up regulated in both TAMR and 
FASR models. However, mRNA analysis by PCR was only able to confirm a 
significant elevation of NQOl expression in TAMR cells, with a substantial 
(over 100%) increase in expression versus w/t MCF7 cells, data suggesting this 
antioxidant may be important in the tamoxifen resistant state rather than 
spanning other endocrine resistant states. In this regard, interestingly Sripathy 
and colleagues (2008) have found that in the presence of the novel protein 
hPMC2, ER beta is recruited as a coactivator complex to mediate 
transcriptional upregulation of NQOl in order to protect breast cancer cells 
against oxidative DNA damage by tamoxifen. This project suggests continued 
exposure to tamoxifen is also associated with the upregulation of NQOl which 
may contribute to cell survival and therefore resistance. Further studies have 
shown association of NQOl with the formation of breast cancer and also 
resistance to chemotherapeutics (Ross et al., 2001; Menzel et al., 2004; 
Fagerholm et al., 2008),
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In agreement with the mixed present and absent call at mRNA level using 
Afiymetrix, CAT required a high cycle numbers of 30 respectively for PCR. 
Affymetrix analysis for CAT showed up regulation in all endocrine resistant 
models with particular significance in the FASR model. PCR analysis verified 
some gene changes, with 20% increase in expression shown in TAMR models 
and over 40% increase in the FASR model. Previous literature has shown that 
CAT, alongside GSH, GPX and GST, TXN and PRDX1, and also SOD, is an 
antioxidant also upregulated following chemotherapy-induced oxidative stress, 
in some instances promoting resistance (Iwao-Koizumi et al., 2005; Sharma et 
al., 2007). Exogenous addition of CAT has also been shown to be able to 
overcome growth inhibition by oxidative stress in ER+ breast cancer cells 
(Noto et al., 1989).
SOD1 also showed some induction in all resistant models by Affymetrix 
analysis, but PCR failed to verify this change although o f note this gene was 
again readily expressed in all cells, and coupled with the observation of Schiff 
and colleagues (2000) showing increases in this gene in their resistant model 
does not rule out a role for this antioxidant enzyme in resistance. Schiff and 
colleagues (2000) found significantly elevated levels of SOD in TAMR cells, 
but this was using an assay kit specifically for SOD activity at the protein level, 
and it may be that TAMR cells have elevated levels of this enzyme active in 
their cytoplasm independent of mRNA expression.
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It has previously been found that tamoxifen treatment was associated with 
increases in certain antioxidants such as NQOl (Sripathy et al., 2008), where 
Schiff and colleagues (2000) had argued that initial tamoxifen treatment was 
again an effective inducer of antioxidant enzymes in responsive cells. 
Therefore, it was important in this thesis to ascertain whether the antioxidant 
genes increases actually began earlier within w/t MCF7 cells during their 
treatment with, and response to, tamoxifen or faslodex, or if the antioxidant 
increases observed in this project were specifically associated with resistant 
states. Tamoxifen or faslodex treated w/t MCF7 cells (using inhibitory doses 
of 0.1 pM for lOdays) were thus tested for total antioxidant capacity. In 
agreement with the findings from Sripathy and colleagues (2008), results here 
showed significantly elevated levels of TAC in w/t MCF7 cells in the presence 
o f tamoxifen treatment (p=0.008) and that there was also increases in the 
presence of faslodex (p=0.001) versus untreated control w/t MCF7 cells.
After sample verification (again by monitoring the pS2 gene), the expression of 
the 11 selected antioxidant genes were similarly explored during anti-hormone 
treatment with tamoxifen or faslodex, by PCR analysis, additionally examining 
oestrogen impact on expression to determine if the genes might be classically 
oestrogen regulated. Of the 11 antioxidant genes analysed, none proved to be 
E2-induced in this study versus w/t MCF7 cells, indicating that in vitro 
oestrogen/ER signalling was unlikely to be required for their expression. GPX2 
was the only antioxidant gene found to be significantly (T-test p<=0.05) down 
regulated in w/t MCF7 cells treated with tamoxifen (50% reduction) or
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faslodex (100% reduction), but was again not classically E2-regulated. 
Interestingly, however, there was more substantial evidence of increases in 
expression during treatment with tamoxifen and/or faslodex for genes 
potentially within the glutathione network (GSTA4, GLRX), as well as 
TXNRD1 from the PRDX/TXN network, and also NQOl and CAT, in keeping 
with a lack of classical E2/ER regulation. TXN and TXNRD2, PRDX6, 
PRDX1 and SOD1 were not tamoxifen or faslodex regulated by PCR in w/t 
MCF7 cells. Thus, GSTA4 and TXNRD1 were T-test significantly (p<=0.05) 
upregulated in the presence of tamoxifen by over 80% and with faslodex by 
over 140% (compared to E2 treated w/t MCF7 cells) equating with Affymetrix 
findings, with increases subsequently retained within resistance by PCR.
NQOl was also upregulated in w/t MCF7 cells treated with Tamoxifen by over 
60% (equating with the data from Sripathy et al., 2008), and also with initial 
faslodex treatment by over 100%, where this upregulation was subsequently 
retained only in the TAMR resistant model. Both the antioxidant genes GLRX 
and CAT were also T-test significantly (p<=0.05) upregulated in faslodex 
treated w/t MCF7 cells by over approximately 100% and 140% respectively, 
subsequently maintained in the FASR model. The GLRX profile again equated 
with the Affymetrix data, although some discrepancy arose for the CAT gene 
since this appeared to be specific to resistance according to Affymetrix analysis 
but this was clearly shown by PCR not to be the case. This discrepancy may 
feasibly be due to differences in probe/primer performance in Affymetrix 
versus PCR analysis of CAT mRNA, or even possibly that the PCR primers
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detect an altered form of CAT that the Afiymetrix studies do not consider (as 
explained on the official Afiymetrix website). While both genes were found to 
be upregulated in TAMR cells, they were not regulated by early tamoxifen 
treatment suggesting that longer treatment o f the MCF-7 cells with this 
antihormone might be needed for instigation of this inductive event (in relation 
to more rapid induction achieved with faslodex which is established as a more 
potent antioestrogen (Wakeling et al., 1991; Osborne et al.,1995; Dowsett et 
al., 2005; Nicholson & Johnson, 2005).
As stated above, the antioxidant genes examined do not appear to be classically 
E2/ER regulated in vitro but 5 o f these genes (GSTA4, GLRX, TXNRD1, 
NQOl and CAT) were clearly antihormone-induced in the thesis. While Schiff 
and colleague (2000) suggested that their tamoxifen-induced oxidative stress 
mechanism was ER regulated, and NQOl has been reported to be tamoxifen 
regulated via ER-dependent ARE activation (Montano M et al., 1997, 1998), 
Kim et al. (2008) reported that the tamoxifen-induced oxidative-stress-related 
events they observed were ER independent. They found basal phosphorylation 
of extracellular signal-regulated kinase (ERK) and p38 kinase increased in 
TAMR cells and that inhibition of ERK significantly decreased the activity of 
minimal ARE protein expression in TAMR cells, with no effect of E2 or 
faslodex on ARE events. Thus it appeared to be the ERK pathway, and not 
oestrogen receptor signalling, involved in the up-regulation of Nrf2/ARE in 
their TAMR cells. The mechanism of induction of antioxidants by 
antihormones thus clearly remains controversial. Indeed, relatively little is
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known about how antihormones can induce (and in turn how oestrogen down 
regulates) gene transcription (Frasor et al., 2003). This is despite microarray 
analysis having found that E2 reduces the expression of a significantly large 
proportion of the genome, with 70% of all the genes regulated by E2 treatment 
of MCF7 cells down regulated and many of these reversed by antihormones 
(Frasor et al., 2003; Deroo et al., 2004).
Interestingly, while some antihormone-induced genes are growth suppressive, 
surprisingly the antihormone induced elements reported to date include known 
growth-promoting genes such as EGFR and HER2, whose induction permits 
cell survival during antihormone treatment and can subsequently be prominent 
drivers o f antihormone resistant growth (Gee et al., 2003). It is thus possible 
that early induction of antioxidant genes/networks (e.g. glutathione; 
PRDX/TXN; and also NQOl and CAT) and potentially parallel TAC increases 
during antihormone treatment of w/t MCF7 cells might also serve to allow 
residual cell survival and could limit growth inhibitory response during the 
rigours of early antihormone treatment, as has been noted with chemotherapy 
and radiotherapy (Yokomizo et al., 1995; Sinha et al., 1998; Gorgan et al., 
2000; Hedley et al., 2004; Ahmadi et al., 2006; Cheng, et al., 2009). Such 
increases could help support a residual cell population for emergence of 
resistance, alongside (and potentially interactive with) the induced EGFR 
during tamoxifen treatment and subsequently into resistance (Gee et al., 2003; 
Knowlden et al., 2003). Interestingly, since some antioxidant genes such as 
CAT (and also SOD) are also upregulated by other agents such as histamines
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(Medina et al., 2007), and several antioxidant genes again such as CAT and 
genes in the glutathione cycle including GST (as well as GSH and GPX) and 
PRDX/TXN networks (e.g. TXN, PRDX1) can also be upregulated following 
chemotherapy (Iwao-Koizumi et al., 2005; Sharma et al., 2007), it is possible 
that induction of some antioxidant genes/networks and parallel increased TAC 
may even comprise a generic stress response mechanism used to survive 
multiple adverse agents, including antihormonal measures.
The observed antihormone induction of antioxidants may imply that, in 
addition to their potential targeting value in resistance, such antioxidants 
co-targeted alongside antihormones could have some therapeutic value during 
the endocrine responsive phase of the disease to prevent emergence of 
resistance, as has been noted for combination anti-EGFR/antihormone 
treatment (Gee et al., 2003). Any antioxidant genes (e.g. GPX2; also TXN and 
TXNRD2) that were found by PCR and Affymetrix analysis not to be induced 
by tamoxifen or faslodex treatment in this thesis but only increased once 
resistance is acquired may of course also potentially become growth- 
contributory once resistance is established. Of note, all antioxidant genes 
shown to be elevated in resistance could also potentially be interactive with any 
known mitogenic contributory pathways in this state, notably EGFR signalling 
in TAMR cells (Knowlden et al., 2003). Increased EGFR signalling has not 
only been previously linked to acquired tamoxifen resistance in vitro but has 
also been reported to be deregulated in further acquired resistant cell models, 
including some FASR lines (Gee et al., 2003; Hiscox et al., 2004; Jones et al.,
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2004; Gee et al., 2005; Jones et al., 2005; Knowlden et al., 2003; McClelland et 
al., 2001).
To examine if the 11 antioxidant genes had any potential interplay with EGFR 
in resistance, the impact of the EGFR inhibitor Gefitinib was investigated on 
antioxidant gene expression in parallel with growth studies in TAMR cells, 
using a dosage known to selectively target the activity of this receptor in such 
cells (luM ; Knowlden et al., 2003). Expression of the antioxidant genes was 
monitored by PCR in mRNA samples prepared from TAMR cells +/- gefitinib 
for 7days. Moreover, growth impact o f additional signal transduction 
inhibitors (STIs) known to target further elements in EGFR signalling and 
further pathways linked to tamoxifen resistance was examined (e.g. MAPK 
signalling using U0126 [Knowlden et al., 2003; Britton et al., 2006] 
wortmannin to target PI3K signalling (Jordan et al., 2004), c-Src activity using 
AZD0530 (Hiscox et al., 2006). and signalling of a downstream nuclear 
transcription factor (NfkB) with parthenolide (Zhou et al., 2005)). MTT 
analysis of these different signal transduction pathway inhibitors in TAMR 
cells confirmed substantial growth inhibition with gefitinib, AZD0530, 
Parthenolide and U0126, although no change was demonstrated with 
wortmannin in this study.
Further exploration of the gefitinib response using 
Ki 67 staining and ApoAlert MMS assays showed that there was also a 60% 
decrease in proliferation in TAMR treated with GEF but only modestly-
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increased apoptosis. These data confirm the relevance of such signalling to 
TAMR growth and were generally in keeping with previous data obtained for 
this model (Knowlden et al., 2003; Hiscox et al., 2006) as well as the emerging 
importance of such signalling in clinical tamoxifen resistance (Gee et al.,
2005).
O f the 11 antioxidant genes further analysed by PCR for response to gefitinib 
in TAMR cells, elements representing the glutathione and also PRDX/TXN 
networks (i.e., the antioxidant genes GSTA4, GLRX, TXNRD1 TXNRD2 and, 
TXN), as well as NQOl and CAT, all showed T-test significant (p<=0.05) 
downregulation, to a greater or lesser extent, in the presence of the growth- 
inhibitory dose of gefitinib implying these antioxidants are all positively 
regulated by EGFR signalling in TAMR cells. Thus, GSTA4 was inhibited in 
TAMR cells treated with TKI by over 40%, GLRX by approximately 20%, 
TXNRD1 by over 90%, TXN by approximately 40%, TXNRD2 by 
approximately 45%, NQOl by over 55% and CAT by approximately 45% 
compared to the untreated TAMR cells. In addition, while PRDX6 and SOD1 
were not regulated by TKI treatment ruling out their involvement in such signal 
transduction pathways, the expression of PRDX 1 detected in TAMR cells was 
also very slightly decreased by 10% with gefitinib suggesting partial EGFR 
regulation. In accordance with the findings linking EGFR to redox balance in 
further cell types reported by Duval and colleagues (2002), who showed that 
enhanced cellular antioxidant defences against mitochondrial oxidative stress 
can occur through EGFR-dependent activation of antioxidant genes (in their
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studies exemplified by GPX), it appears that 8 of the 11 antioxidant genes 
require stimulation by EGFR in the TAMR cells, where the subsequent 
inhibition of this tyrosine kinase has therefore resulted in their downregulation.
Thus, most of these antioxidant genes do appear to interplay with EGFR in 
TAMR cells, where it is known that EGFR can be activated by pro-oxidants 
such as H2O2 (King et al., 1989; Knebel et al., 1996; Rao, 1996) resulting in the 
upregulation of antioxidants (Duval et al., 2002; Kim et al., 2008). 
Interestingly, Kim and colleagues (2008) showed increased expression of 
Nrf2/ARE-dependent anti-oxidant proteins in their tamoxifen resistant breast 
cancer cells and they showed that tamoxifen induced oxidative stress activated 
MAPK signalling and subsequently increased Nrf2 levels to increase ARE 
activity and antioxidant gene expression (Kim et al., 2008). Induction of stress 
responsive and cytoprotective enzymes encoded by their mechanism included 
SOD, CAT, GPX, TXN, NQOl and GST in their TAMR cells. Since 
tamoxifen resistance could be partially reversed by Nrf2 siRNA, this Nrf2 
mechanism contributed to TAMR cell growth. Results of the present 
investigation could link in further specific antioxidant genes downstream and 
also EGFR upstream if this Nrf2 mechanism were to be apparent within our 
own TAMR cells. In this regard, EGFR has previously been shown to regulate 
MAPK activity in these cells (Knowlden et al. 2003) and interestingly Nrf2 
expression has also been shown through a preliminary heatmap analysis to 
increase, as reported by Kim and colleagues (2008), in the resistant cells 
studied in the present project (Dr Gee, personal communication).
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The gefitinib data suggest the antioxidant genes could feasibly be an important 
part o f the EGFR signalling mechanism in TAMR cells, driven by EGFR to 
potentially promote cell survival. The value of these antioxidant genes as 
targets therefore remains possible if they are indeed growth contributory; 
however, whether their individual targeting would further improve on EGFR 
blockade alone in TAMR cells (given that the TKI gefitinib reduces their 
expression to some degree here) is difficult to predict. Since some of the 
antioxidant genes appear to be EGFR regulated, it is also possible that the 
increases detected for these antioxidant genes during antihormone response in 
w/t MCF7 cells could again be a consequence of an antihormone-induced 
oxidative stress mechanism involving increases in EGFR that could 
subsequently maintain cell survival during early treatment (Gee et al., 2003).
While the antioxidant gene findings are certainly interesting, it was important 
in the thesis to consolidate further the concept that interplay might occur 
between EGFR signalling and the antioxidants in the TAMR cells beyond the 
mRNA expression level. To do this, the impact o f the EGFR inhibitor gefitinib 
and further growth factor signalling inhibitors on TAC in TAMR cells was also 
investigated in the project. Paradoxically, there appeared to be no parallel 
relationship between TAC and the EGFR mitogenic pathway in TAMR cells. 
Thus, TAC levels for TAMR cells treated with the TKI, while at 24hours 
significantly down regulated, were surprisingly further up regulated by 7days 
and remained elevated at lOdays. There was thus a difference between most of
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the antioxidant genes examined at the mRNA level at 7 days and the TAC 
findings in the thesis with the TKI. In explanation, it is possible that the 
antioxidant gene mRNA expression measured is not reflective of TAC. In the 
future, antioxidants should thus also be measured at the protein level (e.g. 
using Western blotting) in the breast cancer resistant models versus the 
parental w/t MCF7 cell line to account for their potential replenishment and 
recycling in order to identify if these antioxidants contribute to TAC. 
Pharmacological challenge of any of the induced antioxidant genes /networks 
using antioxidant inhibitors listed in Tables 3.2 and 3.3, or molecular 
knockdown using SiRNA, could further explore if these are contributory to 
TAC and resistant growth. However, altered levels of non-enzymatic 
antioxidants as well as enzymatic antioxidants have also been related to 
changes in signal pathways and are evident in many human cancers (McEligot 
et al., 2005). Therefore it may be that certain non-enzymatic antioxidants 
(which can include lipoic acid, Vitamins C, E, carotenoids, natural flavonoids, 
and melatonin) that have not been accounted for in this investigation may 
actually be playing a crucial role in making up the cellular TAC analysed in 
TAMR cells (Mates et al., 1999; McCall & Frie, 1999; Mathews et al., 2000).
Therefore it may be that despite the expression deregulation of antioxidants 
revealed in this investigation, perhaps these particular antioxidant genes really 
are independent from the TAC increases noted in TAMR cells. Thus, in 
contrast to most of the antioxidant gene data, TAC was not convincingly 
positively EGFR (or associated kinase) regulated in our TAMR model. Indeed
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it was actually further stimulated during growth inhibition by the EGFR 
inhibitor. Only one antioxidant gene examined here, GPX2 (a glutathione cycle 
component) was, like TAC, induced further by TKI and so may be contributory 
in some way not only to the increased TAC detected in the TAMR cells but 
also subsequently to the further increased TAC during gefitinib treatment. 
Thus, the GPX2 gene was shown to be T-test significantly (p<=0.05) 
upregulated in the presence of the TKI gefitinib by over 130% compared to the 
untreated TAMR cells. However, TAC (and potentially any contributory 
GPX2) in TAMR cells does appear to be driven by EGFR-independent 
mechanisms, contrasting the majority o f the particular antioxidant gene 
expression we studied.
In this regard, the TAC in TAMR cells also does not appear to be positively 
regulated by Src or MAPK as TAC analysis o f further signal transduction 
inhibitors in TAMR also showed significant upregulation with AZD0530 or 
U0126. Martin and colleagues (2008) recently discovered that parthenolide 
possesses free radical scavenging activity against a wide range of reactive 
oxygen species in vitro with greater activity than Vitamin C. They also found 
that parthenolide attenuated the formation of UV-induced hydrogen peroxide 
and In vivo, reduced UV-induced DNA damage and apoptosis (Martin et al., 
2008). Given this apparent inherent antioxidant capacity, therefore, the TAC 
increase associated with parthenolide in TAMR cells here may not actually be 
a reliable indication of independence of antioxidant capacity from NficB in
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such cells, and so future studies examining alternative means of manipulating 
NfkB, in parallel with TAC measurement, remain needed.
While probably not EGFR driven, TAC could potentially interplay with IGF1R 
signalling in TAMR cells. Indeed, further growth factor receptors such as the 
IGF1R and other members of the ErbB family have previously been linked 
with oxidative stress (Khan EM, et al., 2006). Moreover, Knowlden and 
colleagues have shown that IGFIR/Insulin receptor substrate-1 (IRS1) 
signalling is also strongly promoted by treatment with gefitinib (Knowlden et 
al., 2008). The present investigation has also shown up regulated TAC in NEW 
DUBS cells at 24hours, 7days, and lOdays compared to w/t MCF7 cells, 
potentially equating with the prominent IGF1R signalling also described for 
these acquired resistant cells (Jones et al., 2004). However, TAC was also high 
in this investigation in cell lines where EGFR and IGF1R signalling are already 
known to not be prominent, for example in the FASR and X-MCF lines (Staka 
et al., 2005). Therefore the TAC induction could also be driven by other as yet 
unknown signalling mechanisms in resistant cells, or the TKI/STI observations 
could even be further supportive of the concept that TAC increases comprise a 
generic stress-induced mechanism launched to anti-tumour agents, as a 
mechanism of residual cell survival during substantial growth inhibition. 
IGF1R and further potential signalling mechanisms contributing to TAC could 
be investigated by future relevant STI challenge. There thus appears to be 
induction of TAC during growth inhibition by antihormone treatments in 
endocrine responsive breast cancer cells, with these increases retained into the
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acquired antihormone resistant models (perhaps contributing to cell survival 
and growth in these states), with TAC then induced further by growth 
inhibitory secondary agents in TAMR cells (e.g. TKI and other STIs) to again 
allow residual cell survival, permitting and maintaining subsequent resistance 
(as in NEW DUBS cells).
If TAC is indeed involved in cell survival and growth, these findings could 
indicate that full blockade of the induced TAC might treat resistance and could 
potentially improve response in TAMR cells when targeted alongside gefitinib. 
In these regards, the investigation has provided a preliminary exploration of 
BSO +/- gefitinib in TAMR, using BSO to potentially target the glutathione 
inducer o f GPX2 (Lewis-Wambi et al., 2009) which could be contributing to 
TKI-induced TAC. Interestingly, Lewis-Wambi and colleagues have recently 
identified and characterised a novel resistant subclone of w/t MCF7 cells, 
MCF-7:2A. This group’s studies suggest endocrine resistant cells can be 
inhibited by higher oestrogen dosages, but interestingly this cell line only 
undergoes dramatic increase in apoptosis (7-fold) in the presence of combined 
treatment of E2 plus BSO, rather than with E2 alone, suggesting the 
antioxidant target of BSO (potentially the elevated glutathione measured in 
these cells) may be contributing to cell survival in this model. Their 
microarray analysis revealed upregulation of the GPX2 antioxidant gene by 40- 
fold in MCF-7:2A cells compared to hormone-responsive MCF-7 cells, where 
BSO almost completely inhibited this increase (Lewis-Wambi et al., 2009).
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Of note, the GSH/GPX system has been reported in other systems to be able to 
defend against elevated levels of oxidative stress to promote cell survival (Fu et 
al., 2007). While not being able to further add to the gefitinib effect, MTT 
analysis promisingly revealed a significant decrease in TAMR growth in the 
present study with lOOuM BSO. This simplistically would suggest that BSO 
targeting of a deregulated glutathione antioxidant pathway could, as in the 
Lewis-Wambi studies, have potential value in treating resistance. However, 
TAC analysis in this thesis (not examined in the Lewis-Wambi study) 
paradoxically showed significant increases in TAC during BSO treatment, 
implying any growth inhibitory effect o f this dosage of BSO was likely to be 
non-specific since the “target” antioxidant capacity was not depleted. This 
agent may thus again simply be promoting a stress response and thus 
increasing TAC during its growth inhibition of TAMR cells. Further study of 
the role of the relationship between GPX2 and TAC needs to be performed in 
the future, perhaps using a GPX2 siRNA approach.
Unfortunately, the data with gefitinib in the TAMR cells also indicate targeting 
of the further antioxidant genes that are increased in resistance is unlikely to 
deplete TAC and thereby any associated cell survival. However, recent studies 
from Kim and colleagues (2008) have shown that blocking Nrf2, a key 
regulator of ARE-mediated transcription and hence potentially of multiple 
antioxidant expression in their own TAMR model, is able to restore tamoxifen 
growth inhibition in TAMR cells (Kim et al., 2008). This implies global 
depletion of ARE activity (and thus presumably many of the cell’s
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antioxidants), if achievable and tolerable, might provide one strategy to target 
the increased TAC and thus deplete growth in cells resistant to endocrine (or 
other targeted) agents. ARE signalling and its regulation should thus be 
examined within our TAMR cells, both in relation to regulation of their 
elevated TAC and their growth in the future.
In addition to monitoring TAC and antioxidant enzymes, this thesis also 
monitored changes in Redox status (ROS level) as a further indicator o f the 
level of oxidative stress in the various acquired resistant models and during 
antihormone or gefitinib response. In keeping with the concept that resistance 
to targeted therapies is associated with an increased oxidative stress and (based 
on existing chemotherapy data and previous tamoxifen resistance findings from 
Schiff et al. [2000] and Kim et al., [2008]) that a signalling/ARE mechanism 
may promote increases in antioxidant capacity to maintain growth and cell 
survival in the resistant state, ROS levels were found to be increased in all the 
acquired resistant models versus w/t MCF7 cells. Thus, there was a 
consistently increased level of ROS in TAMR cells versus w/t MCF7 reaching 
a 190% increase (p=0.01) after lOdays culture. Unique to this investigation 
ROS was shown to also be up regulated in FASR, X-MCF and NEW DUBS 
resistant models in a similar manner to TAMR cells with at least 100% 
increase versus w/t MCF7 cells (T-test p<=0.05). Along with the observations 
of increased antioxidants, the ROS data confirm that cells that have acquired 
resistance to targeted therapies are commonly experiencing increased oxidative 
stress. While Kim and colleagues (2008) reported significantly decreased
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intracellular peroxide production alongside increased antioxidants in their 
TAMR cells (contradicting the findings of this investigation of increased ROS 
alongside increased antioxidants and presumably reflecting considerable ROS 
buffering by the antioxidants in their model), Schiff et al. (2000) also reported 
an increase in oxidative stress in their TAMR model which is in agreement 
with this project.
However, the modestly elevated ROS detected observed does not appear to be 
promoting substantial cell death in the TAMR cells and other resistant models 
(as demonstrated by the growth data findings previously described). The 
parallel elevated TAC may indeed, therefore, be helping to maintain cell 
survival in the face o f their increased oxidative stress. Antioxidants at 
relatively low concentrations are able to compete with oxidizable substrates, 
thus significantly delaying or inhibiting their oxidation and thus preventing 
extreme levels of ROS being reached in cells that would promote cell death 
(Halliwell & Gutteridge, 1989). Moreover, it should be remembered there is 
also literature to indicate modest redox is also capable of triggering other 
signalling mechanisms that could potentially directly contribute to resistant 
growth: for example redox is known to be able to induce AP-1, EGFR 
signalling and diverse kinase activation (King et al., 1989; Knebel et al., 1996; 
Rao, 1996; Schiff et al., 2000; Kim et al., 2008). Future studies could explore if 
there is any ROS cross talk, for example, with EGFR phosphorylation status in 
the resistant cells. For a table of all signalling pathway genes that have been 
associated with increased oxidative stress, as compiled from literature and the
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web based GeneCards® database in this thesis, the reader is referred to 
Appendix 1. Many of such elements are at increased activation in TAMR cells 
(e.g. EGFR, MAPKs; Knowlden et al., 2003) and so it is feasible that the 
modestly-increased ROS levels detected in the resistant models may be 
contributing to the triggering of such signalling and thereby resistant growth.
An increase in ROS was not detected during short term (up to 10 days) 
tamoxifen or faslodex antihormone treatment in w/t MCF7 cells in this 
investigation, where such cells consistently had low ROS levels. Some studies 
have previously described that tamoxifen is capable of causing oxidative stress 
and thereby apoptosis in certain contexts, including in T-leukaemic Jurkat and 
ovarian A2780 cancer cells (Nuwaysir et al., 1998; Wei et al., 1998; Day et al., 
1999; Ferlini et al, 1999; Peralta et al., 2006)). For example, TAM could be 
activated into reactive electrophilic metabolites. However, it also launches 
mechanisms to protect against oxidative lipid and DNA damage by inducing 
phase I and II metabolising enzymes (Nuwaysir et al., 1998; Wei et al., 1998). 
Perhaps any initial ROS induced by antihormones (that could be detrimental to 
cell survival) was rapidly buffered in the endocrine responsive, ER+ w/t MCF7 
cell context by the readily-detectable anti-hormone induced TAC, limiting cell 
death effects with these agents. Interestingly, although antihormones are 
known to promote anti-proliferative effects (Dowsett et al., 2005; Lacey et al., 
2005; Nicholson & Johnson, 2005), all such agents to date exert only small 
pro-apoptotic effects, in keeping with their known induction of EGFR/ErbB2
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survival signalling (Gee et al., 2003). Such antihormone-induced cell survival 
mechanisms may extend to increased TAC.
Given that EGFR signalling has been shown in some systems to be able to 
promote oxidative stress (Rao, 1996) and that EGFR is known to be increased 
in the TAMR cells (Knowlden et al., 2003) it was important to examine the 
relationship between EGFR and ROS within TAMR cells by treating them with 
gefitinib. However, this agent showed at least a 2fold significant (T-test, 
p<=0.05) further up regulation in ROS at 24hours, 7 and lOdays, suggesting 
there is actually no positive regulation of ROS within TAMR cells by EGFR. 
This appears to extend to the additional STIs examined in the thesis (including 
the MAPK signalling inhibitor). However, it does confirm earlier findings by 
Mimeault and colleagues (2005) and Kishida and colleagues (2005) that 
gefitinib promotes ROS in prostate and gastric cancer cells respectively.
TAMR cells also showed a similar significant up regulation of ROS with 
AZD0530, Parthenolide and U0126 (although no change was again observed 
for Wortmanin as in the MTT and TAC analysis). These inhibitor data in 
TAMR cells appear to indicate that it is unlikely EGFR-related signalling is 
promoting their oxidative stress, although this does not preclude increased 
oxidative stress impacting on EGFR activity in the resistant cells, an aspect 
which warrants future study.
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The gefitinib- and other STI-induced ROS in TAMR cells occurred alongside 
these agents promoting significant anti-proliferative effects and growth 
inhibition. The detectable drug-induced oxidative stress in TAMR cells may in 
some way contribute to these anti-tumour effects. However, this oxidative 
stress mechanism encompassed a substantial TAC response in TAMR cells. 
This could potentially defend against excessive ROS and limit STI pro- 
apoptotic effects, enabling residual cell survival in the presence of drug. In 
agreement with this concept, there was only a modest detectable apoptotic 
effect o f gefitinib in the TAMR cells; indeed, the action of such STIs used as 
single agents has to date largely been reported to be cytostatic in cancer.
Halliwell (2006) stated that modestly increased ROS is tolerable and not pro- 
apoptotic in some cancer cells, where this ROS is held at tolerable, beneficial 
levels by the triggered antioxidant response (Haliwell & Cross, 1992). 
However, Halliwell also suggested that if  it were possible to reach excessive 
ROS levels in cancer cells, this may be sufficient to overcome the antioxidant 
buffering mechanism and be able to promote marked cell death and more 
substantial antitumour effects (Halliwell, 2006). Since this could have 
therapeutic implications, this concept has been addressed in this thesis in the 
acquired resistant models using the agent menadione (MSB) whose antitumour 
effects have been under investigation since 1947 (Michell et al., 1947; Mitchell 
et al., 1948; Su et al., 1991). Thor and colleagues (1982) showed that alongside 
the production of H2O2 , menadione generates O2* and semiquinone radicals 
through redox cycling of the quinine. A mechanism where MSB promotes
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excess oxidative stress is also supported by Nutter et al., (1991), who detected 
MSB-induced oxidative stress with increased DNA strand breaks due to OH* 
in MCF-7 cells. Noto and colleagues (1989) demonstrated that MSB at 
~14pg/ml was also able to produce a 50% inhibition of breast cancer (MCF-7) 
cell growth. This was suppressed by the addition of exogenous catalase, 
suggesting the excessive production of H2O2 and thus oxidative stress was 
responsible for this growth inhibition (Noto et al., 1989; Nutter et al., 1991).
Interestingly, induction of excess ROS using the agent MSB in this project 
proved to be highly growth inhibitory not only in w/t MCF7 but also in TAMR 
cells and the other acquired resistant models. Of note, the resistant models 
(which as stated above all had a higher basal ROS level) had an increase in 
sensitivity to the anti-tumour effect o f this agent versus the endocrine 
responsive cells. Thus, MTT for w/t MCF7 cells treated with MSB showed a 
dose dependent decrease in growth with a calculated IC50 of 15.4pM, similar to 
that reported by Noto et al. (1989). TAMR cells also showed a similar dose 
dependent decrease, although they proved more highly sensitive, with a lower 
calculated IC50 of lOpM for MSB. High sensitivity to MSB was also shown in 
FASR, X-MCF and NEWDUBS via MTT analysis, again with considerably 
lower calculated IC50 values versus w/t MCF7 cells of 8.3pM, 7.3 pM, and 
9.3pM respectively. There were increased ROS levels in w/t MCF7 cells, 
TAMR and all the additional resistant cells treated with MSB, confirming that 
MSB induces substantial ROS within these various models. However, higher 
ROS levels were achieved with MSB in the resistant models versus the w/t
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MCF7 cells. In accordance with Halliwell’s concept (2006), perhaps by 
induction of these more extreme ROS levels in the various resistant models 
using MSB, the TAC that may be contributing to their cell survival basally is 
overpowered, allowing oxidative stress-driven cell death in resistant models. 
Future consolidation of this concept (and its relation to DNA damage and lipid 
peroxidation) will be required.
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4.2 Summary of potential redox mechanism in acquired 
resistant breast cancer cells and therapeutic 
implications:
From the in vitro data amassed in this project spanning multiple models and the 
diverse methodological approaches employed, it seems that oxidative stress 
commonly increases in cells that have been exposed long-term and become 
resistant to various endocrine and other targeted therapies, observations that 
extend published tamoxifen and chemotherapy data (Figure 4.1a). This modest 
change in redox may or may not activate pro-proliferative signalling in the 
acquired resistant cells; however, the altered redox does not appear to 
adversely impact on growth rate of the various resistant cells or to be 
associated with high levels of cell death as measured in these cells. Any 
potentially adverse (pro-apoptotic) effects of increased oxidative stress could 
feasibly be being prevented by the marked increased antioxidant capacity that 
this thesis has also detected in all of the acquired resistant cells models. This 
event may thus, as in the chemotherapy resistance scenario, be preventing 
excessive increases in oxidative stress, promoting cell survival and thereby 
contributing to acquired resistant growth with multiple targeted therapies 
(Figure 4.1a).
Interestingly, examination of short-term treatment with multiple antihormones 
in endocrine responsive cells in the thesis also indicated that TAC (and
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expression of some antioxidant genes) commonly begins to be induced during 
early treatment. However, given that ROS increases are not detected in parallel, 
this antioxidant capacity may be overcoming any modest initial ROS induction 
by treatment. Again, the antioxidant increase could be feasibly contributing to 
cell survival, limiting apoptosis (alongside an established role for antihormone- 
induced EGFR/HER2 signalling) during early treatment of endocrine 
responsive cells.
Further targeted therapy with STIs in the established acquired resistant cells 
(such as gefitinib, AZD0530, Parthenolide or U0126 in TAMR) induced 
additional ROS increases (that could perhaps be contributory to their anti­
tumour effect). This implies that ROS is not EGFR promoted in TAMR cells, 
(although these data do not preclude ROS impacting on EGFR signalling as 
part o f the growth regulation in such cells). Importantly, however, such 
treatment also further increased antioxidant capacity. This event may again be 
maintaining residual cell survival and hence limiting maximal STI pro- 
apoptotic effect.
The thesis also determined that there was increased expression of several 
antioxidant genes in the acquired resistant cells (including those potentially 
within PRDX/TXN and glutathione networks), in some instances again 
spanning multiple resistant states. These could potentially have contributed to 
the increased antioxidant capacity increases within resistant cells. However, the 
studies examining impact of gefitinib and other STIs in TAMR cells indicated
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that their total antioxidant capacity, unlike expression of most of these 
antioxidant genes, was not EGFR/kinase signalling regulated suggesting that 
TAC is dissociated from such gene expression in the resistant cells. Thus, 
further genes and signalling mechanisms may drive the increased antioxidant 
capacity in resistant cells. Data in the thesis initially suggested a potential 
contributor could be the GPX2 antioxidant gene; however, this remains to be 
consolidated since application of an agent (BSO) to target its potential 
glutathione mechanism proved equivocal.
With regards to the therapeutic implications of these findings, this thesis has 
suggested that targeting of the identified antioxidant genes increased in 
resistance may not in general be useful in decreasing TAC (as based on the 
gefitinib findings), although as stated above further manipulation of 
GPX2/glutathione is worthy of further investigation. However, given available 
literature, global depletion of TAC, if achievable, could perhaps be useful to 
block cell survival in acquired resistance (and alongside antihormones improve 
initial response), potentially extending to multiple acquired resistant states 
(Figure 4.1b). Equally, however, since the resistant cells have a higher basal 
ROS than their endocrine responsive counterpart, this thesis importantly has 
also been able to show that they may be particularly sensitive to treatment with 
agents which induce more excessive oxidative stress, presumably exceeding 
the buffering capacity of the antioxidant capacity in such cells to promote cell 
death events. Indeed, one such agent (MSB) was substantially growth 
inhibitory in resistant cells, extending to the multiple acquired resistant states
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(Figure 4.1b). The findings in the thesis may thus have therapeutic implications 
for acquired resistance to various targeted therapies (and potentially some 
selectivity, since it was observed that the endocrine responsive cells were less 
sensitive to ROS manipulation). In turn, Beck and colleagues (2009) 
established that Menadione induced oxidative stress should affect cancer cells 
such as w/t MCF7 cells to a greater extent than normal cells, and therefore this 
differential sensitivity could feasibly have clinical applications (Beck et al., 
2009).
The novel findings in this thesis with Menadione that suggest such strategies 
may have relevance in treating acquired resistant states join those increasing 
from other groups who are proposing this may be a useful tool in breast cancer 
therapy. Thus, Akiyoshi and colleagues (2009) have very recently found that 
Menadione caused mitochondrial dysfunction, including a disappearance of 
mitochondrial membrane potential, and that this mitochondrial damage was 
induced by Menadione-induced ROS with subsequent activation of caspase 7 
and 9 in MCF-7 cells (Akiyoshi et al., 2009). They demonstrated that 
Menadione-induced apoptosis (at a calculated I C 5 0  of 14.2pM) was selectively 
initiated by the mitochondria related pathway and suggested that it may be a 
potential growth inhibitory breast cancer treatment (Akiyoshi et al., 2009).
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Figure 4.1
a) Model of the redox balance in acquired resistant breast cancer cells in 
vitro
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b) Potential growth inhibition strategies for acquired resistance based on 
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Pro-oxidant activation of cell growth signalling may enable resistant breast cancer 
cells to grow. In response, antioxidants levels may be increased to buffer any excess 
oxidative stress that may cause cell death, therefore promoting cell survival (a). 
Potential growth inhibitory strategies that promote cell death in these resistant models 
may therefore include induction of pro-oxidants, such as by MSB as demonstrated in 
this thesis, or inhibition of Total Antioxidant Capacity either pharmacologically or by 
SiRNA (b).
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It should be remembered that the relationship between oxidative stress and 
breast cancer growth is complex, as is the feasibility of using agents 
influencing redox, given that manipulation of oxidative stress could potentially 
exert effects on normal tissues (Valko et al., 2006). There remains much still 
to be done, therefore, to consolidate the relevance of antioxidants as 
therapeutic targets in endocrine and anti EGFR resistant breast cancer, or 
promotion of excessive oxidative stress in such cells. However, the findings 
and resultant concepts emerging from this thesis are exciting when considering 
potential treatments for acquired resistance to endocrine agents as well as other 
targeted therapies that are clearly worthy of future exploration given that new 
therapies remain much needed for these adverse states.
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Appendix I -  Compilation of Signal Transduction 
pathway genes related to Oxidative Stress (n=117)
Table 1. Cell signalling proteins associated with oxidative stress.
Alias Name
ADAM 12 metallopeptidase domain 12 (meltrin alpha)
ATI angiotensin II receptor, type 1
AKT1 v-akt murine thymoma viral oncogene homolog 1
AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)
ALS2 Amytrophic lateral sclerosis 2 (juvenile)
AP-1 activating transcription factor 1
AP2A1 Adaptor-related protein complex 2, alpha 1 subunit
Apaf-1 apoptotic peptidase activating factor
APOA1 Apolipoprotein A-I
APP Amyloid beta (A4) precursor protein
ARHGAP26 Rho GTPase activating protein 26
ATF4 activating transcription factor 4 (tax-responsive enhancer element B67)
ATF6 Activating transcription factor 6
BRCA2 breast cancer 2, early onset
BTK Bruton agammaglobulinemia tyrosine kinase
CASP3 Caspase 3, apoptosis-related cysteine peptidase
CASP8 Caspase 8, apoptosis-related cysteine peptidase
CASP9 caspase 9, apoptosis-related cysteine peptidase
c-fos v-fos FBJ murine osteosarcoma viral oncogene homolog
CREB1 AMP responsive element binding protein 1
DAG dystroglycan 1 (dystrophin-associated glycoprotein 1)
DDAH2 dimethylarginine dimethylaminohydrolase 2
EGFR Epidermal growth factor receptor
EGR-1 early growth response 1
ELK1 ELK1, members of ETS oncogene family
ERBB2 erythroblastic leukema viral oncogene homolog 2
ERBB3 v-erb-b2 erythroblastic leukema viral oncogene homolog 3
ERBB4 v-erb-b2 erythroblastic leukema viral oncogene homolog 4
ERN1 Endoplasmic reticulum to nucleus signalling 1
ER Estrogen Receptor 1
ET1 Endothelin-1
FGR Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog
FRA1 FOS-like antigen 1
FYN FYN oncogene related to SRC, FGR, YES
G3BP Ras-GTPase-activating protein SH3-domain-binding protein
GCLC Glutamate-cysteine ligase, catalytic subunit
GCSh glycine cleavage system protein H (aminomethyl carrier)
GPAM Glycerol-3-phosphate acyltrasferase, mitochondrial
GPR132 G protein-coupled receptor 132
GR Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
GRAP2 GRB-related adaptor 2
GRB2 Growth factor receptor-bound protein 2
GRLF1 glucocorticoid receptor DNA binding factor 1
GSH GS homeobox 1
HBEGF heparin-binding EGF-like growth factor
HCK hemopoietic cell kinase
HGF Hepatocyte growth factor (hepapoietin A; scatter factor)
HRAS Harvey rat sarcoma viral oncogene homolog
ICAM intercellular adhesion molecule 1 (CD54), human rhinovirus receptor
IGF1 Insulin-like growth factor 1 (somatomedin C)
IGFBP2 Insulin-like growth factor binding protein 2, 36kDa
IGFBP7 Insulin-like growth factor receptor binding protein 7
IK1P IKK interacting protein
INrf2 kelch-like ECH-associated protein 1
JAK2 Janus kinase 2 (a protein tyrosine kinase)
JNKK mitogen-activated protein kinase kinase 4
JUN v-jun sarcoma virus 17 oncogene homolog (avian)
JUNB Jun B proto-oncogene
LDLR low density lipoprotein receptor (familial hypercholesterolemia)
LPA endothelial differentiation, lysophosphatidic acidG-protein-coupled receptor2
LYN v-yes-1 Yamaguchi sarcoma viral related oncogene homolog
MafF, v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian)
MafG v-maf musculoaponeurotic fibrosarcoma oncogene homolog G (avian)
MafK v-maf musculoaponeurotic fibrosarcoma oncogene homolog K (avian)
MAP3K5 mitogen-activated protein kinase kinase kinase 5
MAPK1 Mitogen-activated protein kinase 1
MAPK10 Mitogen-activated protein kinase 10
MAPK14 Mitogen-activated protein kinase 14
MAPK3 Mitogen-activated protein kinase 3
MAPK7 mitogen-activated protein kinase 7
MAPK8 Mitogen-activated protein kinase 8
MDA7 interleukin 24
MEK mitogen-activated protein kinase kinase 1
MEKK mitogen-activated protein kinase kinase kinase 1
MT1A Metallothionein 1A (functional)
MT1A metallothionein 2A
MT1H metallothionein 1H
MTF1 metal-regulatory transcription factor 1
MYB v-myb myeloblastosis viral oncogene homolog (avian)
MYC v-myc myelocytomatosis viral oncogene homolog (avian)
NFE2 nuclear factor (erythroid-derived 2), 45kDa
NFE2L2 Nuclear factor (enthroid-derived 2)-like 2
NFIX Nuclear fetor I/X (CCAAT-binding transcription factor)
NFKBIANuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitorA
NGF nerve growth factor, beta polypeptide
nPKC-eta protein kinase C, eta
P53 Tumor Protein p53 (Li-Fraumeni syndrome)
PAFR platelet-activating factor receptor
PAK1 p21/Cdc42/Racl-activated kinase 1 (STE20 homolog, yeast)
PDGF1 platelet-derived growth factor alpha polypeptide
PEC AMI platelet/endothelial cell adhesion molecule (CD31 antigen)
PI3K Phosphoinositide-3-kinase, catalytic, gamma polypeptide
PIP3-E phosphoinositide-binding protein PIP3-E
PKC-alpha protein kinase C, alpha
PKC-beta protein kinase C, beta 1
PKC-gamma protein kinase C, gamma
PLA2 phospholipase A2, group IIA (platelets, synovial fluid)
PLCG1 phospholipase C, gamma 1
PPARA peroxisome proliferative activated receptor, alpha
PRKCD protein kinase C, delta
PYK2 proline-rich tyrosine kinase 2
RAC1 Ras-related C3 botulinum toxin substrate 1
RAF1 v-raf-1 murine leukemia viral oncogene homolog 1
ROCK Rho-associated, coiled-coil containing protein kinase 1
SELE selectin E (endothelial adhesion molecule 1)
SHC Src homology 2 domain containing transforming protein 1
SOS1 son of sevenless homolog 1
SP1 Spl transcription factor
SRC1 viral oncogene homolog (avian)
SYK spleen tyrosine kinase
TGFB1 Transforming growth factor, beta induced, 68kDa
TGFB1 transforming growth factor, beta 1 (Camurati-Engelmann disease)
TNF tumor necrosis factor (TNF superfamily, member 2)
Traf2 TNF receptor-associated factor 2
VCAM1 vascular cell adhesion molecule 1
YBX1 Y box binding protein 1
ZAP70 Zeta-chain (TCR) associated protein kinase 70kDa
Appendix II -  Methodology Recipes
csFCS
csFCS was achieved by initially preparing 100ml aliquots of standard FCS (pH 
4.2) left at 4°C for 30minutes to equilibrate. A charcoal (11.1%) and dextran C 
(0.06%) solution was prepared with distilled water and Norit A, and mixed 
well for 1 hour, whereby 5ml of this charcoal solution (5%) was added to each 
100ml aliquot csFCS and incubated (with mild agitation) at 4°C for a further 16 
hours. Any traces of charcoal were removed by centrifugation (12000g for 
40minutes) followed by filtering through grade 4 filter paper. The charcoal 
solution was then readjusted to pH7.2 and passed through 0.2pM membrane 
filter to remove any impurities and contaminating micro-organisms.
TESPA coating
TESPA coating of coverslips was carried out by an initial 5 seconds dipping a 
solution in 6ml TESPA of 300ml Acetone, with 2 minutes subsequent washing 
in Acetone alone, followed by 2x1 minute washes in ultrapure distilled water 
before sterilisation by Autoclaving before use.
